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ABSTRACT

COMMUNITY PHARMACISTS AND SUBSTANCE USE DISORDERS:
ATTITUDES KNOWLEDGE AND PRACTICES

By
Deepika Rao
December 2018

Thesis supervised by Dr. Vincent Giannetti
Background: Substance use disorder (SUD) is a serious health concern affecting a large
proportion of the US population. Community pharmacists are well-positioned to prevent,
screen, and provide appropriate treatment for SUD. Stigma towards these patients and
SUD results in reduced quality of care as well as poor treatment outcomes. It is
imperative that pharmacists have the appropriate knowledge of and attitude towards
prevention, harm reduction, and treatment to develop therapeutic relationships and
improve their delivery of pharmacy services.
Objective: To assess knowledge, practices (with an emphasis upon screening), stigma
and general attitudes of community pharmacists towards SUD and evaluate the
relationship between these factors.
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Methods: A systematic literature review was conducted prior to beginning the study that
identified gaps in the literature. Based on the results of the review, a questionnaire was
developed assessing the following: demographic information, practice and educational
characteristics, knowledge about SUD medications, practices of pharmacists (especially
screening), stigma towards SUD patients and attitude towards harm reduction strategies
and treatment for SUD and a general open-ended question. Online survey methodology
was used to distribute the questionnaire on Qualtrics © (Provo, Utah) software among a
sample of community pharmacists (n =960) from the Duquesne University alumni
network and Giant Eagle Pharmacy chain via an email link. Data was collected over a
period of four months. The data was analyzed using SPSS Statistics 24 (Armonk, NY).
Descriptive data, mean differences and correlations were performed and regression
models were designed to predict knowledge, practice, screening and stigma. Content
analysis with axial analysis was carried out for the protocols obtained from the openended question.
Results: The response rate was 134 (13.9%) and on average pharmacists were 38.3 years
old, mostly female and Caucasian, and the majority had PharmD (vs B.S.) degrees.
Respondents primarily reported working in suburban areas for 15 years and about 37
hours/week on average in pharmacies that filled about 2000 prescriptions/week. Just over
half of the sample reported receiving previous SUD specific education and continuous
education (CE) in SUD and/or naloxone. The majority reported not having any personal
experience with SUD. On average, pharmacists answered 69% of the knowledge
questions correctly, performed about half of the possible clinical services, reported rarely
performing MTM or clinical services, regarded screening as an important practice, had

v

stigmatizing attitudes towards SUD patients and slightly negative attitudes towards harm
reduction strategies and SUD treatment. Having lower stigma was significantly related to
performing MTM and clinical services. Higher screening scores was positively correlated
to higher practice, but lower stigma scores. A combination of predictors was found to be
significant for knowledge, practice, screening and stigma. Number of years worked and
CE in naloxone were significant predictors of knowledge. Low stigma significantly
predicted a higher likelihood of performing clinical services for SUD. Stigma and
number of years worked also predicted screening as an important practice. Screening and
never/rarely performing MTM services predicted high stigma among pharmacists. Scale
of the opioid epidemic, overprescribing and prescriber accountability were some of the
most frequently occurring categories in the protocols.
Conclusion: The study was a comprehensive survey of knowledge, attitudes and
practices of community pharmacists in SUD. Their knowledge of medications, current
practices, their perception of the relevance of screening, assessment of stigma, and their
general attitudes toward SUD were explored. Significant relationships and associations
were found among these factors and descriptive data. These results could help improve
research in the area, increase the role of the pharmacist in SUD, help provide better
health-care, and assist in improving treatment outcomes for patients.
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Chapter 1
INTRODUCTION
This chapter provides an overview of the disorder, its epidemiology, etiology, prevention and
treatment. It also discusses the role of the pharmacist and the need for this study, followed by the
specific objectives of the study.
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I] Diagnosis of Substance Use Disorder (SUD)
1) Previous definition

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5), does not use the terms substance abuse and substance dependence. 1 In the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IVTR), the distinction between abuse and dependence was based on the notion of abuse
being a mild or early stage while dependence was characterized as the more severe
index.2 This was based on a continuum of disease development beginning with use
leading to abuse and finally dependence.3 ‘Abuse’ was characterized as having at least
one of the following factors in the past year: “Recurrent substance use resulting in failure
to fulfill obligations at work, home or school, recurrent substance use in physically
hazardous situations, recurrent substance-related legal problems, continued substance use
despite persistent or recurrent social/interpersonal problems caused or exacerbated by the
substance.”3 ‘Dependence or addiction’ was defined as a continued pattern of use which
resulted in at least three of the following characteristics in the past year:
“Tolerance, withdrawal, substance is taken in larger amounts and
over a longer period than intended, persistent desire or unsuccessful
efforts to cut down or control substance use, a great deal of time is spent in
activities related to obtaining the substance, use of the substance or
recovering from its effects, important social, occupational, or recreational
activities are given up or reduced because of substance use, substance use
is continued despite knowledge of persistent or recurrent physical or
psychological problems caused or exacerbated by the substance.” 3
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However, in practice, abuse was more severe than the defined categories. As
diagnosis of substance abuse previously required only one symptom, it wasn’t sufficient
to address the severity. Therefore, mild SUD in DSM-5 requires two to three symptoms. 2
Also, dependence included ‘tolerance’ as a category which in SUD could be
characterized as requiring more of the substance to get ‘high’ but could also be a normal
body response to any drug.2,3 Therefore, the DSM-5 now refers to SUD in a single
continuum with stages defined as mild, moderate, or severe to indicate the level of
severity. This is determined by the total number of diagnostic criteria met by an
individual.

2) Current Definition
Substance Abuse and Mental Health Services Administration (SAMHSA) defines
SUD as “the repeated use of substances causing clinical and functional impairment, such
as health problems, disability, and failure to meet major responsibilities at work, school,
or home.”1 According to the DSM-5, a diagnosis of SUD is based on signs of impaired
control, social impairment, risky use, and pharmacological criteria, totaling eleven
categories.1 Each specific substance (other than caffeine, which cannot be diagnosed as a
SUD) is addressed as a separate disorder [e.g., alcohol use disorder (AUD), stimulant use
disorder, etc.], but almost all substances are diagnosed based on the same central criteria.
According to the American Psychiatric Association, the original DSM-IV-TR categories
have thus not only been combined, but strengthened in the DSM-5 definition. 2 The eleven
categories are “hazardous use, social/interpersonal problems related to use, neglected
major roles to use, withdrawal, tolerance, used larger amounts/ longer, repeated attempts
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to quit/control use, much time spent using, physical/psychological problems related to
use, activities given up to use and finally craving.” 4

II] Impact of SUD
SUD is related to numerous health as well as social problems leading to an
increase in the risk of hospitalizations and death.5 A study by Daley et al notes that “SUD
is frequently accompanied by numerous medical, psychiatric, psychological, spiritual,
economic, social, family, and legal problems, creating a significant burden for affected
individuals, their families, and society.”6 Traditionally, SUD did not hold prominence in
terms of global health, especially when compared to infectious diseases or noncommunicable diseases such as cancer or cardiovascular disease. Health care services for
SUD have usually been scarce, and in many countries were separated from conventional
health care. The medical, economical and societal resources for SUD health care were
never adequate to bear the burden of the illness. 7 Recently, the misuse and abuse of
controlled substances, especially opiates have increased tremendously adding to the
burden of health care in the United States (US). The increase in abuse of opioids seem to
be mostly related to changes in medication prescribing practices, variations in the
formulation of the drugs, as well as the comparatively easy access due to the internet. 8 In
the mid-1990s, the American Pain Society pushed for the notion of pain as the fifth vital
sign which was followed by the American Medical Association and the Joint
Commission emphasizing that pain needs to be regularly evaluated in all patients and that
the subjective measure of pain by the patient must be respected by the health care
providers. There is growing concern that this led to enhanced use of prescription opioids
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and became a major factor in the current opioid crisis. 9 Apart from misuse of prescription
opioids, abuse of other illicit drugs has also increased. Therefore, although abuse of and
addiction to illicit drugs is not a new phenomenon, the scale, range and growth of the
problem has resulted in it being described as an epidemic. 8

III] Epidemiology
1) Opioid Use Disorder
The recent increase in use and misuse of opioid medications has renewed interest
in SUD. SAMHSA reports that in 2014, an estimated 1.9 million people had an opioid
use disorder related to prescription pain relievers (indicating an increase of about 200,000
in seven years). SAMHSA also estimated that about 586,000 had an opioid use disorder
related to heroin in 2014.1 National estimates from the National Survey on Drug Use and
Health stated that the number of Americans using prescription opioids for nonmedical
purposes increased from 11.0 million in 2002 to 12.5 million in 2007. Of these 12.5
million people, roughly 1.7 million met the DSM-IV-TR criteria for abuse or dependence
in 2007, a number that has gone higher since.10 An estimated 25 million people initiated
non-medical use of prescription opioids between 2002 and 2011. 11 The number of deaths
per year due to opioid overdose reached 16,651 in 2010. 11 The Centers for Disease
Control and Prevention (CDC) reported in 2009 that deaths due to opioid overdose have
more than tripled since 1999.10 The 2007 Treatment Episodes Data Set reported that the
number of patients admitted to SUD treatment facilities due to opiate/opioid (non-heroin)
abuse nearly multiplied four times from 23,000 to higher than 90,000 from 1999 to
2007.10 Mean annual direct health care costs for patients who abused opioids were more
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than eight-fold higher than for non-abusers ($15,884 vs $1,830, P < 0.01). 12 In addition,
the high costs of opioid abuse were directly related to high prevalence of costly comorbidities among the patients as well as high utilization rates of medical services and
prescription drugs by these patients.12

2) Other disorders (Alcohol, Cannabis, Stimulants and Hallucinogens)
SUD, due to misuse of other substances like alcohol and illicit drugs, is also
common in the US. Of the 176.6 million people who consume alcohol in the US, an
estimated 17 million have an AUD.1 According to the CDC, excessive alcohol use causes
88,000 deaths a year in the world. Excessive alcohol use can increase an individual’s risk
of developing serious health problems such as cardiomyopathy, stroke, and liver issues
like hepatitis, liver cirrhosis and steatosis.13 In addition, AUD results in the typical health
and social problems associated with intoxication behaviors and alcohol withdrawal
symptoms. The most used drug after alcohol and tobacco is marijuana. SAMHSA reports
that in 2014, about 22.2 million people (aged 12 and higher) reported using marijuana
during the past month. Of those 22.2 million people, 4.2 million people ages 12 and up
met criteria for a SUD based on marijuana use.1 The most commonly abused stimulants
are amphetamines, methamphetamine, and cocaine. Stimulants can be synthetic (such as
amphetamines) or plant-derived (such as cocaine). In 2014, an estimated 913,000 people
(aged 12 and older) had a stimulant use disorder because of cocaine use, and an estimated
476,000 people had a stimulant use disorder as a result of using other stimulants besides
methamphetamines in the US.1 Also, like stimulants, hallucinogens can be chemically
synthesized (lysergic acid diethylamide, or LSD) or may occur naturally (psilocybin
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mushrooms, peyote) as well. Approximately 246,000 Americans had a hallucinogen use
disorder in 2014.1

IV] Etiology
Historically, many theories have been proposed to define the etiology of SUD.
These theories are categorized in three main subgroups: psychosocial, biological, and
contextual. Although one would assume that multiple theories would help in improved
understanding of the etiology of SUD, this diversity could also convey the lack of
consensus around etiology of SUD.14 However, like the causes of other chronic diseases,
SUD is multifactorial in origin. Etiological research has recognized many factors that
affect drug use and whether or not it progresses towards a SUD. However, no single
factor or set of factors predicts drug use by an individual entirely. It is not necessary that
the same factor will affect all persons in the same way, nor is it essential that the factors
responsible for initiation of drug use are of equal importance in the continuation of use or
development of a SUD. Additionally, each case of SUD is different and there is no
consensus on the specific factors that are involved in all cases of SUD. 15 However, it is
accepted that most cases have at least one of the following factors in some measure.
Knowledge of these factors will help health care providers better identify, screen and
treat patients with SUD. It is also important to design prevention and treatment efforts
based on these risk factors.
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1) Psychosocial Factors
Psychosocial risk factors for SUD are comprised of personality traits and
psychopathology. Even though there is considerable literature regarding the relationship
between personality traits and drug use, especially in adolescents, few studies have
examined the precise role of personality traits in the development of SUD. 15 Most studies
focus on personality traits developed in adolescents and relate it to adult behaviors. One
study noted that the age of onset of consuming alcohol was indicated by several precursor
personality attributes such as lesser levels of conventionality, lesser importance or lower
expectations on academic achievement, more accepting attitudes toward
unconventionality, and lower levels of religiosity. These personality traits typically result
in individuals who are characteristically not concerned with hard work, are more
rebellious, and reject authority. They usually have fewer motives for not drinking or
believe drinking is harmless, and have greater positive expectations about the social
benefits of drinking. They might show aggressive and antisocial behavior in childhood. 15
In another review, the authors concluded that there was a strong relationship between
antisocial behavior and SUD, even though the relationship is not clearly understood. 16
Studies evaluating the association between adolescent personality characteristics and
development of SUD found that many of the characteristics that signaled the onset of
drinking alcohol also predicted misuse of other substances. The most influential
predictors of frequent drug use are variables labeled as the ‘unconventionality variables’
which include rebelliousness, tolerance of deviance, and poor progress in school. These
personality attributes that reflect lower levels of conventionality were also related to more
positive attitudes toward drug use and finally predicted the initiation of substance use.
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For example, the authors noted that in general, adolescents who start to use substances
are more unconventional in their attitudes and values and have fragile ties to the
conventional organizations of school and religion. They stated that this weaker tie is
displayed in more tolerant attitudes toward deviance, lesser religiosity, greater
rebelliousness and opposition to authority, higher disobedience, lower educational
expectations, and more favorable beliefs about substance use. 15 Thus, the personality
attributes related to development of a SUD were exactly the same as the ones that
predicted alcohol misuse.
Adult deviant (such as substance use or abuse) and antisocial behavior patterns
are often preceded by such behaviors in late childhood and early adolescence. These
behaviors together with increasing life stresses that typically occur in adulthood may be
risk factors for development of SUD. For example, conduct disorder has been proved to
precede the onset of or occur concurrently with SUD.15 Therefore, it is important that
health care providers look for such behaviors in youth to reduce the risk of them
developing a SUD.
Although early antisocial behaviors and deviance are risk factors for drug abuse,
the two most common psychopathologies that have been identified frequently with SUD
are depression and an antisocial personality. This means that risk factors might develop
concurrent with development of a SUD as well. Studies that include both clinical and
epidemiological samples have proposed that SUD and psychopathology maybe related.
The authors conducted both inpatient and outpatient surveys and noted that of all the
patients with psychiatric disorders such as antisocial behavior, attention deficit disorder
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(ADD), anxiety disorders, phobic disorders and depression, around one-third had a
SUD.15
Apart from the above internalizing disorders, externalizing disorders like disruptive
behaviors also occur in high rates in both adult and adolescent patients with SUD. 15
These personality traits and psychiatric illnesses could be as a result of SUD, independent
of SUD or be a risk factor for SUD.16 Identifying these risk factors in their patients
should encourage health care providers to screen these patients for SUD.

2) Biological Factors
Genetic vulnerability is the one of the most prominent biological risk factors for
the development of SUD. Family studies are therefore important for detecting genetic
vulnerability for SUD. Studies that have explored generations of SUD patients discovered
that drug use or abuse is elevated among siblings of drug abusers and that there is a direct
association between parents who use or abuse substances and their children using drugs
or having a disorder.15 Therefore, it becomes imperative for health care providers to pay
special attention to individuals with a family history of SUD. The high recurrence of
SUD within generations suggests that family history is one of the most effective
predictors of vulnerability to substance use, which in turn partly stems from genetic
factors. A study conducted in 1994 determined that possession of the dopamine (D 2A1)
allele was significantly associated with occurrence of SUD.17 This is one of the many
possible genetic factors that have been studied.
However, because there are variations in the genetic makeup of families, twin
studies may be more suitable to identify the role of genetic factors in SUD. Many twin

10

studies have provided useful insights and suggest that genetic factors explain some of the
variance in the development of SUD and that a large proportion of the heritability of drug
abuse in adulthood may be attributed to genetic factors that underlie the development of
behavior problems in childhood.15 A study conducted in Virginia reported that twin
resemblance for substance use was not only substantial, but also consistently greater in
monozygotic than in dizygotic twins.18 However, as twins are exposed to the same
environment while growing up, it is necessary to remove any confounding factors that
may occur in these studies. Cross-adoption studies thus provide the optimal study
paradigm for identifying the interaction of genetic and environmental factors in the
development of a trait or disorder. Cross-adoption studies of children of parents with
AUD who were raised by adoptive parents (non-alcoholic) have shown increased risk for
alcohol abuse and dependence compared to adopted children with non-alcoholic
biological parents.15
Physiological influences that may aggravate an individual's susceptibility to
develop SUD could include neurological impairment and amplified sensitivity to a drug.
This is usually because of their biologic make-up which determines responsiveness. 15 For
example, a study noted metabolic variations in Caucasian and Asian races. In contrast to
Caucasians, many Asians were biologically protected from becoming alcoholics. This
was because of the polymorphism of two liver enzymes aldehyde dehydrogenase and
alcohol dehydrogenase-2.15 On the other hand, efficient alcohol metabolism may also
enhance the risk of alcoholism because people are likely to need a higher quantity of
alcohol to experience the same ‘high’ and therefore ingest more. This would facilitate the
addictive potential of alcohol and increase their risk of developing AUD. 15 The authors
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thus noted that “the inability to metabolize a drug may be a protective influence in
continued exposure, whereas efficient metabolism may permit high levels of exposure
conducive to the development of abuse and dependence.” 15
Gender is another important biologic risk factor for development of SUD. A study
evaluating the differences in substance use between genders noted that men tended to use
almost all types of substances more than women. The study also reported that men were
more likely to have emergency department visits or overdose deaths due to substance use
or abuse than women.19 Studies typically report that men among all age groups, have
higher rates of development of SUD than women. However, that does not translate to a
lower risk for women of developing a SUD as compared to men. Additionally, women
may be more susceptible to craving and relapse, which are two important diagnostic
criteria in the DSM-V definition of SUD.19

3) Contextual factors
In addition to the influences of genetic and biological factors (i.e. family factors
that can be both transmitted and non-transmitted) on individual susceptibility for SUD,
unique environmental factors may be involved in the predisposition towards SUD, which
are difficult to measure.15 Hence, the exact mechanism through which family history
results in an increased risk is not clearly understood. Family studies by themselves,
cannot definitively determine these unique environmental effects. These factors are called
contextual factors and are defined as factors external to the individual and occur because
of the social (family or peer group) or broader environment. Moreover, the complex
interaction among these factors contributes to the overall complexity of SUD etiology. 15
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Family factors are the most prominent contextual risk factor in the development
of SUD. Many family factors may be associated with the development of SUD such as
poor parental relations, family disruptions, poor childrearing, substance use or abuse
behaviors in the family, favorable or encouraging parental attitudes to substance use, and
lack of social interaction. Parents may confer an increased risk of SUD on their children
by acting as negative role models. Children in these households observe parents using or
abusing drugs as a coping mechanism. Children usually acquire their coping techniques
through social learning and thus internalize these behaviors as adolescents. 15
Differences in development of SUD in patients belonging to different
socioeconomic classes point towards economic backgrounds being a risk factor. Affluent
families may provide people with resources to acquire illicit substances and this increased
use may lead to development of a SUD. For example, a study observing teenagers from
affluent, suburban families and low socioeconomic status adolescents from inner-city
settings noted that suburban youth reported significantly higher levels of substance use
than inner-city youth.20
The peer environment also makes a considerable contribution to development of
SUD. Generally, among older adolescents, peers have a greater effect than families
because typically, adolescent drug use takes place due to the influence of close friends.
However, peer influence on development of SUD may also occur in a mutually
reinforcing pattern because drug-using adolescents also tend to gravitate towards similar
peers. The contributing effects of peer influences are thus likely to be altered at different
ages.15 A study analyzing peer relationships by social networking practices of the
subjects noted that having friends in that social network, being liked but not too popular,
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and having fewer peers who use substances were significantly related to subjects not
having SUD.21
The contextual factors that have an impact on development of SUD also include
the surrounding community drug use practices and neighborhood disorganization. The
authors noted that communities with high rates of crime, easy accessibility to drugs, and a
general acceptance of drug use and abuse in the community are all associated with
development of SUD among residents of these neighborhoods. 15 The larger sociocultural
environment also has important effects on drug use. The frequency and nature of
representation of substances in the media may have significant effects on the people.
Moreover, social and legal policies (taxes on substances, restrictions on conditions of
purchase and use, legal status) and enforcement of these policies may have vital effects
on rates of SUD development. It is important to note that the effect of these contextual
factors are highly dependent on the degree of acculturation and assimilation of
individuals and their families into the community. 15
Alternatively, the environment can also create a protective sense of self-worth,
identity, and safety. Neighborhood and community factors may thus serve to protect
individuals from developing SUD. For example, restrictions on tobacco use in public are
placed because of the opinions and values of the larger community, which may in turn
deter individuals from using substances and thus decrease the chances of developing
SUD.15
A thorough understanding of all risk factors, especially biologic factors will
enable health care providers to better understand the disease model of SUD. This will
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help in decreasing stigma associated with SUD and help improve attitudes towards
patients and also increase positive attitudes towards prevention and treatment strategies.

V] Prevention
The psychosocial, biological, and contextual factors must all be considered in the
prevention of SUD. A multidimensional assessment of risk factors is essential for
strategically comprehensive prevention efforts.22 Prevention strategies are categorized as
primary or secondary based on when the intervention occurs: primary is before the
behavior occurs (substance use) and secondary is after it occurs but before the behavior
becomes habitual (patient develops a SUD).23 Primary prevention seeks to prevent the
onset of disease. Secondary prevention on the other hand, comprises screening for or
identifying early stages of the disease. It also includes reversing early effects of the
disease if possible. Tertiary prevention attempts to reduce the consequences of the
disease as well as try for remission.22
At every stage of prevention, ‘behavioral immunity’ (a set of behaviors that
prevent people from succumbing to external negative influences) toward drug-seeking
and misuse or abuse must be cultivated. This can be achieved by enhancing the goal of
avoiding substances for both individuals and populations. It is necessary to address both
the patient and the environment in which they live. Prevention of SUD requires a
thorough evaluation of the stressors that affect the patient, and health care providers must
accordingly provide patients with methods to improve self-efficacy in avoiding misuse or
abuse of substances.22
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1) Primary Prevention
Primary or universal prevention efforts are essential because people belonging to
all sections of the society are at risk for experimenting with substances. This is especially
true among teenagers and young adults. It is therefore, necessary to provide preventive
interventions because there can be negative consequences related to even sporadic use
(e.g., substance overdose). Additionally, as discussed above, the etiology of SUD is
complex. Targeting prevention to a specific sample of people that are classified as ‘high
risk’ may lead to excessive false positive findings; thereby wasting resources. This
approach could also lead to incorrect labeling which is highly problematic considering
the sensitive nature of the disease. On the contrary, targeting interventions can also lead
to omitting individuals who require preventive interventions. Moreover, a universal
orientation is generally more cost-effective and logistically feasible because it can be
applied to a larger population using pre-existing structures like schools or work
organizations. It is thus less expensive to provide everyone with the intervention than to
identify and selectively offer preventive services to those most at risk. 23
Individual and environmental intervention strategies are two types of primary
prevention approaches. Some prevention interventions are intended to help individuals
develop the healthy behavior while others focus on creating environments that sustain
that healthy behavior. Research shows that the most effective prevention interventions
tend to incorporate both approaches.24
Many prevention approaches focus on helping people develop the knowledge,
attitudes, and skills they need to alter their behavior. These individual-level strategies
typically include classes on healthy behaviors. Effective classroom-based programs focus
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on both life and social skills while also considering the external influences on substance
use. These programs involve interactions among participants while emphasizing a social
commitment to avoid substances. The programs also commonly include community
components such as the socioeconomic status of people in the community, religious
beliefs and value systems of the community to help relay the message. These programs
are generally conveyed by peer leaders and highlight the benefit of building life skills and
social resistance to illicit substances.24
Environmental strategies take a broader approach than individual-level strategies.
Professionals use environmental strategies to change the factors within the community,
namely physical, social, or cultural factors that may lead to substance use. For example,
prevention strategies could include targeting the laws or norms that are favorable towards
substance use and misuse.24
SAMHSA states that environmental strategies are most effective when
implemented as part of a comprehensive approach. Environmental strategies include
communication and education strategies, which strive for increased awareness. They
create community support for prevention by influencing community norms. They may
also use enforcement methods to deter people from substance misuse. 24

2) Secondary Prevention
Although many individuals experiment with substances as part of their
developmental life cycle, most young individuals do not regularly use illegal drugs and
most of them do not make the transition to developing a SUD. Thus, drug use in itself
may not be the most appropriate goal of prevention. Moreover, the effects of primary
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prevention are usually too insignificant to have a major impact on prevalence of SUD in
the community. Considering the limited resources and reduced budgets of most
governments, it may be more important to focus on abuse and dependence and not merely
the use of drugs.23
Randomized controlled trials have demonstrated that guiding people who misuse
or abuse alcohol in the right direction (secondary prevention) resulted in a decrease in
alcohol consumption and alcohol-related problems.25 Similarly, efforts to screen for and
treat individuals who use opioids but have not developed an opioid use disorder, may
reduce the risk of overdose, psychosocial decline, and medical complications. 26
Patients may use physicians as one of the major sources of opioid pain relievers
(OPR) whether or not they have medical reasons for use of the drugs. An Institute of
Medicine report suggests that among all physicians, primary care physicians may be the
primary source of OPRs. The report specifically states that in 2007, analysis of office
visit data resulted in pain relievers being the most frequently found drug category. In
2008, pain relievers contributed to 10.1% of all drugs prescribed to adults. 27 Interactions
with medical professionals thus are a valuable opportunity for early identification of
opioid use disorder and consequent secondary prevention. However, detection of an
opioid use disorder in these patients can be very difficult because they are often reluctant
to disclose their concerns about developing a SUD. They may fear being judged, being
cut off from a legitimate supply, or being invalidated by the prescribers. Patients fear
being labeled as drug seekers if prescribers assume that they are faking their pain. These
apprehensions of patients must be considered by prescribers before relying on selfreported data. Additional information may need to be collected regarding opioid use in
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the patients. Urine toxicology can be used to verify a patient's self-reported opioid use
history. However, urine toxicology of patients on long-term OPRs such as chronic pain
patients is not a reliable strategy. Moreover, urine toxicology also cannot determine if a
patient is misusing prescribed opioids or other illicit substances by taking extra doses or
by an intranasal or injection route.26 Another concern is that patients may receive opioid
prescriptions from multiple providers, a practice called ‘doctor shopping.’ Doctor
shoppers can be identified through use of state prescription drug monitoring programs
(PDMPs).26 Use of PDMPs could lead to more effective screening and prescribers could
then modify their prescribing practices and provide treatment accordingly. In states that
mandated checking the PDMP before prescribing controlled substances, PDMP
utilization increased and this was correlated with a decline in number of opioid
prescriptions and a severe drop in patients exhibiting doctor shopping behaviors. 26 This
proves the effectiveness of this secondary prevention strategy.
Although primary and secondary prevention strategies have their respective
advantages and shortcomings, these interventions do not have to be viewed as mutually
exclusive approaches. Rather they are mutually supportive programs and do not need to
be opposing alternatives in most cases. There are many advantages to have a combination
approach where the disadvantages of one strategy is nullified by the other. For example,
while universal interventions can be used to promote an ‘antidrug’ message in the larger
society, selective interventions can be designed based on the universal message thereby
reinforcing the message and avoiding the cost of developing a new targeted message.
Moreover, the risk of incorrectly labeling individuals as high-risk in secondary
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prevention programs can be avoided by delivering the same targeted message within
universal prevention programs.23

3) Harm reduction
Prevention programs especially primary and secondary, typically focus on risk
reduction. Another approach to prevention is to enhance protective factors. Several
studies have noted that protective factors can moderate the effects of risky environments,
reduce susceptibility while increasing resilience of the patients. 15 Protective factors such
as positive relationships within families, non-deviant siblings and peers, high academic
achievement, and some amount of conventionality such as low rebelliousness and
obedience to broad social norms reduce the effect of risk factors in adolescents.
Protective factors in adulthood include those that increase responsibilities such as
employment, marriage, and childrearing.15
Many of the protective factors can also help to reduce the effects of negative
environmental risk factors. For example, substance use by one parent maybe offset by the
non-use of the other. A supportive family while growing up provides an external system
that helps to cope with stress.15 However, specific protective factors are applicable at
certain stages of life and research needs to be conducted to determine those appropriate
factors in every age group. Moreover, the exact mechanism of their protection needs to be
studied. Harm reduction is based on increasing these protective factors while reducing
harms due to SUD.
Harm reduction is not a goal but an approach or strategy to reduce harms of SUD.
The aim of harm reduction is to reduce the negative consequences of drug use rather than
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to cure SUD. It aims to decrease the adverse events typically associated with substance
abuse, especially when quitting use is not highly probable. These strategies can however,
be harmonious with an eventual goal of abstinence.28 Harm reduction strategies are
directed towards altering drug using behaviors and effects (acquisition, drug use, and
withdrawal).29 The United Nations Office on Drugs and Crime (UNODC) described the
harms as high-risk situations, such as criminal behavior. Harms are related to the drug
used, the amount consumed, and the method of administration. The purity of the drug or
drugs consumed, dose consumed, duration and frequency of use, mode of administration
are factors that affect the harms that accompany overdose or intoxication. Physical state
(nutrition, tolerance, etc.) and psychological factors (expectations) of the individual may
also be important factors. Drug withdrawal harms on the other hand are related to factors
that affect the patient’s work and social functioning. Withdrawal can also be related to
physical and psychological issues and is usually correlated with high-risk activities, and
criminal behaviors, which in turn are harms related to drug use. Therefore, they create a
vicious circle.29
General harm reduction strategies include education, brief interventions and
counseling focused on changing high-risk behaviors as well as interventions to reduce
injury and violence. The purpose of education is to provide accurate information about
the consequences and risks of drug use and promote behaviors that reduce risk. 29
Education programs usually include information on biological and psychosocial risks of
SUD, risks of overdose, infectious diseases, and comorbid disorders. Brief interventions
might include acute therapy, cognitive behavioral therapy (prolonged), and motivational
interviewing (MI).29 A study evaluated MI versus standard care for individuals in an
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emergency room following an alcohol-related event. The study reported that patients who
received MI had a significantly lesser incidence of drinking and driving, traffic
violations, and alcohol-related injuries than patients who received standard care. 30
Counseling commonly involves strategies to change the environment such as changing
alcohol containers (from bottles to plastic glasses), prohibiting beverages with high
concentrations of alcohol, recruitment of individuals in the community, etc. 29
Specific strategies also include pharmacological interventions. One aim of these
interventions is to reduce the risk of contracting or transmitting HIV and other infectious
diseases by substituting injected substance with non-injecting drugs. 29 A meta-analysis of
studies conducted in the United Kingdom showed that opioid substitution therapy was
associated with reduction in new hepatitis C infections [adjusted odds ratios (AORs) =
0.41, 95% confidence interval (CI): 0.21–0.82)].31 Drug substitution also leads to patients
obtaining legal drugs dispensed under the care of a health professional, so the risk of
overdose and other medical complications is minimized. Furthermore, drug substitution
helps to reduce crime and the high-risk behaviors that patients typically exhibit since it
reduces the urgency of acquiring the drug. Additionally, drug substitution allows health
professionals like pharmacists to keep in contact with the patients, which aids in keeping
them in treatment and thereby reduces relapse.29
Needle/syringe exchange programs include strategies to prevent the sharing of
injecting equipment and for the safe disposal of non-sterile injecting paraphernalia. These
programs raise awareness and knowledge of the risk of contracting infectious diseases
(e.g. HIV, HCV, etc.) through injecting drugs, provide information and assistance on the
steps to inject safely, offer sterile injecting equipment, if possible, communicate practical
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steps on how to disinfect needles, syringes and other equipment, increase access to safe
disposal or deliver sessions on how to dispose of non-sterile equipment. 29 The metaanalysis also reported that implementation of both opioid substitution treatment and
needle/syringe exchange programs together, were associated with a reduction in self‐
reported needle sharing by 48% (AOR 0.52, 95% CI: 0.32–0.83) and mean injecting
frequency by 20.8 injections per month (95% CI: −27.3 to −14.4). 31
Overdose prevention is another important harm reduction strategy. Naloxone, a
short-acting opioid antagonist, overturns the respiratory depressing effects of opioids and
prevents overdose among patients.29 A study evaluating the effectiveness of overdose
training reported that 96% of the overdose episodes were reversed due to naloxone
administration.32 Other drugs, such as methadone, which in contrast have similar
properties to heroin and morphine, act as maintenance treatments but also help to reduce
overdose. Since they are not injected, they reduce the risk of HIV and hepatitis infection,
and criminal acts and other high risk behaviors.29
UNODC suggested some other overdose management strategies like “peer-to-peer
education in first aid and cardiopulmonary resuscitation (CPR), establishing
collaborations among peers, and encouraging peers to seek help and call an ambulance
when an overdose is suspected.”29 Use of non-injection routes of administration over
injection routes for substances, voluntary HIV counseling and testing for patients,
prevention and management of infections, and wound care and maintenance are some
other SUD specific harm reduction strategies.29
Prevention efforts can also double up as treatment strategies. A study reported
that substitution (e.g., methadone, buprenorphine) and antagonist (e.g., naltrexone)
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medications in conjunction with psychosocial treatment have been shown to be effective
not only in harm reduction but also as treatment by enabling recovery. 22

VI] Treatment
Treatment for substance use disorders are comprised of many components that
can be broadly classified into three main categories: psychological, support based, and
pharmacological (medication).

1) Psychological treatment
Counseling is the primary form of psychological treatment. Counseling can be
provided at the individual or group level. Individual counseling focuses on decreasing or
discontinuing substance use, skill building, adherence to a recovery plan, and personal
and professional outcomes. Group counseling is frequently used in addition to individual
counseling to provide social reinforcement for successful recovery. 33
Counselors provide a variety of services to patients in treatment for SUD
including assessment, treatment planning, and counseling. Counseling typically involves
therapies like motivational enhancement therapy, contingency management, and/or
cognitive behavioral therapy. Motivational enhancement therapy helps people with SUD
to build motivation and commit to precise plans to get involved in treatment and pursue
recovery. It is generally used early in the treatment process to engage people and
encourage them to procure further treatment. Cognitive-behavioral therapy helps patients
to distinguish and discontinue negative lines of thinking and behavior. For example, it
might help a person become conscious of the stressors, circumstances, and feelings that
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lead to substance use so that the patient can avoid them or avoid substance use when they
occur. Contingency management is intended to provide incentives to reinforce such
positive behaviors.33
Some forms of counseling are tailored to specific populations. For instance,
young people need a different set of treatment services as compared to older adults to
guide them towards recovery. Therefore, treatments for youth frequently involve a family
component (especially parent/guardian involvement), that may not be a part of other
counseling programs.33 Also, specific factors like peer substance use, school
environment, and personality may have to be considered when treating youth. Another
example is counseling tailored for women because of gender differences in risk factors
for SUD, as discussed previously.

2) Support services
Recovery support services are non-clinical services that are used along with
treatment to support individuals in their recovery period. Peers or patients who are
already in recovery commonly provide these services. According to SAMHSA, recovery
support can include the following:
“Transportation to and from treatment and recovery-oriented activities,
employment or educational supports, specialized living situations, peer-topeer services, mentoring, coaching, spiritual and faith-based support,
parenting education, self-help and support groups, outreach and
engagement, staffing drop in centers, clubhouses, respite/crisis services, or
‘warmlines’ (peer-run listening lines staffed by people in recovery

25

themselves) and education about strategies to promote wellness and
recovery.”33
While support groups do not work for everyone and are not a treatment
requirement, they are an important component of the SUD treatment system. Alcoholics
Anonymous or Narcotics Anonymous are 12-step facilitation programs to guide and
support engagement in treatment. However, support groups are not considered as formal
treatment.33

3) Medication
Using medication to treat SUD is often referred to as medication-assisted
treatment (MAT). In this model, medication is used along with counseling and the
previously discussed behavioral therapies. Medications act as agonists or partial agonists
of the receptors that lead to reduction in cravings and other withdrawal symptoms. They
can also block the rewarding feeling that occurs after substance use, or induce negative
symptoms when a substance is taken that deter the patients from using the substances.
Although, MAT has been primarily used for the treatment of opioid use disorder, it can
be used for treatment of some other SUDs.33
MAT using methadone, buprenorphine, or extended-release injectable naltrexone
plays a critical role in the treatment of opioid use disorders. SAMHSA reported that more
than 300,000 people received some form of MAT for an opioid use disorder in 2011. 33
Opioid agonist therapies not only reduce the effects of opioid withdrawal and cravings
but also increase retention in treatment. Additionally, they reduce risky behaviors that
lead to transmission of HIV and viral hepatitis such as using opioids by injection. MAT
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with extended-release injectable naltrexone reduces the risk of relapse to opioid use and
helps control cravings.33 It is also particularly useful for individuals who move from a
controlled setting like jail or residential rehabilitation where abstinence has been imposed
to an environment where they may be at a risk for relapse. It can also be used in
situations where maintenance with an opioid agonist is not appropriate or the agonist is
not available.33
Medications can assist in the treatment of AUD as well. Acamprosate is a
medication that reduces symptoms of prolonged withdrawal and has been demonstrated
to help individuals with AUD. Moreover, patients who have achieved abstinence go on to
maintain abstinence for longer periods due these medications. Naltrexone, a medication
primarily developed to block the effects of opioids, has also been used to reduce craving
in those with AUD. Disulfiram is another medication which changes the way the body
metabolizes alcohol, resulting in unpleasant symptoms including flushing, and nausea if a
person consumes alcohol after taking the medication. 33

4) Combined treatment
A patient accessing treatment may not need every one of these components, but
each plays an important role. These systems are implanted in a broader community
setting and the support provided by various parts of that community plays an important
role in overall treatment. Treatment can be provided in inpatient or residential sessions.
This happens within specialty SUD treatment facilities with a broader behavioral health
focus, or by specialized units within hospitals. Longer-term residential treatments can be
as long as six to twelve months and are relatively uncommon. These programs focus on
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helping individuals change their behaviors in a highly structured setting. Shorter term
residential treatments are much more common, and typically have a focus on
detoxification. They provide initial intensive treatment and prepare the patient for a
return to community-based settings. An alternative to inpatient or residential treatment is
partial hospitalization or intensive outpatient treatment. These programs make
participants attend very intensive and regular treatment sessions multiple times a week
early in their treatment phase. After completing the initial partial hospitalization or
intensive outpatient treatment, individuals often continue into regular outpatient treatment
which meets less frequently and for fewer hours per week to help sustain their recovery. 33
Combined treatment is thus much more effective than providing only one type of
treatment. Pharmacists can play a critical role in assisting at various points in the overall
treatment of the patients.

VII] Pharmacists and SUD
In response to the increasing prevalence of these disorders, funding of prevention
programs and projects designed to lessen or eliminate the threat of SUD has increased in
the past decade. Despite these funds, adequate resources have not been invested in an
important area that holds great potential as a prevention strategy. Improved education and
training of the millions of people who constitute the health professions workforce will
contribute towards decreasing the high rates of incidence and prevalence of SUD. 34
Improved education and training will lead to higher rates of screening for SUD and
excessive substance use, increased counseling of substance users to avoid development of
a disorder, and more patients being provided appropriate treatment for SUD to enhance
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remission. Very little consideration has been given to training primary health care
professionals - physicians, nurses, pharmacists, dentists, physician assistants,
psychologists, social workers, and others - to treat the millions of individuals and their
families affected by SUD.34 Health care professionals play a central role in the
identification of SUD as well as facilitating an increased accessibility to treatment for
patients.35 Pharmacists as highly accessible health care professionals, are in an
appropriate position to help prevent and treat SUD. They should prepare themselves to
perform these functions as a matter of professional responsibility as the prevalence of
these disorders increase.36 Pharmacists are often the first point of contact for patients
accessing the health care system, especially in the community setting. Pharmacists
frequently help patients with the management of minor but self-limiting symptoms.
Furthermore, community pharmacists deliver many preventive and primary health care
services and treatments including medication reviews, disease management (e.g., mental
health and lifestyle management) and routine health care such as smoking cessation and
weight loss programs.37 With respect to SUD, community pharmacists often offer their
expert knowledge and insight into the regulatory aspects of substance abuse treatment to
patients. This is especially true in regard to MAT for SUD. Pharmacists, as a specialized
service, can assess and manage the pharmacotherapy of patients with SUD and their
comorbid conditions. For example, they can contribute in developing plans for pain
management in patients with SUD. They are trained to acquire detailed medication
histories from patients and to assist them in adhering to their treatment regimens. As new
medications are developed to treat SUD, community pharmacists are well positioned to
increase access to these novel therapies safely and efficiently. 38 However, most patients
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with SUD do not seek assistance or receive treatment for their disorders. Only 14.7% of
people with SUD received professional help in 2008.39 Hence, even though treatment
increases the possibility of recovery, patients usually do not disclose or admit to having
problems with substance use and so do not receive appropriate treatment. Since the
majority of patients with SUD seek treatment primarily for other minor problems (such as
headaches), community pharmacists can play a critical role in screening these patients
and identifying the underlying disorder and thereby increase accessibility to treatment. 35

VIII] Need for the study
Several factors are associated with treatment utilization in SUD. In addition to the
nature and severity of the disease, the awareness of the need for treatment among patients
and their willingness to seek help depends on the patient’s sociodemographic
characteristics. The unmet need for treatment is usually the highest among the elderly
population, racial-ethnic minorities, low income groups, patients without insurance, and
rural populations.39 These unmet needs are further augmented by negative attitudes of the
health care providers resulting in treatment interruption or avoidance. Negative attitudes
of health professionals towards patients with SUD lead to poor communication between
the health care professional and patient, and reduced therapeutic cooperation. It could
also lead to attribution of SUD symptoms to other illnesses and is referred to as
diagnostic overshadowing.35 Although attitudes of healthcare professionals towards
substance abuse have been evaluated previously, there is a general lack of studies
conducted specifically with community pharmacists. Health care professionals, especially
pharmacists should have basic knowledge of prevention and treatment strategies. Primary
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prevention such as educational efforts and secondary prevention such as screening are
important roles for pharmacists to play. Also, positive attitudes towards harm reduction
strategies will increase if pharmacists have knowledge of the effectiveness of these
strategies. Moreover, an increasing number of states have initiated outpatient naloxone
dispensing recently; however, across the nation, there is limited exposure to this unique
practice and limited appreciation for the role of a pharmacist within this clinical setting.
Additional awareness is needed regarding the attitudes, knowledge and practices of the
community pharmacist and what barriers to their practice exist and how they can be
overcome.40
Therefore, the specific aims of the study are as follows:


Assess the basic knowledge of community pharmacists regarding SUD
medications.



Assess the screening practices of community pharmacists for opioid drug abuse.



Assess stigma among community pharmacists toward SUD.



Assess attitudes towards needle exchange/dispensing and provision of naloxone
for patients.



Identify the relationship between knowledge, attitudes and stigma with offering of
clinical pharmacy services for patients with SUD.



Identify the predictors of knowledge, stigma, screening and offering of clinical
services for SUD.
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Chapter 2
SYSTEMATIC LITERATURE REVIEW
This chapter describes the systematic literature review, specifically its objectives,
method, results and conclusion.
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I] Introduction
Even though considerable research has been conducted on SUD, studies with a
focus on the community pharmacists are scarce and have limitations that need to be
assessed. The purpose of conducting the systematic literature review was to study the
available literature on community pharmacist and substance use disorders and identify
gaps that need to be addressed. The specific aims of the review were:
1. To conduct a systematic literature review to identify papers describing
community pharmacist attitudes, knowledge and practices in treating
substance use disorder.
2. To provide a basis for a quantitative survey of community pharmacist
attitudes, knowledge and practices with SUD patients.
3. To make policy, practice and research recommendations based on identified
gaps in the literature as well as results of the survey.

II] Method
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines were used to conduct the review.41 The search was conducted in
PubMed, Scopus and Psych-INFO electronic databases up to December 2017. (Figure 1)
Select key terms included “Pharmacist,” “Substance Use Disorder,” “Attitudes,” and
pharmacy practice terms like “Medication therapy management” and “Drug Abuse
Screening.” The exclusion criteria included reviews, RCTs or pharmacological studies,
and non-English articles. The inclusion criteria were studies with the community
pharmacists in the sample or as the focus of the paper, in the area of SUD; attitudes,
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knowledge, practices (specific or general) of pharmacists and policies applicable to the
pharmacist roles.
The search strategy for PubMed involved three sub-searches that were then
combined.


The first included (Pharmacists [MeSH] OR Pharmacist*[tiab] OR
Pharmacist*[ot]) AND (("Substance-Related Disorders"[MeSH] OR
"Substance-Related Disorder"[tiab] OR "Substance-Related Disorder"[ot]
OR "Substance-Related Disorders"[tiab] OR "Substance-Related
Disorders"[ot]) OR ("Drug Overdose"[MeSH] OR "Drug Overdose"[tiab]
OR "Drug Overdose"[ot] OR "Substance Dependence"[tiab] OR
"Substance Dependence"[ot] OR "Substance Dependent"[tiab] OR
"Substance Dependent"[ot]) OR ("Opioid-Related Disorders"[MeSH] OR
"Opioid-Related Disorder"[tiab] OR "Opioid-Related Disorder"[ot] OR
"Opioid-Related Disorders"[tiab] OR "Opioid-Related Disorders"[ot]) OR
("Opiate Dependence"[tiab] OR "Opiate Dependence"[ot] OR "Opiate
Dependent"[tiab] OR "Opiate Dependent"[ot]) OR ("Prescription Drug
Misuse"[MeSH] OR "Prescription Drug Misuse"[tiab] OR "Prescription
Drug Misuse"[ot]) OR ("Overdose Prevention"[tiab] OR "Overdose
Prevention"[ot]) OR ("Medication-assisted treatment"[tiab] OR
"Medication-assisted treatment"[ot]) OR ("Opiate Substitution
Treatment"[MeSH] OR "Opiate Substitution Treatment"[tiab] OR "Opiate
Substitution Treatment"[ot] OR "Opioid-Related Disorders/drug
therapy"[MeSH] OR "Opioid-Related Disorders/rehabilitation"[MeSH])
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OR ("Substance Abuse Detection"[MeSH] OR "Substance Abuse
Detection"[tiab] OR "Substance Abuse Detection"[ot] OR "Drug abuse
screening"[tiab] OR "Drug abuse screening"[ot]) OR ("Needle-Exchange
Programs"[MeSH] OR "Needle-Exchange Program"[tiab] OR "NeedleExchange Program"[ot] OR "Needle-Exchange Programs"[tiab] OR
"Needle-Exchange Programs"[ot]) OR ("Harm Reduction"[MeSH] OR
"Harm Reduction"[tiab] OR "Harm Reduction"[ot]) OR
“Narcotics”[mesh] OR “Narcotic Antagonists”[mesh] OR Narcotic*[tiab]
OR Narcotic*[ot])


The second involved (Pharmacists [MeSH] OR Pharmacist*[tiab] OR
Pharmacist*[ot]) AND (("Substance-Related Disorders"[MeSH] OR
"Substance-Related Disorder"[tiab] OR "Substance-Related Disorder"[ot]
OR "Substance-Related Disorders"[tiab] OR "Substance-Related
Disorders"[ot]) OR ("Drug Overdose"[MeSH] OR "Drug Overdose"[tiab]
OR "Drug Overdose"[ot] OR "Substance Dependence"[tiab] OR
"Substance Dependence"[ot] OR "Substance Dependent"[tiab] OR
"Substance Dependent"[ot]) OR ("Opioid-Related Disorders"[MeSH] OR
"Opioid-Related Disorder"[tiab] OR "Opioid-Related Disorder"[ot] OR
"Opioid-Related Disorders"[tiab] OR "Opioid-Related Disorders"[ot]) OR
("Opiate Dependence"[tiab] OR "Opiate Dependence"[ot] OR "Opiate
Dependent"[tiab] OR "Opiate Dependent"[ot])) AND ((Knowledge
[MeSH] OR Knowledge [tiab] OR Knowledge [ot]) OR (Attitude [MeSH]
OR Attitude*[tiab] OR Attitude*[ot] OR "Attitude of Health
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Personnel"[MeSH]) OR (Belief*[tiab] OR Belief*[ot]) OR (Social
Stigma[MeSH] OR Stigma*[tiab] OR Stigma*[ot] OR destigma*[tiab] OR
destigma*[ot]) OR ("Red flag"[tiab] OR "Red flag"[ot] OR "Red
flags"[tiab] OR "Red flags"[ot]))


The third search was (Pharmacists [MeSH] OR Pharmacist*[tiab] OR
Pharmacist*[ot]) AND (Acamprosate[tiab] OR Campral[tiab] OR
Disulfiram[tiab] OR Antabuse[tiab] OR Naltrexone[tiab] OR
Vivitrol[tiab] OR Methadone[tiab] OR Dolophine[tiab] OR
Buprenorphine[tiab] OR Suboxone[tiab] OR Naloxone[tiab] OR
Narcan[tiab] OR Fentanyl[tiab] OR Morphine[tiab] OR Heroin[tiab] OR
Codeine[tiab] OR Oxycodone[tiab] OR Oxycontin[tiab] OR
Hydrocodone[tiab] OR Vicodin[tiab] OR Meperetin[tiab] OR
Demerol[tiab] OR Methadone[tiab] OR Dolophine [tiab])

The final search was Search 1 OR Search 2 OR Search 3. The same strategy was
modified and used for Psych-INFO and Scopus databases.
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Identification

Records identified through
Pubmed, Psych-INFO, Scopus
databases searching
(n = 3,592)

Eligibility

Screening

Records after duplicates removed
(n = 2,509)

Records screened
(n = 2,393)

Full-text articles
assessed for eligibility
(n = 424)

Records excluded
(n = 1,969)

Full-text articles
excluded, with reasons
(n =271)
Reviews = 3
Non- English = 26
Pharmacological studies
= 36
Irrelevant = 206

Included

Studies included in
qualitative synthesis
(n = 153)

Records excluded
(Additional duplicates
identified through
Covidence software)
(n = 116)

Figure 1: Schematic representation of methodology used and selection criteria. Search and selection
criteria were conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines
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III] Results of the review
Table 1 presents the total number of the studies included for qualitative synthesis.
They are divided in rows according to the factors being discussed (attitudes, knowledge,
practices or policies). The columns present the specific focus of the study like syringe
exchange, naloxone, educational or if they are general in nature.
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Table 1: Results of the systematic review [Number of studies (Percentage)]
Factors

Needle
Exchange

Naloxone

Students /
Educational

Others

Total
studies

Number (Percentage of all 153 studies)
Attitudes

21(13.7)

9 (5.8)

2 (1.3)

25 (16.3)

57 (37.2)

Knowledge

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.6)

1 (0.6)

Practices

3 (1.9)

3 (1.9)

0 (0.0)

11 (7.1)

17 (11.1)

Attitudes,
Knowledge

0 (0.0)

1 (0.6)

3 (1.9)

2 (1.3)

6 (3.9)

6 (3.9)

0 (0.0)

0 (0.0)

12 (7.8)

18 (11.7)

0 (0.0)

0 (0.0)

0 (0.0)

2 (1.3)

2 (1.3)

1 (0.6)

10 (6.5)

5 (3.2)

36 (23.5)

52 (33.9)

Attitudes,
Practices
Attitudes,
Knowledge,
Practices
Policy
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Table 2 presents all the studies included for the qualitative synthesis. The first author,
year of publication, location where the study was conducted, factor assessed in the study,
primary focus of the study, study design or method of data collection, primary (relevant)
conclusion drawn and the corresponding reference is included in the table.
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Table 2: Extraction Table: Details of the studies included for qualitative synthesis

Number

Author

Year

Location

Factor

Focus of
study

Study Design
/ Method

1.

Adams

2016

US

Practice

Prescriptive
authority

Descriptive

2.

Akers

2017

Policy

Naloxone

3.

Alcorn
AlShatnawi

2014

Washingt
on State
US

Policy

Naloxone

Intervention
study
Summary

2016

US

Attitude

Students

Summary

5.

Andrews

2013

New
Jersey

Policy

Roles

Intervention
study

6.

Babcock

2017

Policy

Naloxone

Commentary

-

7.

Bachyrycz

2017

Policy

Naloxone

Secondary
database

8.

Bailey

2014

US

Practice

Naloxone

Interview

9.

Bakhireva

2017

New
Mexico

Practice

Naloxone

10.
11.

Baldwin
Baldwin

2009
1998

Policy
Policy

Education
Roles

12.

Blake

2009

Practice

MTM

Patients at risk of opioid overdose feel comfortable asking for
naloxone kits from a pharmacist
Pharmacists can play a role in contacting providers, provision
of products, education of patients and providers, and
dissemination of information.
Need for intervention focused on pharmacists' concerns. Must
include education to multiple audiences, and address
provider-level, system-level, and society-level barriers.
Pharmacists interested in and open to receiving education and
training for implementation of MTMS.

4.

41

West
Virginia
New
Mexico

US
US
West
Virginia

13.

Blumenthal

2002

US

14.

Bratberg

2015

US

Attitude
&
Knowledg
e
Policy

Focus group,
electronic
survey
Commentary
Summary
Mailed
survey

Primary Conclusion
2 categories of current pharmacist prescriptive authority:
collaborative prescribing and autonomous prescribing.
Take-home naloxone program successfully implemented in
community pharmacies.
Significant proportions of student pharmacists are at high risk
for SUD.
Pharmacist-led pain management consult service effectively
addressed patient's needs and modified drug-seeking
behaviors.

Ref
ere
nce
42
43
44
45

46

47

48

49

50

51
52
53

Students

Focus group,
interview

Pharmacy students had divided opinions about selling
syringes to patients. To prepare students pharmacy schools
should increase training about HIV/AIDS and SUD.

54

Roles

Commentary

-

55

15.

Brooks

2001

Utah

Policy

Roles

Mailed
survey

Pharmacists who attend SUD training programs perform more
chemical dependency activities than other pharmacists.
GIS mapping is valuable in monitoring the impact of
overdose prevention efforts, like effect of naloxonedistributing pharmacies on overdose rates,
A binary view of patients (over-users and abusers) not helpful
in understanding the issues of SUD.
Most pharmacy visits did not achieve a full score, illustrating
the need for improved awareness of how to assess and
manage patients requesting non-prescription analgesics
containing codeine.

16.

Burrell

2017

Pennsylva
nia

Policy

Roles

Descriptive

17.

Butler

2010

New
Zealand

Attitude

General

Interview

18.

Byrne

2018

Australia

Practice

Naloxone

Covert
simulation

Policy

Codeine

Focus group,
content
analysis

Difficulties are encountered by community pharmacists when
supplying codeine containing preparations in negotiating
patient awareness and compliance. Potential ways to deal with
misuse and dependence were discussed.

60

56

57

58

59

Carney

2016

20.

Carpenter

2017

US

Policy

Education

Content
analysis

Online naloxone training materials for pharmacists included
limited content on communication.

61

21.

Case

1998

Maine

Attitude
& Practice

Needle/Syri
nge
Exchange

Telephone
survey

Drug paraphernalia laws and pharmacy policies may have
prevented patients from purchasing syringes.

62

Interview

42

19.

Ireland,
South
Africa,
United
Kingdom

22.

Chaar

2013

Australia

Attitude

Opioid
substitution
therapy

23.

Chaar

2011

Australia

Practice

Barriers

Summary

24.

Chiarello

2016

US

Attitude
& Practice

Needle/Syri
nge
Exchange

Interview

25.

Chiarello

2015

US

Attitude

General

Interview

Barriers were stigma and fear, the nature of an opt-in scheme,
professionals' moral responsibilities, lack of awareness and
knowledge, and disproportionate distribution of clients and
lack of financial support.
Increased education along with favorable law and
organizational policies and decentralization of syringe
provision could increase access to clean needles and decrease
public health risks.
Pharmacists engage in medical and legal gatekeeping that
lend themselves to different identities, have different foci,
patterns of action, and orientations. Pharmacists' decisions
have effects on patients' access to care and contact with the
justice system.

63

64

65

66

26.

Clarke

2001

London

Attitude

27.

Cobaugh

2003

US

Policy

Needle/Syri
nge
Exchange
Roles

28.

Cobaugh

2014

US

Policy

Roles

Descriptive

29.

Cochran

2015

US

Attitude
& Practice

Roles

Electronic
survey

Screening

Intervention
evaluation,
content
analysis

Interview
Commentary

Cochran

2016

US

Policy

31.

Coffin

2002

New York
City

Attitude

32.

Coffin

2000

New York
City

Attitude

Attitude

Needle/Syri
nge
Exchange

Telephone
and in-person
interview
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30.

Needle/Syri
nge
Exchange
Needle/Syri
nge
Exchange

Telephone
survey
Telephone
survey

33.

Cooper

2010

Los
Angeles,
San
Francisco

34.

Crawford

2014

New York

Attitude

Needle/Syri
nge
Exchange

Intervention
study

35.

Davis

2017

US

Policy

Naloxone

Descriptive

36.

Deibert

2006

Washingt
on state

Attitude

Needle/Syri
nge
Exchange

Telephone
survey

37.

Deitz

2011

US

Policy

Evaluation

Intervention
study

Strong commitment by pharmacists to provide services
despite difficulties with programs.
Pharmacies should promote guidelines on opioid therapy
(pain management agreement plans, dispensing, and waste
disposal) and educational initiatives targeting patients and
providers.
Pharmacy-based screening and brief intervention should
consider practice location and pharmacists' interest in
addressing SUD issues.
Focus of screening efforts should be on pharmacists'
knowledge of MTM. Screening should be multidimensional to
enable patient-centered interventions that involve additional
disciplines.
Some pharmacists were registered for the program but did not
support selling syringes and others were supportive, but not
registered.
Need for tailored continuing education for pharmacists on
HIV/Hepatitis C prevention among SUD patients and to
address syringe disposal issues.
Non-prescription syringe sales were influenced by
pharmacists' perception. Some negative consequences of the
program were reported.
Structural interventions may be an optimal method to alter
attitudes towards highly stigmatized populations like SUD
patients.
Pharmacists are uniquely situated to reduce potential opioid
overdose risk. Awareness and utilization of state laws will
help.
Structural changes like policy reform and pharmacy outreach
may increase syringe access. Interventions should address
pharmacy policies and pharmacist attitudes and policies.
Multimedia Web-based programs could be a helpful addition
to substance misuse prevention services.

67

68

69

70

71

72

73

74

75

76

77

78
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38.

Deyo

2015

Oregon

Policy

Roles

Descriptive,
survey

39.

DiPaula

2015

US

Policy

MAT

Intervention
study

40.

Duvivier

2017

US

Policy

Roles

Intervention
study

41.

Edwards

2017

US

Attitude

Naloxone

Electronic
survey

42.

Farley

1999

Louisiana

Attitude

Needle/Syri
nge
Exchange

Mailed
survey

43.

Fass

2011

Florida

Attitude

PDMP

Mailed
survey

44.

Fedorova

2013

Russia

Attitude

45.

Fiellin

2014

US

Policy

46.

Fischer

2016

47.

Fleming

2001

48.

Fleming

2014

49.

Fleming

2013

North
America
Ireland &
England/
Wales

Needle/Syri
nge
Exchange
Buprenorphi
ne

Interview

Program improvements and health care system changes would
enable using and responding to PDMP information while
treating SUD.
Physician and pharmacist collaboration optimized care of
buprenorphine-maintained patients.
Pharmacist involvement in crucial initiatives like responsible
opioid prescribing, expanded access to MAT and naloxone,
and education shows their impact in SUD prevention and
treatment.
Pharmacists had positive attitudes toward screening and
endorsing naloxone kits and were willing to participate in the
program.
Pharmacists’ role in this area can be promoted through
education and/or training and development of referral systems
for patients.
Majority of pharmacists were in favor of implementing a
PDMP for controlled substances.
Training pharmacists will reduce negative attitudes. Including
syringes in the federal list of mandatory medical products sold
by pharmacies might increase access.

79

80

81

82

83

84

85

Summary

-

86

-

87

Policy

PDMP

Summary

Attitude
& Practice

Roles

Mailed
survey

Texas

Attitude
& Practice

Roles

Mailed
survey

Texas

Attitude

PDMP

Electronic
survey

Training programs, support systems, and adequate
remuneration must be established before pharmacists can
contribute entirely to prevention and treatment of SUD.
Older pharmacists with a BS. Pharm degree may be more
willing to provide counseling to patients based on their work
experience and additional CPE related to controlled
substances.
Prescriber request rates were higher than pharmacists and
online access for providers resulted in higher request rates per
100,000 population.

88

89

90

45

Interventions that address pharmacists’ attitude, subjective
norms, perceived behavioral control, and perceived obligation
may increase their intention to use PDMP data.
Rural community pharmacy practice has unique barriers to
deliver MMT services which may require a coordinated,
multi-pharmacy approach.
Developing medication purchasing cooperatives and
increasing the role of methadone maintenance treatment
programs in palliative care can help treat SUD patients.
Pharmacists were divided in their willingness to initiate
naloxone dispensing. Those who were confident in their
ability to identify overdose risks were more willing.
Targeting the individual and social environment through a
multilevel community-based intervention decreased high-risk
behavior, predominantly among African American patients.
Reducing the negative attitude towards patients and the legal
and cultural barriers, and strengthening the pharmacists' role
will help empower patients to use these programs.
Participation of community pharmacists in the prevention of
HIV among SUD patients is a viable policy, but several
problems need to be overcome before implementation.
To reduce patients' exposure to HIV, pharmacists should be
educated about HIV prevention and injection drug use and be
included in prevention programs, including legal pharmacy
NS sales.
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50.

Fleming

2014

Texas

Attitude

PDMP

Survey

51.

Fonseca

2017

North
America

Attitude

MAT

Interview

52.

Francoeur

2011

US

Policy

Roles

Descriptive

53.

Freeman

2017

Kentucky

Attitude

Naloxone

Electronic
survey

54.

Fuller

2007

New York
City

Attitude
& Practice

55.

Gabay

2016

US

Policy

56.

Ghaddar

2017

Lebanon

Attitude

57.

Glanz

1989

England
and Wales

Attitude

58.

Gleghorn

1998

Baltimore

Attitude

Needle/Syri
nge
Exchange

Telephone
survey

Attitude

Naloxone

Focus group

To overcome stigma of naloxone receipt, improved public
awareness of naloxone and pharmacist training regarding
naloxone and SUD are essential.

100

Attitude

PDMP

Electronic
survey

Current PDMP use with the prevalent systems had inadequate
impact on pharmacy practice.

101

Policy

Naloxone

Case study

-

102

59.

Green

2017

60.

Green

2013

61.

Green

2015

Massachu
setts and
Rhode
Island
Connectic
ut and
Rhode
Island
US

Needle/Syri
nge
Exchange
Naloxone
Needle/Syri
nge
Exchange
Needle/Syri
nge
Exchange

Intervention
study
Commentary
Interview
Mailed
survey

92

93

94

95
96

97

98

99
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62.

Hagemeier

2015

Tennessee

Attitude
and
Practice

63.

Hagemeier

2013

Rural
Appalachi
a

Attitude

General

Survey

64.

Hagemeier

2014

Tennessee

Attitude

Communicat
ion

Mailed
survey

65.

Hagemeier

2016

Appalachi
a

Attitude

Communicat
ion

Focus group

66.

Hagemeier

2017

Tennessee

Practice

Communicat
ion

Mailed
survey

67.
68.

Hall
Harvin

2011
2015

Australia
US

Policy
Policy

Roles
Roles

Commentary
Commentary

69.

Haug

2016

-

Attitude

Naloxone

Content
analysis

70.

Hemming

2016

US

Policy

Roles

Summary

71.

Hill

2012

Glasgow

Attitude

Naloxone

Survey

72.

Holdsworth

2015

US

Policy

General

Descriptive

73.

Hoppe

2014

US

Policy

Roles

Commentary

74.

Ibragimov

2017

Tajikistan

Attitude

Stigma

Interview

75.

Irwin

2012

United
Kingdom

Practice

Patient
interaction

Interview

MTM

Mailed
survey

Dissemination of treatment information, improvements SUD
specific continuous education and in communicative selfefficacy beliefs of pharmacists, are significantly associated
with increased provision of treatment information by
community pharmacists.
Pharmacists perceived a larger number of patients to be
abusing opioid pain relievers as compared with their
prescriber colleagues.
Community pharmacists are aware of SUD prevalence and
value their role in communicating with patients but believe
their ability to do so effectively is hindered by a lack of
confidence, training, and time.
Despite the perceived importance of engaging in SUD
communication, pharmacists reported that communication is
uncomfortable, diverse, multifactorial, and often avoided.
Community pharmacists are less confident in their ability to
communicate with patients about their SUD as compared to
non-SUD patients.
Pharmacist training and reform of naloxone administration
procedures are required to improve treatment outcomes and
reduce stigma.
There is strong support across stakeholders for the training
and supply of naloxone to patients and their family/friends.
A more formalized risk-based strategy focused upon ideal
patient education and required follow-up was proposed.
Local sociocultural context, religious beliefs, and social
conservatism may facilitate stigmatizing beliefs which shapes
pharmacists’ overall attitude.
The provision of training and support, especially to
inexperienced pharmacists could further reduce the negative
impact of patient aggression

103

104

105

106

107

108
109

110
111
112

113
114

115

116

76.

Jackson

2016

US

Policy

Roles

Descriptive

Approaching patient with empathy in a nonjudgmental
manner and by facilitating a patient’s knowledge of SUD
pharmacists can effectively participate in treatment.

117

Methadone

Intervention
study

Marginal change in attitude towards methadone programs;
substance misuse and knowledge of methadone among
pharmacists after structured educational training

118

77.

Jones

2005

UK

Attitude
&
Knowledg
e

78.

Jones

1998

Lothian

Attitude

Harm
reduction

Mailed
survey

Pharmacists are making a vital contribution to the
management of SUD but believe that there is scope for
improvements in service provision.

119

79.

Jones

2002

US

Policy

Needle/Syri
nge
Exchange

Summary

-

120

Opioid pain
relievers

Mailed
survey

47

80.

Joranson

2001

Wisconsin

Attitude
&
Knowledg
e

81.

Kim

2014

US

Policy

Education

Electronic
survey

82.

Kimberlin

1999

Florida

Policy

Education

Intervention
study

83.

Klein

2001

New York

Attitude

Needle/Syri
nge
Exchange

Mailed
survey

General

Mailed
survey

MTM

Telephone
survey

Screening

Focus group

84.

Lafferty

2006

Florida

85.

Lawrinson

2008

Australia

86.

Leong

2015

Manitoba

Attitude,
Knowledg
e&
Practice
Attitude,
Knowledg
e&
Practice
Practice

Pharmacists play a pivotal role in ensuring patient access to
SUD medications. Also, the improper knowledge and
negative attitudes of pharmacists could contribute to a failure
to dispense prescription pain relievers.
The extent of pharmacy experiential education in SUD is
limited and variable.
Pharmacists who received the intervention were more likely
to provide information and assess for problems than
pharmacists who didn’t receive it.
Most pharmacists supported the program and were willing to
participate.
Neurobiological basis for SUD, standards of care, and pain
management guidelines weren’t widely understood. Research
needed to determine the educational needs of pharmacists to
help them in detecting, preventing, and treating SUD.
Pharmacists were generally positively predisposed to
providing treatment. Embracing a shared-care approach
between general practitioners and pharmacists might help
provide better treatment.
Patient – level barriers, pharmacist – level barriers and system
– level barriers to effective practice were identified.

121

122

123

124

125

126

127

48

Interview,
focus group
Intervention
study

Need for improved systems for managing patients at risk for
medication misuse, diversion, and overdose like increased
access to electronic medical records and providing additional
continuing education.
Improved syringe disposal options, continuing education
programs, and clarification of existing laws and regulations
would encourage more pharmacists to sell syringes.
Behavioral discrimination occurred based on stigmatizing
attitudes and familiarity with patients may have a destigmatizing effect.
Expansion of services to treat SUD patients better were well
supported by the pharmacists.
A naloxone and harm reduction educational program across
all four years of the Pharm D curriculum was implemented.

General

Summary

-

Attitude
& Practice

General

Mailed
survey

Scotland

Attitude

General

Telephone
interview

1999

Scotland

Attitude

General

Mailed
survey

Matheson

2002

Scotland

Practice

General

Mailed
survey

98.

McCormic
k

2006

New
Zealand

Attitude

General

Mailed
survey

99.

McLaughli
n

2006

Ireland

Attitude

General

Focus group,
interview

100.

McVeigh

2017

Ireland

Attitude
& Practice

Needle/Syri
nge
Exchange

Telephone
interview

87.

Leong

2016

Canada

Attitude

-

88.

Lewis

2002

Colorado

Attitude

89.

Lim

2016

US

Policy

Needle/Syri
nge
Exchange
Naloxone

90.

Luty

2010

UK

Attitude

Stigma

91.

Mackridge

2010

England

Practice

General

92.

Maguire

2017

Ohio

Policy

Education

93.

Manchikant
i

2007

US

Policy

94.

Matheson

2016

Scotland

95.

Matheson

1999

96.

Matheson

97.

Electronic
survey
Interview
Summary
Survey

Pharmacist attitudes and service engagement improved over
time due to training. Communication with the wider SUD
team could be further advanced.
The active backing of local health boards, professional
authorization, further education and remuneration might
encourage pharmacists' participation in drug misuse services.
Correcting negative attitudes could encourage pharmacists to
provide services and enhance services in SUD treatment.
Community pharmacy involvement in SUD increased largely
in methadone dispensing and supervision. Pharmacists are
more proactive in counseling due to greater training.
Attitudes towards various aspects of service provision to SUD
patients are a complex concept.
Most of the pharmacists were unprepared and unwilling to
meet the challenge of caring for SUD patients, with many
displaying negative attitudes.
Increase of program coverage and targeted service delivery
within national care pathways for SUD is necessary.

128

129

130

131

132

133
134

135

136

137

138

139

140

141

Attitude
&
Knowledg
e

Students

Intervention
study

101.

Monteiro

2017

Rhode
Island

102.

Morrison

2000

New York
City

Practice

Stocking
opioids

Survey

103.

Myers

1998

Canada

Attitude

Needle/Syri
nge
Exchange

Mailed
survey

104.

Ngyuen

2017

Pacific
Northwest

Policy

Roles

Summary

Naloxone

Electronic
survey
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105.

Nielsen

2016

Australia

Attitude
&
Knowledg
e

106.

Nielsen

2007

Australia

Attitude
& Practice

Buprenorphi
ne

Survey

107.

Norwood

2016

Indiana

Attitude
& Practice

PDMP

Survey

108.

Norwood

2016

Indiana

Practice

PDMP

Intervention
study

109.
110.

Olivia
Owen

2017
2014

US
US

Policy
Policy

Naloxone
Roles

Descriptive
Commentary

111.

Palmer

2017

Kentucky

Policy

Naloxone

Intervention
study

112.

Pankonin

2008

Vietnam

Attitude

Needle/Syri
nge
Exchange

Interview

Workshop focused exclusively on opioid misuse can be used
to simulate the complex issues surrounding SUD and to
highlight the importance of inter-professional teams. It was
well received with high levels of satisfaction among students.
Pharmacies in predominantly nonwhite neighborhoods do not
stock sufficient medications to treat patients with severe pain
adequately.
While organizational, educational and policy changes may
enable program development, individual pharmacy and
pharmacist discretion is important.
Pharmacists contribute to SUD prevention by helping to
detect fraudulent prescriptions, staying current with existing
guidelines, and being aware of new safety programs.
Community pharmacists were willing to supply naloxone.
Low levels of knowledge about naloxone pharmacology and
administration highlight the importance of training
pharmacists about overdose prevention.
Pharmacists' perceptions of issues related to buprenorphine
affected attitudes towards patients and the program. They
believed that a significant level of diversion was occurring.
Use of PDMP programs were based on number of reported
barriers and overall concern about the prevalence of SUD in
the community.
Integration of PDMPs in pharmacy practice may improve a
pharmacist's ability to make informed clinical decisions and
use professional judgment to prevent drug abuse.
The program was successful as part of a health care system.
The swift organization of the training program to a wide
variety of pharmacists resulted in a considerable number of
naloxone-certified pharmacists.
Pharmacies contributed a significant proportion of the total
syringe supply to patients. They could be an effective vehicle
for increasing harm reduction services with enough support.

142

143

144

145

146

147

148

149

150
151

152

153

Parsons

2009

US

Policy

Needle/Syri
nge
Exchange

Summary

114.

Penm

2017

Ohio

Policy

General

Intervention
study

115.

Peterson

2007

Australia

Attitude

116.

Peterson

1999

Australia

Policy

117.

Philbin

2009

Mexico

Attitude

118.
119.

Price
Pricolo

2017
2017

US
Australia

Policy
Attitude

Harm
minimizatio
n
Roles
Needle/Syri
nge
Exchange
Roles
Naloxone

120.

Raisch

2005

US

Attitude

Naloxone

121.

Rich

2002

Rhode
Island

Attitude

Needle/Syri
nge
Exchange

122.

Rivera

2010

New York
City

Practice

123.

Roberts

2007

Glasgow

Attitude

124.

Roberts

1998

Glasgow

Policy

Needle/Syri
nge
Exchange
Needle/Syri
nge
Exchange
Roles

125.

Robertson

2015

Scotland

Policy

Roles

Mailed
survey

126.

Rose

2014

San
Francisco

Attitude
& Practice

Needle/Syri
nge
Exchange

Interview

50

113.

Mailed
survey
Commentary
Interview
Commentary
Summary
Survey,
interview
Survey

Survey
Mailed
survey
Summary

Pharmacists were recognized as a vital component of the state
strategy to addressing SUD by promoting responsible
prescribing and adopting prevention practices.
Improving the number and expertise of health professionals,
and providing adequate support for them, would address some
of the problems of harm minimization strategies.
Only half of the pharmacists believed these could be feasibly
implemented, citing barriers involving religion, police, and
lack of political will, public awareness, and funding.
The majority of pharmacists voiced positive attitudes and
perceptions regarding patients treated for SUD.
There was high level of support for nonprescription syringe
sales to patients. The correlation between the willingness to
sell non-prescription syringes to patients and their beliefs
suggested that educational interventions might encourage
pharmacists to participate in these programs.
Pharmacists were a frequent source of nonprescription
counseling for their patients They may be amenable to
providing relevant counseling services to patients.
Pharmacists were willing to participate in the program due to
recognition of an acute clinical need, rather than potential
financial gain.
Pharmacist care for SUD patients has evolved from
medication supply to a more clinical approach that included
actively monitoring patients, managing their minor ailments
and being engaged with the wider care team.
Pharmacists wanted the opportunity to broaden their role as
critical partners in public health matters related to injection
drug use through these programs.
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Pharmacies were selling nonprescription syringes to
individuals perceived to be IDUs with no major problems.
Pharmacists do not feel integrated enough in the network of
care to drug misusers and ask for more training and better
recognition of their role.
The accessibility of naloxone dispensing at pharmacies,
patient education, and safe drug disposal kiosks are crucial
prevention initiatives to address the opioid epidemic and
reduce the burden of opioid overdose.
A national controlled substance dispensing reporting system
that uses existing PBM networks would be considerably more
effective than the existing options.
Service provision was positively associated with confidence
in both, knowledge about HIV and counseling patients
regarding drug misuse.
Attending the course had the effect of increasing knowledge
of HIV/AIDS and increasing confidence in counselling SUD
patients.
More communication between providers and the community
pharmacists, further training, new forms of service provision,
and greater value of their role were suggested.
Community pharmacy play an important role in delivering
treatment, including prescribing services, to SUD patients.
There is unexploited capacity and moderate support for newer
roles of pharmacists.
PDMP can be an issue for pharmacists and it can cause
disruption to their work.
Pharmacists who had insufficient confidence in
communication with prescribers and who were fearful of
problems with a prescriber, reported that they rarely referred
to a prescriber.
Students would be more comfortable providing opioid
substitution treatment if greater education and training were
available.
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Access to sterile syringes through nonprescription sales was
strong. Although almost half of the pharmacists reported
stocking and selling naloxone to prevent opioid overdose
deaths, there is much room for improvement in access and
training among pharmacy staff members.
Patients’ access to sterile syringes from pharmacies would be
increased by providing pharmacists with professional
education programs and removing or modifying the restrictive
Board of Pharmacy regulation governing syringe sales.
Tailored educational material can help in regulating the
pharmacists' fear and strengthen the benefits of over-thecounter naloxone use.
Pharmacist who had patient experience were more positive
about dispensing treatment and less worried about safety,
diversion and patients’ impact on the pharmacy’s public
image.
There were no formal or legislative obstacles for providing
harm reduction services at pharmacies. Addressing negative
attitudes through educational courses involving pharmacists
willing to be public health educators can increase access.
Online training is an appropriate and economical method of
improving pharmacists' clinical skills
Community pharmacists are very accessible and in an ideal
position to provide services to SUD patients. However,
pharmacists require additional support in the form of better
health system integration, as well as remuneration models.
Some problems were encountered in implementing the harm
minimization model, but these may be alleviated by further
training and greater collaborative working by pharmacists.
Pharmacists and pharmacy student respondents
overwhelmingly felt that educational preparation in this area
is important and lacking in some areas.
US state alcohol and drug agencies demonstrated a robust
response to the opioid crisis. They have followed and
expanded on a range of evidence-based initiatives aimed at
the opioid crisis.
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Particular attention should be focused upon considering
number of clients per pharmacy and improving professional
communication between pharmacists and prescribers.
Policies to incorporate pharmacists as active partners in HIV
prevention should promote the sale of syringes without a
prescription to patients as an acceptable public health practice.
Individual experiences of pharmacists influenced overall
perceptions, pharmacists differentiated between SUD patients
and others, some pharmacists demonstrated an understanding
of the importance of sterile syringes.
Most pharmacists supported the idea of a pharmacy-based
naloxone intervention. But several barriers were identified,
including misinformation about naloxone, interpersonal
relationships with patients, and costs of such an intervention.
Health systems should build upon the willingness of
pharmacists in order to address the health needs of SUD
patients.
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IV] Attitudes
1) General
Of the 153 papers included for qualitative synthesis, 57 (37.2%) papers discussed
only attitudes of pharmacists towards SUD. Almost half of them (25; 13.7% of total)
discussed general attitudes towards SUD and patients misusing or abusing drugs. Overall
positive attitudes were reported in all papers but 20% or less of every sample had
negative attitudes such as perceiving patients as exhibiting illegal behaviors, stigma, fear
and discrimination, or unfavorable opinion of harm minimization strategies in each study.
Generally, pharmacists saw themselves as both medical and legal gatekeepers when
treating patients and made decisions accordingly, which would ultimately have
consequences on the treatment provided to the patient. 66 Pharmacists in turn saw patients
as ‘over users’ or ‘abusers’ and had more favorable attitudes towards providing treatment
or harm reduction strategies to ‘over users’.58 However, a study by Chaar et al noted that
“positive attitudes, functional relationships with patients/stakeholders, professional
satisfaction and financial rewards were found to motivate pharmacists to provide services
for these patients.”63(p426) Also, pharmacists perceived the prevalence of SUD to be much
higher than prescribers suggesting a more serious attitude towards the problem, even
though their perceived self-efficacy to provide treatment to this population was low. 104
Familiarity with the patient, ease of access to medical history information and to the
prescribing physician were related to better attitudes and greater perceived selfefficacy.128 A study conducted in Scotland also reported that pharmacists are motivated to
provide services to this population by being conscious of the needs of the community,
having a desire to reduce the extent of diseases like HIV and hepatitis C infection, and to
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expand their professional services.136 Another study conducted by the same authors
reported that attitudes were associated with the practice site, gender, and number of years
registered as a pharmacist. On controlling these factors, attitude was found to be an
independent predictor of whether needles/syringes were sold. 137 A study by McKormick
et al characterized the overall attitude of pharmacists by evaluating attitudes towards four
principal factors that shape the general attitude, namely- “the general results of
dispensing methadone to opioid misusers (outcomes of treatment); the effect of opioiddependent clients on a pharmacy (pharmacy factors); reducing harm associated with drug
use (harm reduction); and engaging with drug users (patient interaction).” 139 Attitudes
varied based on the factor being studied. Increased education and training for pharmacists
can be possible methods to improve attitudes towards SUD patients. 188

2) Needle exchange
Attitudes towards needle exchange or even non-prescription syringe sales covered
a wide array of positive and negative in all the studies. A study conducted in 2001 by
Clarke et al, reported that pharmacy-based needle exchange programs were appreciated
by users and the chief source of their injecting equipment. Differences in opinions about
such programs between pharmacists and patients were related to the extent of privacy in
the transaction. Although pharmacists reported difficulties with these practices,
pharmacists also showed a high level of commitment towards providing needle or syringe
exchange.67 A study conducted in Baltimore reported that while most pharmacists (87%)
were aware of the needle exchange program, 78.3% also embraced the program.
However, only 67.4% supported selling non-prescription needles and syringes in
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pharmacies, indicating more favorable attitudes towards needle/syringe exchange than
selling them without prescriptions.99 This was also seen in a study conducted in Denver,
where only 50% of the surveyed pharmacists supported non-prescription syringe sales but
everyone supported syringe exchange.129 The hypothesis that attitudes towards harm
reduction strategies would be more positive in large metropolitan areas did not hold true.
Implementation of the Expanded Syringe Access Demonstration Program (ESAP) that
permitted selling syringes without a prescription helped improve attitudes of pharmacists
in studies conducted in New York.72 However, a survey conducted before
implementation of the program reported that of the 4392 licensed pharmacies, 139
(15.9%) indicated that they would definitely not participate in the program and 7.4% left
this question unanswered.124 On the other hand, many pharmacies mandated proof of a
medical condition (80% in Los Angeles[LA] and 30% in San Francisco [SF]). Some also
refused non- prescription syringe sales if the customer was a suspected injection drug
user (74% in LA, 33% in SF). However, the authors also reported that the odds of an
overall positive attitude were significantly higher among pharmacists who believed
syringe access was important for preventing HIV among patients (AOR = 2.95; 95% CI =
1.10-7.92).74 Additionally, a proposed intervention such as offering medical or social
service referrals during syringe sale itself to patients improved attitudes of pharmacists
towards the practice. The improved attitudes were specific towards the negative
community factors of this harm reduction strategy like improper syringe disposal,
loitering, increased illegal drug use that may occur.75 A study reported that the most
frequently quoted reason for not selling needles or syringes was fear of increasing drug
use due to their sale. However, many pharmacists also reported that they would in fact
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conduct a sale if the patient had a referral from an support agency or clinic. 83 Other
reported reasons were, incorrectly disposed syringes, fears about staff and customer
safety, and corporate concerns.97 Staff safety was the foremost concern in an international
study while remuneration was the smallest concern but pharmacists had overall positive
attitudes.144 A study in Mexico evaluated attitudes towards needle exchange programs
(NEPs), syringe vending machines, structural barriers, and safer injection facilities. They
also asked for suggestions for implementation of these programs from the pharmacists.
Of these interventions, NEPs were considered the most suitable (75%); however, only
half the surveyed sample believed these could be practicably implemented. The
pharmacists mentioned barriers involving religion, law enforcement agencies, lack of
public awareness and funding sources, and lack of political resolve to implement the
program.158 Although administrative, educational, and policy reforms may aid expansion
of such programs, the attitudes of individual pharmacies and pharmacists are essential for
effective implementation of harm minimization strategies like needle or syringe
exchange.144

3) Naloxone
Attitudes towards naloxone were generally more positive than other harm
reduction strategies. Pharmacy standing dispensing orders for naloxone and the
regulations regarding dispensing naloxone to friends/family of patients and first
responders are controversial topics and studies measured attitudes of pharmacists towards
this. One study reported that the majority of the pharmacists surveyed were of the opinion
that the supply of naloxone to patients and their caregivers was a good policy and would
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contribute towards decreasing deaths due to drug overdose. However, the pharmacists
also stated that this supply should be made available only after suitable training on
resuscitation techniques and administration of naloxone was provided to the patients and
caregivers.112 A focus group study by Green et al regarding pharmacists attitudes towards
naloxone reported four themes: “consumer fear of future consequences if requesting
naloxone; pharmacists' concerns about practice logistics related to naloxone; differing
perceptions of how opioid safety is addressed in the pharmacy; and solutions to
addressing these barriers.”100 The study also compared the opinions of the patients across
different pharmacies and found that they differed in awareness of naloxone and
availability at pharmacies. However, all patients expressed support for the pharmacist's
role in the provision of naloxone. They also preferred a universal dispensing of naloxone
based on clear criteria.100 This shows that both pharmacists and patients have positive
attitudes towards naloxone distribution. Studies also assessed attitudes towards take home
naloxone (THN) kits. A study reported that of the total sample 79.8% of respondents
(pharmacists) strongly agreed or agreed that pharmacists should be recommending THN
kits. Pharmacists working in areas with larger populations and full-time pharmacists were
more likely to agree with this statement. Furthermore, 60.6% of pharmacists and
pharmacists who had work experience for less than or equal to 15 years were more
willing to participate in the THN program. Additionally, lack of time and education about
the program were the most commonly stated barriers to implementation of the THN
program as perceived by the pharmacists.82 This demonstrates an overall positive attitude
towards the THN program. Some studies however, also reported negative attitudes; for
example, a study reported that only some (20.4%) of the surveyed community
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pharmacists felt comfortable selling naloxone without a prescription (i.e. on the basis of a
standing order). The authors also proposed that specialized educational materials
designed for pharmacists can help in reducing the pharmacists' fears and stress the
benefits of over-the-counter naloxone dispensing. 182 Generally, pharmacies support
naloxone provision to patients and care-givers using standing orders. However, there may
be other concerns like stigma of receiving naloxone. Improving public awareness of
naloxone and training pharmacists about naloxone and addiction may help to reduce the
concerns that patients have to face. Pharmacists could also offer naloxone through a
universal opt-out strategy which the patients favor. This strategy is where all patients
meeting specific evidence-based criteria are offered naloxone and there is no place for
discrimination, leading to decreased chances of pharmacist attitudes affecting the service.
Targeted or opt-in strategies where only patients assumed to be high risk or patients who
request it are offered naloxone have a greater chance of patients being refused naloxone
or unaware patients never benefitting from its use. 100

4) Others
Attitudes towards treatment for SUD were also reviewed. A study evaluating
attitudes of pharmacists towards medications reported that most pharmacists (77.5%)
were not highly concerned about theft or break-ins, which could be a barrier to store and
dispense medications. Most pharmacists (70%) also stated that they would be willing to
partake in opioid dependence treatment as the medications become available
commercially, indicating an overall positive attitude towards SUD patients and treatment.
The majority of respondents (85%) stated that SUD patients did not cause problems at
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their pharmacies. When asked about buprenorphine/naloxone (Suboxone®) specifically,
most respondents did not express increased concern regarding prescription forgery (75%)
or diversion (80%) of buprenorphine/naloxone as compared to their experiences in
administering other narcotic medications. Most pharmacists thus expressed positive
attitudes regarding buprenorphine/naloxone and the patients treated for SUD. 161 Another
study discussing methadone maintenance treatment (MMT) reported some pharmacistrelated barriers to providing MMT services which could be barriers towards providing
other treatments as well. These barriers included an increased workload leading to longer
operating hours, concerns about safety due to burglary, apprehensions about community
resistance, and availability of methadone training programs.92
Of the two studies that evaluated stigma specifically, one was a qualitative study
conducted in Tajikistan where main themes included the following: “the significance of
religion in defining attitudes towards drug use; labelling of patients, negative stereotypes
(SUD patients are prone to crime, violence, and irrational aggression; inflict harm to
families and society; are able to control drug use), emotions triggered by patients (fear,
sympathy) and discrimination against patients (rejection, isolation, ostracism, limiting
resources to patients).”115 The other study reported definite behavioral discrimination
based on stigmatizing attitudes towards patients and concluded that increased
acquaintance with these patients may have a de-stigmatizing effect. 131 It did not,
however, evaluate the practice characteristics of pharmacists to be able to conclude that
experience was a predictor of stigma. Although these studies do point towards a possible
relationship between greater years of experience in treating patients and lesser
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stigmatizing attitudes, further research is necessary to comprehensively establish this
relationship.

V] Knowledge
Only one study assessed exclusively knowledge of pharmacists and was an
evaluation of a training program on opioid substitution treatment. It reported
enhancements in the confidence and skills of pharmacists after the training program
which was established through both the quantitative and qualitative analyses. 185 Thus, the
study truly evaluated the knowledge of SUD treatments or the disorder in general among
pharmacists.

VI] Attitudes and Knowledge
Six studies looked at both attitudes and knowledge among pharmacists but the
focus of studies ranged from educational program evaluation, policy, naloxone or student
populations. One study evaluated the effect of an educational program and reported
minimal change in attitude towards methadone programs, substance abuse in general, and
knowledge of methadone among pharmacists after a structured educational training
program in this area.118 This finding points towards a need to include training as part of
the curriculum in pharmacy schools itself, since attitudes and knowledge are more easily
affected at a younger age. Subsequent training programs like these would then act as addon to the basic education. Another study evaluated attitudes towards and knowledge of
policies in SUD treatments and harm minimization strategies among pharmacists and
found that not all pharmacists knew what constitutes legitimate dispensing practices for
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controlled substances under federal or state regulations, especially in emergencies or for
patients with terminal illnesses like cancer. Also, many were unaware of the important
differences among addiction, physical dependence, and tolerance. Moreover, many
pharmacists did not view chronic prescribing or dispensing of opioids for longer periods
to chronic pain patients as a lawful and acceptable medical practice. This was particularly
true when the patient had a history of opioid use disorder, pointing towards a stigmatizing
attitude by pharmacists towards SUD patients that would affect their practice. 121 A study
that assessed attitudes and knowledge of naloxone among pharmacists reported that they
were willing to receive training about naloxone (n = 479, 80.5%) and provide naloxone
with a prescription (n = 537, 90.3%) but fewer (n = 234, 40.8%) were willing to supply
naloxone without the prescription, negating the use of harm reduction strategy of
standing orders. Also, positive attitudes towards harm reduction in general were related to
a higher disposition to supply naloxone with a prescription (OR = 1.15, 95% CI = 1.111.19) as well as over-the-counter (OR = 1.13, 95% CI = 1.09-1.17). Moreover,
pharmacists were rarely confident that they could identify patients with SUD (n = 203,
34.1%) and counsel them on overdose and naloxone use (n = 190, 31.9%), indicating low
perceived self-efficacy. On evaluating their knowledge, pharmacists seemed to fare
poorly with mean naloxone knowledge scores of 1.8 out of 5. The study also asked the
pharmacists for their negative attitudes towards naloxone provision and more than half of
the sample identified lack of time, training, reimbursement, and especially lack of
knowledge, thus establishing a relationship between attitudes and knowledge. 146 Two of
the three studies assessing student knowledge were related to evaluation of the
curriculum and an educational workshop.54,142 The third study assessed student
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knowledge regarding opioid substitution therapy (OST) and reported that the average
scores on the knowledge questions were 3.7, 4.2 and 4.2 out of 8 for inexperienced,
indirectly experienced (worked at a site that provided OST but did not practice
themselves) and directly experienced students respectively. Overall, respondents showed
a positive attitude towards the OST program, but only 33% of respondents said they
would be comfortable providing OST as a new graduate. 179 This indicates that providing
training as part of the curriculum does not completely enable new pharmacists to practice
in SUD treatment; further experience or experiential education may be necessary.
Overall, only one of the studies evaluated the relationship between attitudes and
knowledge levels and if one predicted the other. Further research in this area is necessary.

VII] Practices
Papers assessed pharmacist practices relating to naloxone, PDMP programs,
MTM services, and general roles. A study found that 33% of the sampled pharmacists
dispense naloxone in a community-pharmacy setting, and 67% within an outpatient
clinic-based location, signifying that the majority (90%) of the sampled pharmacists
dispense naloxone. 49 The main barriers to not dispensing naloxone were identified as
out-of-pocket costs for patients; time constraints for pharmacists; and insufficient
reimbursement for pharmacists. On the other hand, the study also identified the main
facilitators as increased awareness among patients and family members about the need
for naloxone, amplified consciousness of the general public, and additional training for
pharmacists on how to counsel high-risk patients about naloxone. 50 With respect to
MTM services, a survey reported that pharmacists were not only comfortable in
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providing MTM services, but were also likely to use services that aid in the development
of MTM services and disease-state management. Moreover, they had a positive view of
the value of such services to patients, but reported that lack of time tended to be a barrier
to providing these services.53 With regards to syringe/needle exchange a study conducted
in a Swiss region reported that pharmacists do not feel sufficiently assimilated in the
network of care that is available to SUD patients like physicians, treatment clinics, and
other facilities. The pharmacists identified a need for additional training and improved
recognition of their role within this network.170 Another study reported that factors
associated with non-prescription sales of syringes or needles included the resulting long
hours of operation, the level of experience with and interest in harm reduction activities,
and the geographical location of the practice site (presence in areas with high SUD
prevalence). Interestingly, although access to non-prescription sale of sterile syringes was
easy due to availability of sites in most geographical areas, access to naloxone was
limited. The surveyed pharmacists expressed interest in naloxone education to understand
the benefits, applications as well as the needs for effective distribution. 180 This shows that
although, barriers to practice exist, the pharmacists are motivated to improve their roles
in distributing naloxone as a harm reduction strategy. In general, a study evaluating how
pharmacists treat SUD patients concluded that community pharmacists were less
confident in their ability to communicate with patients about SUD as compared to nonSUD scenarios.107 This is an important finding as it points towards a barrier that exists
when dealing with SUD patients in general and not just a specific treatment or harm
minimization strategy. Therefore, increasing their comfort level and confidence to treat
SUD patients would help improve their practices which can be achieved by increasing

64

their knowledge and improving their attitudes towards SUD and patients with SUD.
Additional research is required to definitely demonstrate a relationship between these
factors.

VIII] Attitudes and Practices
Some studies discussed both attitudes and practices and evaluated a relationship
between them. Specific practices like screening, counseling, syringe exchange and MTM
services were discussed. One study reported that pharmacists, who expressed interest in
being directly involved in screening and in projects that developed brief interventions for
patients with SUD were most likely to report current screening. Pharmacists who
reported currently screening for SUD and who reported wanting to improve the health
and quality of life of patients who misuse or abuse prescription opioids were most likely
to currently counsel patients while screening them. 70 A study evaluated the pharmacist’s
attitude towards and use of a PDMP program and awareness of prescription drug abuse in
general and found that they used the PDMP program more if they were highly concerned
about the high SUD prevalence in the community. 148 A study evaluating counseling and
PDMP roles of pharmacists concluded that older pharmacists with a BS in Pharmacy
degree may be more disposed to provide counseling to patients with SUD, probably due
to their longer work experience and additional CE related to SUD that they might have
received over the years.89 In contrast, another study reported that there was evidence that
the longer the respondent had been a community pharmacist, the greater the negatively
stigmatizing attitudes towards patients with SUD. However, those providing services to
these patients had more positive attitudes towards persons with HIV and drug misusers in
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general when compared to non-providers.173 This suggests that experience with treating
patients with SUD and not necessarily the number of years of community pharmacy
experience is a predictor of positive attitudes towards patients with SUD. Another longterm study that included surveying pharmacists at four different time points across a
twenty-year period, evaluated attitudes using a scale, and its relationship to offering of
clinical services. They found that the attitude score was consistently a significant
predictor in all four years for SUD treatment and providing needle exchange. 135 They also
found that attitudes improved over time with more experience and in turn improved their
practice indicating a symbiotic relationship between the two factors.

IX] Attitudes, Knowledge and Practices
There were only two studies that assessed all three factors, one of which was
conducted in the United States. This study evaluated a relationship between knowledge
and practices, while relating their knowledge levels back to their education. They found
that pharmacists (67.5%) described partaking in two hours or less of SUD education in
pharmacy school while 29.2% reported having received no SUD education whatsoever. It
was also reported that pharmacists who had greater amounts of SUD specific education
were more likely to correctly answer questions relating to the science of addiction and
substance abuse counseling. Furthermore, pharmacists who reported more education were
more confident about counseling and counseled patients more commonly. Surprisingly,
majority of pharmacists (53.7%) reported that they had never referred a patient to a
physician, a treatment clinic or other services throughout their career. 125 Although, the
paper assessed knowledge and practices, attitudes towards SUD were not sufficiently
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evaluated. The only item that appeared to address attitudes asked respondents how they
perceived patients and their role in treating SUD. The largest number (48.9%) believed
their role was both (healthcare provider and police) followed by pharmacists who
reported that they perceived themselves as healthcare providers (44.1%). Very few
(6.4%) perceived themselves only as police. Moreover, pharmacists were also asked how
patients should be treated; as patients with brain disorders, as people with illegal
behaviors, or as both. The majority of the pharmacists (71.3%) answered as both. 125 This
indicates a conflicted attitude towards patients with SUD and may lead to further
stigmatizing behaviors.
The second study was focused on attitudes and knowledge towards a single role:
opioid substitution treatment in a sample of Australian pharmacists. Pharmacists showed
high levels of support for the program and most (98%) intended to provide and continue
to provide the treatment. Sixty-four per cent of all pharmacists indicated that they were
willing to handle additional clients. This finding was significantly higher (90%) among
rural pharmacists. However, no other roles of the pharmacist were evaluated. 126

X] Policy
Papers mostly discussed general policy changes, with naloxone and syringe
exchange being the focus of most studies, followed by policies concerning specific roles
of the pharmacist like screening, MTM services, and PDMP programs. A study
discussing implementation of a take home naloxone program identified many issues that
need to be addressed including selecting the appropriate product for the patient,
implementing collaborative practice agreements, providing training materials to
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pharmacists, handling both patient and provider expectations seamlessly, increasing
partnerships among different stakeholders, and finally the perception of the entire
community with regards to the program.43 Another study evaluating online naloxone
training materials for pharmacists following standing orders found that the materials had
limited content on how to communicate with patients and caregivers. 61 This demonstrates
that policy changes need follow-up to ensure that pharmacists are provided with adequate
support for effective implementation of the policy. Policy changes at the individual
pharmacy level can also help improve SUD treatment. One study evaluated
implementation of a pain management program by pharmacists for SUD patients which
effectively addressed patient's needs while also succeeding in modifying drug-seeking
behaviors of the patients. A significant decrease in drug usage was noted during the
program's pilot testing period and this change was also persistent over time. 46 Another
study evaluated the development of a screening framework called the ADAPT-ITT model
(a model for adapting evidence-based behavioral interventions to new populations in
varied settings) that incorporated screening, intervention, prevention, and referral to
treatment. The authors concluded that screening efforts in the model benefit most from
pharmacists' knowledge of treatment medications. It was also noted that screening as a
practice was most efficient when it was multidimensional (including all healthcare
providers and in depth screening for all types of SUD) and enabled patient-centered
interventions.71
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XI] Summary of Review
Overall, the systematic literature review identified large gaps in the research
conducted with the community pharmacist and substance use disorders. Although,
attitudes were sufficiently evaluated, attitudes towards treatment like buprenorphine and
naltrexone were not adequately assessed. Stigma, which is the biggest factor of overall
attitude, was not evaluated adequately. There was a significant lack in studies assessing
knowledge of the pharmacists. Practices were evaluated in some studies but important
roles like screening and patient monitoring were not measured. Very few studies
evaluated more than one of the three factors and even fewer established a relationship
between the two factors. Only one US study evaluated all factors but only descriptively.
This review indicates a need for a study that assesses attitudes, especially stigma, in depth
knowledge of treatments and their practice in terms of all possible roles of the
pharmacist. There is also a need to assess the relationship between the factors and
evaluate the predictors of these factors.

69

Chapter 3
METHODOLOGY
This chapter describes the design of the study, population, the survey instrument in detail,
data collection and data analysis. Relevant appendices are attached at the end of this
document.

70

I] Study Design
The study was a cross-sectional descriptive study utilizing electronic survey
questionnaire methodology.

II] Study Population
The study population included a non-probability sample of n = 960 community
pharmacists from the tristate area (Pennsylvania, Ohio and West Virginia) who were
either part of the Giant Eagle Pharmacy chain (n = 910) or the alumni network of
Duquesne University School of Pharmacy (n = 50). The email with link was sent to
personal contacts at both sites who then sent it out to all pharmacists on their respective
email lists.

III] Instrument
The questionnaire (Appendix 1) included mostly closed-ended questions with one
open-ended question, with a mixture of items from a standardized instrument 195 as well as
investigator-designed items. Questions designed to collect respondent demographics were
included. The standardized instrument included in the survey and adapted for the study
goals was a generalized measure of stigma regarding SUD, which is available in the
public domain. The investigator-designed portion of the survey included items regarding
pharmacist knowledge, attitudes towards harm reduction strategies and practices
specifically for the screening of SUD as well as provision of medication therapy
management and clinical services for SUD. The open-ended question was designed to
collect information on views of the pharmacist regarding the current opioid epidemic
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which was included at the end of the survey. The questionnaire was divided into four
sections (followed by the open-ended question) as described in detail below:

1) Background Information
a) Demographics
Items regarding respondent age, gender, race, pharmacy degree and other degree
attainment (e.g. masters or PhD) with their respective year of graduation and board
certifications were included in this sub-section.
b) Practice Characteristics
This sub-section included items on number of years worked in the pharmacy,
average number of hours worked per week, number of pharmacists per shift, and
prescriptions filled per week. Items also included how often respondents dispense SUD
medication and the most frequently dispensed medication. Moreover, the sub-section
consisted of questions regarding practice location, patient socioeconomic class and
respondent position in the pharmacy (e.g. manager, owner). More than one choice could
be selected for pharmacy position.
c) Education
This sub-section was focused on the SUD related education/training of
respondents. Items asked respondents if they received SUD education in pharmacy
school. The pharmacists who reported that they received SUD education were asked if
the education they received was adequate to treat patients on a Likert scale from strongly
disagree to strongly agree. Pharmacists were also asked to report if they had CE by
marking CE in SUD and/or CE in naloxone. Finally, an item assessing their personal
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experience with SUD was included, framed to determine if their friends, family or they
had SUD, in order to reduce social desirability bias to an extent.

2) Knowledge
The second section on the questionnaire assessed responder knowledge on SUD
medication, with respect to their pharmacology, regulations, dispensing, and side effects.
The individual items (8) were developed using a medical newsletter 196 and expert
opinion. Items were designed as multiple choice or true/false questions. A personal
response item evaluating responders’ opinion on their current knowledge of SUD
medication was included in this section. To discourage respondents from looking up the
answers to the questions, instructions for this section also stated that it was not a test of
their individual knowledge but an aggregate assessment of pharmacist knowledge.

3) Practice
a) Services provided
This sub-section assessed several possible roles that pharmacists can provide in
the treatment of SUD patients. Primarily, an item asking respondents if they play any role
in providing services to SUD patients and if so, which particular duties were performed,
was included. The item evaluated roles such as dispensing medication, counseling,
private space provision, patient monitoring, providing information on side effects,
recommending therapy changes and referring patients to practitioners. Additionally,
items regarding frequency of provision of MTM services and clinical services for SUD
were included.
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b) Screening
Of all the services provided by pharmacists, the study aimed to focus on screening
for SUD. Therefore, items assessing the importance of screening for SUD in the
pharmacists’ opinion were developed. The individual items (9) were developed based on
the ‘red flags’197 released by the CDC. Each item had a Likert scale response set
consisting of: not important, somewhat important, very important and extremely
important.

4) Attitudes
a) Stigma
The standardized stigma scale called the Perceived Stigma of Substance Abuse
Scale (PSAS)195 was utilized after minor changes for our study objective. The editing
consisted of changing the statements from ‘Most people…’ to ‘Most pharmacists…’ and
only six of the eight original items were incorporated in the questionnaire. The items had
a response set of a Likert scale ranging from strongly disagree to strongly agree.
b) Harm reduction
The final sub-section consisted of items (4) assessing attitudes towards different
harm reduction strategies, such as non-prescription needle dispensing, naloxone,
suboxone and naltrexone dispensing. The items were designed as general statements
regarding pharmacists to establish social distance and reduce social desirability bias.
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5) Qualitative
The survey concluded with an open-ended question asking pharmacists’ views on
the current opioid epidemic. The question was designed to be general so as to illicit a
wide variety of responses and views that might not have been captured in the survey, and
also gave the opportunity to pharmacists to discuss issues that were not addressed in the
survey but might have been important.

IV] Data Collection
1) IRB Approval and Informed Consent
The study was approved by the Institutional Review Board (IRB) of Duquesne
University. The proposed study acquired an “exempt” according to the category reserved
for ‘Anonymous Surveys - No risk’ from the IRB on 03/02/2018. Along with the
questionnaire, the recruiting email (Appendix 2) was also submitted to the IRB for
verification. It was used to inform respondents of the IRB approval, the anonymous,
voluntary, and temporal (approximately 10-15 minutes) nature of the survey. As it was an
online survey, submission of the survey was considered as consent to participate in the
study and participants were informed of the same. No personal identifiers were collected
or stored and the survey data was password protected. To provide an incentive to
participate in the study the respondents were asked to provide their email in their
responses for an opportunity to win one of twenty Amazon gift certificates ($30 value)
based on a random drawing of all respondents.
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2) Pilot testing
The questionnaire was pilot tested by five community pharmacists for face and
content validity as well as any other expertise-based suggestions. The specific questions
used for pilot testing are included in Appendix 3. All relevant edits and comments were
included in the survey that was sent out.

3) Survey administration
The survey was administered using Qualtrics© (Provo, UT) via an email link. The
link was active from 03/09/2018 to 07/09/2018. The body of the email contained a brief
description of the survey and incentive information followed by the link to the survey.
The questionnaire was sent out in three different stages. Initially, the survey was
distributed to a subset of pharmacists who were Giant Eagle community pharmacists
(n=100) on 03/12/2018. This was followed by distribution of the link among Duquesne
alumni (n =50) on 03/14/2018. Finally, the email was sent out to the complete list of
Giant Eagle community pharmacists (n = 810) on 04/19/2018. Reminders were sent out
on 05/03/2018 and 06/22/2018.

V] Data analysis
1) Quantitative
The data from this study was analyzed using SPSS Statistics 21 (IBM Corp;
Armonk, NY). Descriptive statistics was generated to assess participant demographic,
practice, and educational characteristics, knowledge, practices, screening services, stigma
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and attitudes. Frequencies as number and percentage or means and standard deviations
are reported as applicable.
The knowledge questions (8) were also used as a scale with each correct response
receiving one point. Therefore, the highest knowledge scores a respondent may receive is
8. To assess the reliability of the scale, a Kuder-Richardson 20 (KR-20) correlation
coefficient was used as binary variables (1= correct, 0 = incorrect) were used in the scale
and the questions had varying difficulty levels.
Apart from frequencies of each duty performed in the practice question, a practice
scale was also developed. The pharmacists scored one point for each duty that they did
perform for a highest possible total of seven. To assess the reliability of the scale, a KR20 coefficient was used because of the presence of all binary variables in the scale (1 = if
they perform the duty, 0 = if they don’t perform the duty) and the duties had varying
importance in practice.
For the screening sub-section individual frequencies of all possible responses of
every item was assessed and a scale was developed as well. The scale was scored as 1=
not important, 2 = somewhat important, 3 = very important and 4 = extremely important.
The mean score and standard deviations of all items were assessed and a total mean and
standard deviation of all pharmacists on all items were calculated.
Individual frequencies of all possible responses of every item on the standardized
stigma scale were assessed. The stigma scale was developed where 1 = strongly disagree,
2 = disagree, 3 = agree and 4 = strongly agree. Mean responses with standard deviations
of all items were calculated. Finally, the mean score of all pharmacists on the stigma
scale from one to four where 1= highest stigma and 4 = least stigma was also reported.
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One item ‘most pharmacists think less...’ was reverse coded so that all items are
directionally aligned for this calculation. Reliability statistics were performed using the
response set of strongly disagree to strongly agree as a continuous scale.
With regards to the attitude statements, frequencies of every possible response on
each item were reported. An attitude scale was developed where 1= strongly disagree, 2 =
disagree, 3 = agree and 4 = strongly agree. Mean scores and standard deviations of
individual items were also reported. Finally, the mean score of all pharmacists on the
overall attitude scale is reported which could therefore range from one to four, where 1
was negative and 4 was positive attitude. The questions regarding buprenorphine and
naltrexone were reverse coded for this calculation. Reliability statistics were performed
using the response set of strongly disagree to strongly agree as a continuous scale.
Differences in knowledge, stigma and practice scores were stratified by specific
demographic variables such as, age (≥40 and <40), gender, degree attained (PharmD and
BS in Pharmacy), whether or not they had SUD education as part of their curriculum, and
personal experience with SUD. Pharmacists who did not wish to disclose whether or not
they had personal experience were not included in the analysis. Independent sample t
tests were performed at the 0.05 (α) significance level. The mean stigma scores and
standard deviations of each group were reported along with the t-values and
corresponding significance.
The following were calculated: mean differences in knowledge, stigma and
practice scores among pharmacy location groups (rural, suburban and urban), patient
socioeconomic levels (impoverished, low, middle and high income), frequency of MTM
services and clinical services, and their responses on the attitude questions. One-way
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ANOVA tests were performed. The mean practice scores and standard deviations of each
group were reported along with the F-values and corresponding significance.
Factors like knowledge, stigma and practice scores were correlated to practice
variables like number of years worked, number of hours worked per week, SUD
prescriptions dispensed per week, adequacy of SUD education and screening score.
Bivariate correlations were performed. Analysis also included building four regression
models to predict (1) knowledge levels specific to SUD, (2) engagement of pharmacists
in clinical services for SUD, (3) engagement of pharmacists in assessment for potential
prescription drug abuse (screening), and (4) level of stigma towards the patient.
A multiple linear regression analysis was conducted to predict knowledge scores.
The predictors planned to be included in the model were age, degree attained, SUD
education, personal experience, CE in SUD, gender, CE on naloxone, number of years
worked, SUD medication dispensing frequency and stigma mean scores. The VIF statistic
was used to check for multi-collinearity. Due to high correlations between the planned
predictor variables, age, degree attained and SUD education, these variables were
removed from the model. The assumptions for linear regression were evaluated before
running the model. Independence of observations was assessed using the Durbin-Watson
statistic. Normality of the model was evaluated by using the residual histogram and the
normal predicted probability (P-P) plot. Homoscedasticity of the model was observed by
using the scatterplot of the residuals. Linearity of data would be thus implied, if the above
assumptions were met.
An ordinal regression was carried out to predict practice or the frequency of
pharmacists offering clinical services to SUD patients. The variables included in the

79

model were stigma mean scores, knowledge mean scores, attitude mean scores, practice
scores, gender and personal experience. The assumptions of ordinal regression were
evaluated before conducting the analysis. Multi-collinearity was checked for by running a
multiple linear regression, following which age, degree attained, and SUD education
were removed from the model due to high correlations. Occurrence of proportional odds
was evaluated by the test of parallel lines.
A multiple linear regression model was planned to predict screening scores. The
predictors included in the model were age, degree attained, SUD education, personal
experience, gender, knowledge, number of years worked and stigma mean scores. The
VIF statistic was used to check for multi-collinearity. Due to significant correlations
between the originally planned predictor variables, age, degree attained, and SUD
education, these variables were removed from the model. The assumptions for linear
regression were evaluated before running the model. Independence of observations was
assessed using the Durbin-Watson statistic. Normality of the model was evaluated by
looking at the residual histogram and the normal predicted probability (P-P) plot. The
dependent variable or screening mean score was converted to its square root form
because it failed to meet this assumption. Homoscedasticity of the model was evaluated
by looking at the scatterplot of the residuals. Linearity of data would be thus implied, if
the model met the above assumptions.
A multiple linear regression model was planned to predict stigma scores.
However, the model failed the tests of assumptions of regression. As transformations did
not help produce a valid model, a new stigma scale was developed. In this scale only sum
of the individual responses was used instead of the means. From the questionnaire, the
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response scale was 1 = strongly disagree, 2 = disagree, 3 = agree and 4 = strongly agree
and there were six items in the stigma section. Therefore, stigma scores could range from
6 to 24, with 6 being highest stigma and 24 being least stigma. One item was recoded for
this calculation. Based on the frequency distribution of these scores three categories of
stigma (high, medium and low) were developed. Subsequently, an ordinal regression was
carried out to predict stigma scores. However, the originally planned predictor
combination failed the tests for parallel lines. Therefore, the research question was
changed with predictors like MTM services and screening scores added based on
previously found significant correlations. Based on literature, where pharmacy factors
like location site and patient socioeconomic class were found to be significantly
correlated with stigma, these were added to the model as well. Multi-collinearity was
checked by running a multiple linear regression, following which age, degree attained,
pharmacy location, knowledge scores and SUD education were removed from the model
due to high correlations. The variables finally included in the model were screening
scores, practice scores, patient socioeconomic class, MTM services, and CE in SUD. The
assumptions of ordinal regression were evaluated before conducting the analysis.
Occurrence of proportional odds was evaluated by the test of parallel lines.

2) Qualitative
Content analysis including axial analysis 198 on the obtained responses was
performed. Codes were developed based on an iterative process. The codebook
(Appendix 4) contained twenty codes that included themes such as overprescribing,
policy recommendations, education, and stigma. This was followed by axial analysis of
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protocols that established relationships between the codes. Axial analysis consisted of
identifying relationships between the identified themes and picking the most frequently
occurring relationships. These themes were then assessed to look at the corresponding
intervening codes, codes that are consequences of the theme, intervening codes and codes
that appear to be action strategies.
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Chapter 4
RESULTS
This chapter includes description of the response rate and tables consisting of the results
of the data analysis (Table 3 to Table 32). All tables are preceded by a short description
in which significant results have been mentioned and explained.
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I] Response rate
The survey was sent out to 960 community pharmacists and received 134
responses (partial and complete) leading to a response rate of 13.96% for the quantitative
survey. Of the 134 pharmacists who responded to the survey, 52 (38.81%) answered the
open-ended question. Fifty responses were usable and were included in the qualitative
analysis. Forty-three (32.08%) responses were received from the initial cohort of 100
Giant Eagle and 50 Duquesne University pharmacists. A total of 82 (61.19%) responses
were received after the email was sent out to the final list. The number of responses
received after the two reminders were 6 (4.47%) and 3 (2.24%) respectively.
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II] Descriptive
Table 3 presents self- reported demographic data. The average age of the respondents
was 38.3 years (SD = 10.69) with almost 62% of the respondents below 40 years of age.
The majorly of the respondents were female and Caucasian and had obtained the Pharm
D (vs the BS) degree. Only 20 (14.92%) respondents reported that they had obtained
other degrees apart from their pharmacy degrees, primarily consisting of Bachelor
degrees in various fields.
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Table 3: Demographics (n = 134)
Variable

Number (Percentage)

Age (years)
Less than 40#
40 and greater
Not answered^

83 (61.9)
49 (36.6)
2 (1.5)

Gender
Male
Female
Not answered^

50 (37.3)
82 (61.2)
2 (1.5)

Race
Caucasian
African American
Asian
American Indian
Hispanic
Pacific Islander
Other

121 (90.3)
3 (2.2)
5 (3.7)
0 (0.0)
1 (0.7)
0 (0.0)
2 (1.5)

Degree attained
Pharm D
BS Pharmacy
Not answered^

87 (64.9)
44 (32.8)
3 (2.2)

Other degrees
Masters
PhD
Other

3 (2.2)
2 (1.5)
15 (11.2)

Mean (Standard deviation)
38.30 (10.69)

# Age categories were arbitrary
^ Questions the responders viewed but chose not to answer.
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Table 4 presents data regarding self - reported practice characteristics of the pharmacists.
About 88% of the pharmacists answered the question regarding their work experience
and on average had worked for about 15 years. The same pharmacists reported that they
worked for about 37 hours per week and on average two to three pharmacists worked per
shift at their pharmacies. The number of prescriptions filled per week varied from as low
as 75 to as high 10,000 resulting in a mean of 2105.17 and a large standard deviation of
1262.24. This was due to the presence of a few outliers in the case of part-time workers
and one respondent with the high response, who probably worked in a large organization.
Invalid responses were from pharmacists who stated they work in call centers or float
among different pharmacies and responded “varies” or “not applicable”. Buprenorphinenaloxone (Suboxone®) was the most commonly dispensed SUD medication. The majority
of pharmacists reported that they dispensed SUD prescriptions ‘sometimes’ in any given
week. Practice location was primarily sub-urban and patients belonged to low and
middle-income socioeconomic classes according to the pharmacists. Respondents were
mostly full-time pharmacists and pharmacy managers.
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Table 4: Practice Characteristics (n = 134)
Variable

Number (Percentage)

Number of years worked
Responded
Not answered^
Missing$

118 (88.06)
2 (1.5)
14 (10.4)

Number of hours/week
Responded
Not answered^
Missing$

118 (88.06)
2 (1.5)
14 (10.4)

Pharmacists/shift
Responded
Not answered^
Missing$

118 (88.06)
2 (1.5)
14 (10.4)

Prescriptions filled /week
Valid responses
Not answered^
Missing$
Not applicable

116 (86.57)
2 (1.5)
14 (10.4)
2 (1.5)

SUD prescriptions/week
Never
Rarely
Sometimes
Frequently
Not answered^
Missing$

9 (6.7)
23 (17.2)
35 (26.1)
51 (38.1)
2 (1.5)
14 (10.4)

SUD Medication
Buprenorphine-naloxone
Buprenorphine
Naloxone
Naltrexone
Other
Not applicable
Not answered^
Missing$

55 (41.0)
33 (24.6)
12 (9.0)
6 (4.5)
3 (2.2)
2 (1.5)
9 (6.7)
14 (10.4)

Practice Location
Urban
Sub-urban
Rural
Not answered^
Missing$

26 (19.4)
71 (53.0)
21 (15.7)
2 (1.5)
14 (10.4)
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Mean

Standard Deviation

15.06

9.82

37.13

9.49

2.26

3.00

2105.17

1262.24

3.08#

0.97

Patient Socioeconomic
Class
Impoverished
Low
Middle
High
Not answered^
Missing$

7 (5.2)
51 (38.1)
51 (38.1)
6 (4.5)
5 (9.7)
14 (10.4)

Pharmacy Position@
Full time staff pharmacist
Part time staff pharmacist
Pharmacy Manager
Pharmacy Owner
Not answered^
Missing$

56 (41.8)
21 (15.7)
40 (29.9)
3 (2.2)
5 (3.7)
12 (9.0)

# Mean of all responses measured on a scale from 1 to 4 (where 1= Never, 2= Rarely, 3= Sometimes and 4=
Frequently)
^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
@ More than one choice could be selected for pharmacy position and so the frequencies do not add up to 134.
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Table 5 presents educational characteristics of pharmacists. A total of 71 pharmacists
(53%) reported that they received SUD education as part of their curriculum. The
majority (59.2%) of these pharmacists agreed that this education was adequate to treat
patients. With regards to CE, 73 (54.5%) and 91(67.9%) pharmacists reported that they
have had CE in SUD and naloxone respectively. Since, there was no option to choose if
they hadn’t received CE, no conclusion can be drawn on the responders who did not
choose either CE. Although a majority (64.2%) of pharmacists reported that they have no
personal experience with SUD, 22.4% reported that they did.
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Table 5: Educational Characteristics (n=134)
Variables

Number
(Percentage)

SUD Education
Yes
No
Not answered^
Missing$

71 (53.0)
48 (35.8)
1 (0.7)
14 (10.4)

Adequacy of SUD education (n =71)
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^

71 (53.0)
2 (2.8)
24 (33.8)
42 (59.2)
2 (2.8)
1 (1.4)

Continuous education
SUD
Naloxone

73 (54.5)
91 (67.9)

Personal experience
Yes
No
Prefer not to disclose
Not answered^
Missing$

30 (22.4)
86 (64.2)
2 (1.5)
1 (0.7)
15 (11.2)

Mean

2.63#

Standard Deviation

0.59

# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and
4 = Strongly agree).
^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
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Table 6 presents data on the questions in the knowledge section. Questions are listed
individually with frequencies of each possible response reported. Only three items did not
have a clear majority, namely- ‘-- is an opioid receptor antagonist’, ‘buprenorphine
potentiates opioids’ and ‘naltrexone started within 7 days…’ This shows that there wasn’t
consensus on these items unlike other items that were easier to answer.
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Table 6: Knowledge (Individual items) (n=134)
Item and responses

Number (Percentage)

--- is a Schedule III controlled substance.
Naloxone
Buprenorphine#
Naltrexone
Not sure
Not answered^
Missing$

4 (3.0)
100 (74.6)
2 (1.5)
2 (1.5)
1 (0.7)
25 (18.7)

--- is an opioid receptor antagonist and can reduce tolerance to opioids.
Naloxone
Buprenorphine
Naltrexone#
Not sure
Not answered^
Missing$

26 (19.4)
11 (8.2)
61 (45.5)
9 (6.7)
2 (1.5)
25 (18.7)

-- is the drug of choice for emergency treatment of opioid overdose.
Naloxone#
Buprenorphine
Naltrexone
Not sure
Not answered^
Missing$

102 (76.1)
0 (0.0)
6 (4.5)
0 (0.0)
1 (0.7)
25 (18.7)

Is a prescription required for dispensing naloxone in your state?
Yes
No#
Not sure
Not answered^
Missing$

16 (11.9)
90 (67.2)
2 (1.5)
1 (0.7)
25 (18.7)

Buprenorphine can be used to potentiate opioids.
True
False#
Not sure
Not answered^
Missing$

50 (37.3)
33 (24.6)
25 (28.7)
1 (0.7)
25 (18.7)

Naloxone can be administered orally.
True
False#
Not sure
Not answered^
Missing$

22 (16.4)
83 (61.9)
3 (2.2)
1 (0.7)
25 (18.7)

Opioid administration to a patient on naltrexone is an effective pain management
strategy.
True
False#
Not sure
Not answered^
Missing$

2 (1.5)
99 (73.9)
7 (5.2)
1 (0.7)
25 (18.7)
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Naltrexone can be started within 7 days of last opioid therapy
True
False#
Not sure
Not answered^
Missing$
^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
# Correct answers
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44 (32.8)
23 (17.2)
41 (30.6)
1 (0.7)
25 (18.7)

Table 7 presents the knowledge questions as a scale with frequencies of correct answers.
The total mean is the mean of all responders’ scores. ‘—is drug of choice for emergency…’
and ‘—is schedule III…’ were the questions with the highest frequency of correct answers
(76.1% and 74.6% respectively). In contrast, pharmacists fared poorly on naltrexone can
be started…’ and ‘buprenorphine can potentiate…’ with only 17.2% and 24.6% of correct
answers respectively. On the item assessing responders’ opinion on their current
knowledge level regarding SUD medication therapy, most pharmacists agreed that they
had good current knowledge.
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Table 7: Knowledge Scale (n = 134)
Item

Correct
Number
(Percentage)

I have good current knowledge on medication therapy for SUD
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$

3 (2.2)
14 (10.4)
79 (59.0)
12 (9.0)
1(0.7)
25 (18.7)

Q1. --- is a Schedule III controlled substance.

100 (74.6)

Q2. --- is an opioid receptor antagonist and can reduce tolerance to
opioids.

61 (45.5)

Q3. -- is the drug of choice for emergency treatment of opioid
overdose.

102 (76.1)

Q4. Is a prescription required for dispensing naloxone in your state?

90 (67.2)

Q5. Buprenorphine can be used to potentiate opioids.

33 (24.6)

Q6. Naloxone can be administered orally.

83 (61.9)

Q7. Opioid administration to a patient on naltrexone is an effective
pain management strategy.

99 (73.9)

Q8. Naltrexone can be started within 7 days of last opioid therapy.

23 (17.2)

Mean

Standard
Deviation

2.93#

0.59

5.52@

Total

1.20

# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4
= Strongly agree)
@ Mean knowledge score of all pharmacists on a scale of 0 to 8.
^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
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Table 8 presents reliability statistics of the knowledge scale. The KR-20 coefficient was
high (0.84) indicating that it is a reliable scale for this population. This result occurred
despite varying correlations from low (0.104) to high (0.759) among the individual items
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Table 8: Reliability Statistics of Knowledge Scale: Inter-correlation matrix (n =134)
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Q1

Q2

Q3

Q4

Q5

Q6

Q7

Q8

Q1

1.000

.464

.759

.615

.293

.567

.746

.174

Q2

.464

1.000

.477

.352

.104

.470

.441

.180

Q3

.759

.477

1.000

.615

.280

.606

.743

.162

Q4

.615

.352

.615

1.000

.141

.467

.633

.192

Q5

.293

.104

.280

.141

1.000

.234

.261

.153

Q6

.567

.470

.606

.467

.234

1.000

.514

.153

Q7

.746

.441

.743

.633

.261

.514

1.000

.226

Q8

.174

.180

.162

.192

.153

.153

.226

1.000

Standardized KR-20 coefficient: 0.84

Table 9 presents results of the practice section. There was almost an equal distribution
between respondents who played a role in SUD services and those who didn’t. The 56
(41.8%) pharmacists who played a role in SUD services were asked to specify which
duties they perform on the practice scale. The mean score on the practice scale (3.53) was
low. The table also reported how often pharmacists performed MTM services in general
and clinical services for SUD patients. On average, pharmacists reported that they rarely
performed both these services.
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Table 9: SUD related practice (n= 134)
Variable

Number
(Percentage)

Role in SUD services
Yes
No
Not answered^
Missing$

56 (41.8)
52 (38.8)
1 (0.7)
25 (18.7)

Duties/ Practice Scale
Dispensing medication
Counseling patients
Provision of private space
Patient monitoring/assisting self-monitoring
Advising about side effects
Recommending/advocating therapy changes
Referring patients to practitioners
Not answered^
Missing$

56 (41.8)
46 (34.3)
41 (30.6)
30 (22.4)
13 (9.7)
28 (20.9)
19 (14.2)
9 (6.7)
1 (0.7)
3 (2.2)

MTM services
Never
Rarely
Sometimes
Frequently
Not answered^
Missing$

31 (23.1)
25 (18.7)
29 (21.6)
17 (12.7)
1 (0.7)
31 (23.1)

Clinical services
Never
Rarely
Sometimes
Frequently
Not answered^
Missing$

33 (24.6)
52 (38.8)
14 (10.4)
2 (1.5)
2 (1.5)
31 (23.1)

Mean

Standard Deviation

3.53@

1.76

2.31#

1.08

1.85#

0.73

@ Mean practice score of all pharmacists on a scale of 0 to 7.
# Mean of all responses measured on a scale from 1 to 4 (where 1= Never, 2= Rarely, 3= Sometimes and 4=
Frequently)
^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
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Table 10 presents reliability statistics of the practice scale. The overall reliability of the
scale was not extremely high (KR-20 = 0.66). This was probably due to the negative
correlation of patient monitoring with dispensing and counseling duties.
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Table 10: Reliability Statistics of Practice Scale: Inter correlation matrix (n = 56)
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Dispensing
medication

Counseling
patients

Provision of
private space

Advising about
side effects

.108

Patient
monitoring/assisting
self-monitoring
-.037

.078

Recommending/
advocating
therapy changes
.059

Referring
patients to
practitioners
.176

Dispensing
medication

1.000

.625

Counseling patients

.625

1.000

.303

-.033

.262

.286

.231

Provision of private
space
Patient
monitoring/assisting
self-monitoring
Advising about side
effects
Recommending/adv
ocating therapy
changes
Referring patients
to practitioners

.108

.303

1.000

.234

.393

.178

.193

-.037

-.033

.234

1.000

.275

.214

.326

.078

.262

.393

.275

1.000

.312

.025

.059

.286

.178

.214

.312

1.000

.291

.176

.231

.193

.326

.025

.291

1.000

Standardized KR-20 coefficient = 0.66

Table 11 reports the results on the screening scale. Of the pharmacists who responded to
this section, most pharmacists reported that all the red flags were ‘extremely important’.
However, due to missing data the average response on all items individually tended
towards ‘very important’. Finally, the mean score of all pharmacists on the overall
screening scale (3.40) indicated that pharmacists are of the opinion that screening is very
important.
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Table 11: Screening scale (n =134)
Red Flag (RF)

Number
(Percentage)

RF 1. Repeatedly receiving "cocktailed" prescriptions
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$

0 (0.0)
9 (6.7)
38 (28.4)
51 (38.1)
5 (3.7)
31 (23.1)

RF 2. Failure of prescribers to individualize dosing strategies for patients
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$

3 (2.2)
20 (14.9)
42 (31.3)
33 (24.6)
5 (3.7)
31 (23.1)

RF 3. Receiving multiple prescriptions for the strongest/most addiction-prone
formulations
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$

0 (0.0)
9 (6.7)
37 (27.6)
52 (38.8)
5 (3.7)
31 (23.1)

RF 4. Requests for early refills from patients
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$

1 (0.7)
5 (3.7)
36 (26.9)
56 (41.8)
5 (3.7)
31 (23.1)

RF 5. Prescribers located far away from pharmacy sending prescription
requests
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$
RF 6. Receiving a large volume of prescriptions for controlled substances by
one particular physician
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$
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Mean

Standard
Deviation

3.43#

0.66

3.07#

0.82

3.44#

0.66

3.50#

0.65

3.50#

0.72

3.43#

0.76

1 (0.7)
10 (7.5)
26 (19.4)
61 (45.5)
5 (3.7)
31 (23.1)

1 (0.7)
13 (9.7)
27 (20.1)
57 (42.5)
5 (3.7)
31 (23.1)

RF 7. Patients travelling in groups to the pharmacy to pick up controlled
substances
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$
RF 8. Receiving requests for controlled substance prescriptions to be paid for
with cash
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$
RF 9. Prescribers verifying prescriptions as legitimate when contacted, but
without explanation other than their own directive
Not important
Somewhat important
Very important
Extremely important
Not answered^
Missing$
Total

3.59#

0.68

3.48#

0.65

3.36#

0.84

3.40@

0.49

1 (0.7)
7 (5.2)
22 (16.4)
65 (48.5)
8 (6.0)
31 (23.1)

0 (0.0)
8 (6.0)
35 (26.1)
55 (41.0)
5 (3.7)
31 (23.1)

3 (2.2)
14 (10.4)
26 (19.4)
55 (41.0)
5 (3.7)
31 (23.1)

^Not answered were questions the responders viewed but chose not to answer.
$ Missing were questions the responders did not view.
# Mean of all responses measured on a scale from 1 to 4 (where 1= Not important, 2= Somewhat important, 3= Very important
and 4= Extremely important)
@ Mean screening score of all pharmacists on a scale of 1 to 4 (where 1= Not important, 2= Somewhat important, 3= Very
important and 4= Extremely important)
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Table 12 presents reliability statistics of the screening scale. The scale proved to be
extremely reliable in this population with a reliability coefficient of 0.99. This was
probably because only one item was not strongly correlated with the others (RF 7 or
‘patients traveling in groups…’) with high correlations between other red flags.
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Table 12: Reliability statistics of Screening Scale: Inter correlation matrix (n =103)
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RF 1

RF 2

RF 3

RF 4

RF 5

RF 6

RF 7

RF 8

RF 9

RF 1

1.000

.999

1.000

1.000

.999

.99

.777

.999

.999

RF 2

.999

1.000

.999

.999

.999

.999

.778

.999

.999

RF 3

1.000

.999

1.000

1.000

1.000

.999

.780

.999

.999

RF 4

1.000

.999

1.000

1.000

1.000

.999

.779

.999

.999

RF 5

.999

.999

1.000

1.000

1.000

.999

.777

1.000

.999

RF 6

.999

.999

.999

.999

.999

1.000

.777

.999

.999

RF 7

.777

.778

.780

.779

.777

.777

1.000

.777

.775

RF 8

.999

.999

.999

.999

1.000

.999

.777

1.000

.999

RF 9

.999

.999

.999

.999

.999

.999

.775

.999

1.000

Standardized Cronbach’s Apha = 0.99

Table 13 presents the results of the stigma scale. Most pharmacists disagreed on all
statements, indicating a stigmatizing attitude on all statements except the ‘Most
pharmacists think less...’ statement. The mean scores on each item were less than three
which proved the same result. On average, pharmacists scored a total of 2.19 out of 4 on
the stigma scale indicating prevalence of stigmatizing attitudes.
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Table 13: Stigma scale (n = 134)
Item

Number
(Percentage)

Most pharmacists would willingly accept someone who has
been treated for substance use as a close friend.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Most pharmacists believe that someone who has been treated
for substance use is just as trustworthy as the average citizen.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Most pharmacists would accept someone who has been treated
for substance use as a teacher of young children in a public
school.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Most pharmacists would hire someone who has been treated
for substance use to take care of their children.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Most pharmacists think less of a person who has been in
treatment for substance use.&
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Most pharmacists would be willing to date someone who has
been treated for substance use.
Strongly disagree
Disagree
Agree

109

Mean

Standard
Deviation

2.39#

0.64

2.26#

0.59

2.51#

0.53

1.70#

0.60

2.38#

0.62

2.09#

0.70

5 (3.7)
50 (37.3)
35 (26.1)
3 (2.2)
1 (0.7)
40 (29.9)

6 (4.5)
59 (44.0)
28 (20.1)
1 (0.7)
0 (0.0)
40 (29.9)

7 (5.2)
65 (48.5)
21 (15.7)
0 (0.0)
1 (0.7)
40 (29.9)

35 (26.1)
52 (38.8)
7 (5.2)
0 (0.0)
0 (0.0)
40 (29.9)

4 (3.0)
53 (39.6)
33 (24.6)
3 (2.2)
1 (0.7)
40 (29.9)

19 (14.2)
48 (35.8)
27 (20.1)

Strongly agree
Not answered^
Missing$

0 (0.0)
0 (0.0)
40 (29.9)
2.19@

Total

0.43

^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4
= Strongly agree)
& Item is reverse coded for mean calculations.
@ Mean stigma score of all pharmacists on a scale from 1 to 4(where 1 = Strongly disagree, 2 = Disagree, 3 = Agree
and 4 = Strongly agree) and (where 1 = Highest stigma and 4 = Lowest stigma)
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Table 14 presents reliability statistics of the stigma scale. The stigma scale demonstrated
limited reliability in this sample as the standardized and non-standardized correlation
coefficient was 0.63 was 0.50 respectively. This could be due to the particular sample or
due to the elimination of two items from the original scale which reduced the overall
reliability of the scale.
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Table 14: Reliability statistics of stigma scale: Inter correlation matrix (n =94)
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… as a close
friend.
… is just as
trustworthy as the
average citizen.
… as a teacher of
young children in
a public school.
… hire someone
who has been
treated for
substance use to
take care of their
children.
… think less of a
person who has
been in treatment
for substance use.
…willing to date
someone who has
been treated for
substance use.

… as a
close
friend.

… is just as
trustworthy as
the average
citizen.

… as a teacher of
young children
in a public
school.

…think less of a
person who has
been in
treatment for
substance use.
.000

… willing to date
someone who has
been treated for
substance use.

.998

…hire someone who
has been treated for
substance use to take
care of their
children.
.136

1.000

.071

.071

1.000

.071

.401

.052

.367

.998

.071

1.000

.151

-.002

.183

.136

.401

.151

1.000

.131

.445

.000

.052

-.002

.131

1.000

.180

.180

.367

.183

.445

.180

1.000

Standardized Cronbach’s alpha = 0.63

.180

Table 15 presents the results of the attitude scale. With respect to frequencies of
responses on individual items and average attitude score on individual items, pharmacists
showed a moderate positive attitude. However, the mean score of all pharmacists on the
attitude scale showed was slightly negative (2.25 out of 4).
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Table 15: Attitude Scale (n =134)
Item

Number
(Percentage)

Pharmacists dispensing needles without prescriptions (or a
demonstrated legitimate medical need) leads to an increase
in frequency of substance abuse.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Pharmacists dispensing naloxone acts as a safety net
leading to an increase (or encouragement) in substance
abuse.&
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Dispensing buprenorphine/naloxone (Suboxone®) is an
effective way for pharmacists to assist in the overall
treatment of SUD.&
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Pharmacists dispensing oral/long acting naltrexone is an
effective method to treat SUD.
Strongly disagree
Disagree
Agree
Strongly agree
Not answered^
Missing$
Total

Mean

Standard
Deviation

2.29#

0.89

2.22#

0.72

2.74#

0.62

2.73#

0.64

2.25@

0.47

16 (11.9)
46 (34.3)
21 (15.7)
11 (8.2)
0 (0.0)
40 (29.9)

14 (10.4)
47 (35.1)
31 (23.1)
2 (1.5)
0 (0.0)
40 (29.9)

2 (1.5)
27 (20.1)
57 (42.5)
7 (5.2)
1 (0.7)
40 (29.9)

3 (2.2)
26 (19,4)
58 (43.3)
7 (5.2)
0 (0.0)
40 (29.9)

^ Questions the responders viewed but chose not to answer.
$ Questions the responders did not view.
# Mean of all responses measured on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4
= Strongly agree).
& Item reverse coded for mean calculations.
@ Mean score of all pharmacists on the attitude scale.
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Table 16 presents reliability statistics of the attitude scale. The reliability of the scale was
extremely low (0.24). This was probably because the scale measured attitudes towards
two distinct topics:- harm minimization and SUD treatment.
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Table 16: Correlation coefficient: Inter correlation matrix (n = 94)
Pharmacists dispensing
needles without
prescriptions leads to an
increase in frequency of
substance abuse.
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1.000
Pharmacists dispensing
needles without
prescriptions leads to an
increase in frequency of
substance abuse.
.302
Pharmacists dispensing
naloxone acts as a safety
net leading to an increase
(or encouragement) in
substance abuse.
-.193
Dispensing
buprenorphine/naloxone
(Suboxone®) is an
effective way for
pharmacists to assist in the
overall treatment of SUD.
.280
Pharmacists dispensing
oral/long acting naltrexone
is an effective method to
treat SUD.
Standardized Cronbach’s alpha= 0.24

Pharmacists dispensing
naloxone acts as a
safety net leading to an
increase (or
encouragement) in
substance abuse.
.302

Dispensing
buprenorphine/naloxone
(Suboxone®) is an effective way
for pharmacists to assist in the
overall treatment of SUD.

Pharmacists dispensing
oral/long acting naltrexone is
an effective method to treat
SUD.

-.193

.280

1.000

-.104

.079

-.104

1.000

.081

.079

.081

1.000

III] Mean differences
Table 17 presents the results of the t-tests performed to assess mean differences in the
knowledge scores among descriptive variables. No significant results were obtained.
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Table 17: Mean differences in knowledge scores (t tests)
Variables

n

Mean^

Standard
Deviation

Age
Less than 40
40 and greater

67
40

5.61
5.38

1.29
1.03

Gender
Male
Female

39
68

5.74
5.40

1.19
1.20

Degree
Pharm D
B S Pharmacy

72
35

5.58
5.40

1.26
1.06

SUD Education
Yes
No

65
42

5.60
5.40

1.21
1.09

Personal experience
Yes
No

27
78

5.70
5.45

1.17
1.22

α= 0.05
^ Mean knowledge scores on a scale of 0 to 8.
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t

df

Significance
(2 tailed)

0.99

105

0.33

1.45

105

0.152

0.74

105

0.46

0.82

105

0.41

0.94

103

0.35

Table 18 presents the results of the ANOVA conducted to analyze mean differences in
knowledge scores among practice characteristics and responses to attitude statements. No
significant results were obtained.
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Table 18: Mean differences in knowledge scores (ANOVA)
Variables

n

Mean^

Standard
Deviation

F

Significance
(2 tailed)

Pharmacy location
Rural
Suburban
Urban

106
21
59
26

5.55
5.48
5.47
5.77

1.18
1.17
1.14
1.31

0.61

0.55

Income
Impoverished
Low
Middle
High

104
7
46
45
6

5.56
5.00
5.61
5.58
5.67

1.19
1.53
1.29
1.03
1.21

0.56

0.65

MTM Services
Never
Rarely
Sometimes
Frequently

101
31
24
29
17

5.51
5.42
5.21
5.83
5.59

1.20
1.18
1.29
1.23
1.00

1.28

0.29

Clinical services
Never
Rarely
Sometimes
Frequently

101
52
14
2
33

5.46
5.33
5.38
6.21
4.00

1.32
1.32
1.37
0.70
1.41

2.64

0.05

0.61

0.61

Attitudes
1. Pharmacists dispensing needles without
prescriptions
Strongly disagree
Disagree
Agree
Strongly agree

93

5.53

1.19

16
45
21
11

5.44
5.69
5.29
5.45

1.41
1.20
1.00
1.13

2. Pharmacists dispensing naloxone acts as a safety net
Strongly disagree
Disagree
Agree
Strongly agree

93
14
47
30
2

5.53
5.29
5.64
5.40
6.50

1.19
1.44
1.26
0.93
0.70

0.89

0.45

3. Dispensing buprenorphine is an effective strategy
Strongly disagree
Disagree
Agree
Strongly agree

92
2
26
57
7

5.52
6.00
5.50
5.53
5.43

1.19
0.00
1.24
1.14
1.72

0.12

0.95

93

5.53

1.19

1.52

0.22

4.

Pharmacists dispensing naltrexone
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Strongly disagree
Disagree
Agree
Strongly agree

3
26
57
7

α= 0.05
^ Mean knowledge scores on a scale of 0 to 8.
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6.00
5.15
5.61
6.00

1.00
1.12
1.10
1.92

Table 19 presents the results of the t-tests conducted to assess the mean differences in the
stigma scores among the demographic variables. No significant results were obtained.
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Table 19: Mean differences in stigma scores (t tests)
Variables

n

Mean^

Standard
Deviation

Age
Less than 40
40 and greater

58
36

2.23
2.12

0.42
0.43

Gender
Male
Female

37
57

2.18
2.19

0.42
0.43

Degree
Pharm D
B S Pharmacy

63
31

2.25
2.07

0.42
0.42

SUD Education
Yes
No

57
37

2.24
2.10

0.42
0.42

Personal
experience
Yes
No

23
69

2.20
2.18

t

df

Significance
(2 tailed)

1.30

92

0.20

-0.06

92

0.95

1.91

92

0.06

1.56

92

0.12

0.14

90

0.89

0.33
0.46

α= 0.05
^ Mean stigma score on a scale from 1 to 4 (where 1 = Strongly disagree, 2 = Disagree, 3 = Agree and 4 = Strongly
agree) and (where 1 = Highest stigma and 4 = Lowest stigma)
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Table 20 presents the results of the ANOVA performed to assess mean differences in
stigma scores among practice characteristics and responses on the attitude questions. The
ANOVA was significant on comparing mean stigma scores with MTM services [ F (3,
90) = 2.99, p = 0.03] and on comparing clinical services [ F (3,89) = 2.98, P = 0.04].
Scheffe’s post-hoc test revealed that there was a significant difference between the mean
stigma scores of pharmacists who never performed MTM services and those who
frequently performed MTM services (p = 0.04). However, post-hoc tests could not be
performed for clinical services as the ‘frequently’ group had only one case.
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Table 20: Mean differences in stigma scores (ANOVA)
Variables

n

Mean^

Standard
Deviation

F

Significance
(2 tailed)

Pharmacy location
Rural
Suburban
Urban

94
20
51
23

2.19
2.20
2.11
2.35

0.43
0.43
0.40
0.45

2.54

0.09

Income
Impoverished
Low
Middle
High

92
7
42
39
4

2.18
2.14
2.15
2.22
2.13

0.42
0.59
0.38
0.44
0.42

0.23

0.88

MTM Services
Never
Rarely
Sometimes
Frequently
Never vs frequently$

94
28
22
27
17

2.19
2.07
2.14
2.19
2.44

0.43
0.47
0.41
0.37
0.37

2.99

0.03*

Clinical services
Never
Rarely
Sometimes
Frequently

93
31
48
13
1

2.19
2.06
2.23
2.33
3.00

0.42
0.39
0.44
0.35
.

2.98

0.04*

Attitude
Pharmacists dispensing needles without prescriptions
Strongly disagree
Disagree
Agree
Strongly agree

94
16
46
21
11

2.19
2.13
2.28
2.11
2.03

0.43
0.45
0.34
0.53
0.45

1.63

0.18

Pharmacists dispensing naloxone acts as a safety net
Strongly disagree
Disagree
Agree
Strongly agree

94
14
47
31
2

2.19
2.35
2.23
2.07
2.00

0.43
0.30
0.40
0.50
0.24

1.73

0.17

Dispensing buprenorphine is an effective strategy
Strongly disagree
Disagree
Agree
Strongly agree

93
2
27
57
7

2.20
2.00
2.28
2.15
2.29

0.42
0.24
0.42
0.43
0.38

0.85

0.47

Pharmacists dispensing naltrexone is effective
Strongly disagree
Disagree
Agree
Strongly agree

94
3
26
58
7

2.19
2.17
2.28
2.17
2.05

0.43
0.17
0.46
0.42
0.47

0.66

0.58

0.04*

*Significant at p < 0.05
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^ Mean stigma score of all pharmacists on a scale from 1 to 4(where 1 = Strongly disagree, 2 = Disagree, 3 = Agree
and 4 = Strongly agree) and (where 1 = Highest stigma and 4 = Lowest stigma)
$ Scheffe’s post hoc test
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Figure 2 is the graphical representation of the mean stigma scores of pharmacists
grouped according to their frequency of performing MTM services. A clear increase in
stigma scores is visible from pharmacists who never perform MTM services to those
frequently perform them. A higher stigma score corresponds to lesser stigmatizing
attititudes.
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Figure 2: Mean differences in stigma scores with MTM services
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Figure 3 is the graphical representation of the mean stigma scores of pharmacists
grouped according to their frequency of performing clincal servicces. A clear increase in
stigma scores is visible from pharmacists who never perform clinical services to those
frequently perform them. A higher stigma score corresponds to lesser stigmatizing
attititudes.
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Figure 3: Mean differences in stigma scores with clinical services
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Table 21 presents the results of the t tests assessing mean differences in practice scores
among demographic variables. No significant results were obtained.
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Table 21: Mean differences in practice scores (t tests)
Variables

n

Mean^

Standard
Deviation

Age
Less than 40
40 and greater

38
15

3.5
3.6

1.83
1.64

Gender
Male
Female

15
38

3.07
3.71

1.58
1.81

Degree
Pharm D
B S Pharmacy

42
11

3.40
4.00

1.80
1.61

SUD Education
Yes
No

32
21

3.38
3.76

1.76
1.79

Personal
experience
Yes
No

14
37

3.57
3.41

1.74
1.74

α= 0.05
^ Mean practice score of pharmacists on a scale of 0 to 7.
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t

df

Significance
(2 tailed)

-0.19

51

0.85

-1.20

51

0.23

-1.00

51

0.32

-0.78

51

0.44

0.30

49

0.76

Table 22 presents results of the ANOVA assessing mean differences in practice scores
among practice characteristics and responses on the attitude questions. No significant
results were obtained.
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Table 22: Mean differences in practice scores (ANOVA)
α= 0.05

Variables

n

Mean^

Standard
Deviation

F

Significance
(2 tailed)

Pharmacy location
Rural
Suburban
Urban

53
12
25
16

3.53
3.83
3.16
3.88

1.76
1.70
1.72
1.86

1.04

0.36

Income
Impoverished
Low
Middle
High

52
2
29
18
3

3.50
6.00
3.38
3.56
2.67

1.77
0.00
1.52
2.12
1.15

1.67

0.19

MTM Services
Never
Rarely
Sometimes
Frequently

50
12
13
15
10

3.74
3.42
3.85
3.87
3.80

1.58
1.51
1.46
1.69
1.81

0.21

0.89

Clinical services
Never
Rarely
Sometimes
Frequently

49
26
10
1
12

3.76
3.08
3.88
4.10
5.00

1.59
1.51
1.66
1.45
.

1.15

0.34

Attitude
Pharmacists dispensing needles without prescriptions
Strongly disagree
Disagree
Agree
Strongly agree

47
9
23
10
5

3.77
3.56
3.74
3.70
4.40

1.55
1.51
1.51
1.77
1.67

0.33

0.81

Pharmacists dispensing naloxone acts as a safety net
Strongly disagree
Disagree
Agree
Strongly agree

47
7
24
15
1

3.77
3.86
3.71
4.00
1.00

1.55
1.46
1.37
1.81
-

1.21

0.32

Dispensing buprenorphine is an effective strategy
Strongly disagree
Disagree
Agree
Strongly agree

47
0
15
27
5

3.77
3.73
3.70
4.20

1.55
1.44
1.64
1.64

0.21

0.81

Pharmacists dispensing naltrexone
Strongly disagree
Disagree
Agree
Strongly agree

47
1
12
28
6

3.77
3.00
4.00
3.57
4.33

1.55
1.60
1.55
1.63

0.57

0.64

^ Mean practice score of pharmacists on a scale of 0 to 7.
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IV] Bivariate Correlations
Table 23 presents correlations between knowledge scores and practice variables. None of
the bivariate correlations were significant.

135

Table 23: Correlations between knowledge scores and practice variables
Variable

n

Pearson Correlation

Significance (two-tailed) (p value)

Number of years worked

106

-0.09

0.35

Number of hours worked/week

106

-0.04

0.72

SUD prescriptions/week

106

0.12

0.21

Adequacy of SUD education

65

0.12

0.36

Screening score

98

0.04

0.72

α= 0.05
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Table 24 presents correlations between stigma scores and practice variables. None of the
bivariate correlations were significant except screening scores. Interestingly, there was a
negative correlation (-0.25) and higher stigma scores meant lesser stigma. Therefore,
there was a relationship between having high stigma and regarding screening as an
important practice.
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Table 24: Correlations between stigma scores and practice variables
Variable

n

Pearson Correlation

Significance (two-tailed) (p value)

Number of years worked

94

-0.18

0.08

Number of hours worked/week

94

-0.04

0.73

SUD prescriptions/week

94

0.01

0.90

Adequacy of SUD education

57

-0.13

0.34

Screening

92

-0.25

0.01*

*Significant difference at p < 0.05
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Table 25 presents correlations between practice scores and practice variables. None of
the bivariate correlations were significant except screening scores. There was a positive
correlation (0.31) indicating a relationship between performing more interventions for
SUD patients and regarding screening as an important practice.
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Table 25: Correlations between practice scores and practice variables
Variable

n

Pearson Correlation

Significance (two-tailed) (p value)

Number of years worked

53

0.13

0.37

Number of hours worked/week

53

-0.15

0.27

SUD prescriptions/week

53

0.17

0.23

Adequacy of SUD education

32

-0.10

0.58

Screening score

50

0.31

0.03*

*Significant difference at p < 0.05
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V] Regression Models
1) Knowledge
A multiple linear regression analysis was conducted to predict knowledge scores. The
predictors included in the model were personal experience with SUD, CE in SUD,
gender, CE on naloxone, number of years worked, SUD medication dispensing frequency
and stigma mean scores. The assumptions for linear regression were met. Independence
of observations was confirmed by the Durbin-Watson statistic (1.26). The residual
histogram was normal and the predicted probability (P-P) plot was mostly linear, thereby
establishing normality of the model. The scatterplot of the residuals was spread evenly on
both sides of the origin, proving homoscedasticity of the model. Linearity of data was
thus implied. The linear combination of the included variables significantly predicted
knowledge scores [F (8, 85) = 3.83, p < 0.01] with an R 2 and adjusted R2 of 0.27 and 0.20
respectively. The regression coefficient was:
Knowledge score = 3.41 + 0.11 (CE SUD) + 0.07 (Personal experience: yes) + 0.01
(Personal experience: not disclosed) -0.21(Years worked) + 0.11 (SUD medication
dispensing frequency) + 0.34 (CE Naloxone) – 0.05 (Stigma score)
The individual relative strengths of the predictors are reported in Table 26. Gender,
number of years worked and CE in naloxone were significant predictors individually as
well. This also meant that with an increase of one year of work experience, knowledge
score would decrease by 0.21 on average and pharmacists who have had CE in naloxone
had on average a knowledge score higher by 0.34 than those who did not.
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a) Normality assumption

Figure 4: Histogram of residuals of knowledge regression model
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Figure 5: Normal Predicted Probability plot of knowledge regression model
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b) Homoscedasticity assumption

Figure 6: Scatterplot of residuals Vs predicted values for knowledge regression model
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Table 26: Regression model of Knowledge scores (n = 94)
Unstandardized
Coefficients
B
Std. Error

Standardized
Coefficient
Beta

t

Significance

2.15

0.03*

Constant

3.41

1.58

CE SUD

0.56

0.52

0.11

1.07

0.29

Personal experience (yes)

0.40

0.57

0.07

0.70

0.49

Personal experience (not disclosed)

0.26

1.93

0.01

0.13

0.89

Number of years worked

-0.05

0.03

-0.21

-2.14

0.04*

SUD medication dispensing
frequency

0.28

0.24

0.11

1.13

0.26

Gender

0.04

0.02

0.17

1.80

0.08

CE Naloxone

1.78

0.56

0.34

3.21

0.00*

Stigma score

-0.28

0.55

-0.05

-0.52

0.61

*Significant difference at p<0.05

145

2) Practice
An ordinal regression was carried out to predict the frequency of pharmacists offering
clinical services to SUD patients. The variables included in the model were stigma mean
scores, knowledge mean scores, attitude mean score, gender and personal experience with
SUD. The assumptions of ordinal regression were met. Occurrence of proportional odds
was confirmed by the test of parallel lines [χ2 = 18.00 (p = 0.12)]. The model fit proved to
be significant [χ2 = 17.25 (p = 0.01)] and had a pseudo R2 of 0.37 (Nagelkerke). In this
model, all threshold values were significant. The individual estimates or regression
coefficients of the predictors are reported in Table 27. Stigma was the only significant
predictor individually. This meant that an increase in stigma scores by one point meant an
increase of 3.18 units of ordered log odds of the pharmacist ‘frequently’ offering clinical
services instead of ‘sometimes’, ‘sometimes instead of ‘rarely’ and ‘rarely’ instead of
‘never’. In other words, increase in stigma scores or reduced stigma was correlated with
an increase in the odds of the pharmacist offering clinical services.
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Table 27: Regression model of clinical services (n = 101)
Variable

Estimate

Std. Error

Wald Statistic

df

Significance

Clinical services
Threshold^
1
2
3

11.59
14.90
17.53

4.07
4.38
4.55

8.11
11.56
14.89

1
1
1

0.00*
0.00*
0.00*

Stigma Score

3.18

1.00

10.14

1

0.00*

Knowledge Score

0.36

0.30

1.44

1

0.23

Attitude Score

1.20

0.84

2.03

1

0.15

Practice Score

0.28

0.22

1.60

1

0.46

Gender
Female
Male

0.55
0

0.74

0.55

1
0

0.46

Personal experience
Yes
No

-0.58
0

0.72

0.65

1
0

0.42

*Significant difference at p <0.05
^ Threshold 1 = cutoff value between never and rarely offering clinical services
2 = cutoff value between rarely and sometimes offering clinical services
3 = cutoff value between sometimes and frequently offering clinical services
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3) Screening
A multiple linear regression model was created to predict screening scores. The
predictors included in the model were personal experience, gender, knowledge, number of
years worked, and stigma mean scores. The assumptions for linear regression were met.
Independence of observations was confirmed using the Durbin-Watson statistic (1.46). The
transformation of the dependent variable produced a normal plot as reported below.
Homoscedasticity of the model was observed by looking at the evenly spread out
scatterplot of the residuals, as reported below. Linearity of data was thus implied. The
linear combination of the included variables significantly predicted screening scores [F (6,
84) = 2.50, p = 0.03] with an R2 and adjusted R2 of 0.15 and 0.09 respectively. The
regression equation was:
Square root of screening score = 1.92 – 0.15(Gender) – 0.22(Stigma score) +
0.07(Knowledge score) + 0.08(Personal experience: yes) + 0.18(Personal
experience: not disclosed) + 0.22(years worked)
The individual relative strengths of the predictors are also reported in Table 28.
Stigma scores and work experience were significant predictors individually. This meant
that increase in stigma score by one point meant a decrease in the square root of the
screening score and an increase in the years worked by one year meant an increase in the
square root of screening score, both by 0.22.
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a) Normality assumption

Figure 7: Histogram of residuals of screening regression model.
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Figure 8: Normal predicted probability plot of screening regression model
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b) Homoscedasticity assumption

Figure 9: Scatterplot of residuals Vs predicted values of screening regression model
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Table 28: Regression model of screening scores (n = 91)
Unstandardized
Coefficients
B
Std. Error
Constant

1.92

0.09

Gender

-0.00

0.00

Stigma score

-0.07

Knowledge score

Standardized
Coefficient
Beta

t

Significance

22.09

0.00*

-0.15

-1.47

0.15

0.03

-0.22

-2.14

0.04*

0.00

0.01

0.07

0.70

0.49

Personal experience (yes)

0.03

0.03

0.08

0.77

0.40

Personal experience (prefer not to
disclose)

0.20

0.12

0.18

1.72

0.09

Number of years worked

0.00

0.00

0.22

2.03

0.045*

*Significant difference at p < 0.05
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4) Stigma
Table 29 presents the frequency distribution of the stigma total scores. As evident the
stigma scores 12, 13, and 14 have very high frequencies compared to scores before 12
and after 14. Therefore, three categories of stigma were based on this distribution with
low stigma = 1 (stigma scores 15 to 18), medium stigma = 2 (stigma scores 12 to 14) and
high stigma = 3 (stigma scores from 6 to 11).
Subsequently, the results of the ordinal regression are presented. The variables
included in the model were screening scores, practice scores, patient socioeconomic
class, MTM services, and CE in SUD. The assumptions of ordinal regression were met.
Occurrence of proportional odds was confirmed by the test of parallel lines [χ 2 = 5.21 (p
= 0.82)]. The model fit proved to be significant [χ 2 = 18.77 (p = 0.03)] and had a pseudo
R2 of 0.40 (Nagelkerke). Both threshold values were significant, meaning there was a
significant difference between pharmacists who had low and medium as well as medium
and high stigma scores. The individual estimates or regression coefficients of the
predictors are reported in Table 30. Of all the predictors in the model, screening scores
and ‘never’ and ‘rarely’ performing MTM services were found to be significant
individually. The result indicated that an increase in screening scores by one point meant
an increase of 1.98 units of ordered log odds of the pharmacist falling in the medium
stigma category instead of low and being in the high stigma group instead of medium.
Pharmacists who never performed MTM services were 3.03 times more likely to have
high stigma as compared to medium and medium stigma as compared to low stigma than
those who frequently performed MTM services. Pharmacists who rarely performed MTM
services as compared to those who frequently performed MTM services were 2.30 times
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more likely to fall in the high stigma group than medium and medium stigma group than
low stigma.

154

Table 29: Frequency distribution of stigma total scores
Stigma total score

Number

Percentage

6.00

1

0.7

7.00

2

1.5

8.00

2

1.5

9.00

1

0.7

10.00

6

4.4

11.00

8

5.9

12.00

15

11.1

13.00

23

17.0

14.00

12

8.9

15.00

6

4.4

16.00

8

5.9

17.00

4

3.0

18.00

6

4.4

Total

94

69.6

low stigma = 1 (stigma total scores from15 to 18),
medium stigma = 2 (stigma total scores from 12 to 14),
high stigma = 3 (stigma total scores from 6 to 11).
(Categories based on frequency distribution)
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Figure 10: Histogram of frequency distribution of stigma total scores
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Table 30: Regression model of stigma total scores (n = 94)
Variable

Estimate

Std. Error

Wald Statistic

df

Significance

Stigma scores
Threshold^
1
2

7.21
11.22

3.19
3.57

5.10
9.87

1
1

0.02*
0.00*

Screening score

1.98

0.86

5.30

1

0.02*

Practice Score

-0.43

0.25

2.82

1

0.09

Patient socioeconomic
class
Impoverished
Low
Middle
High

3.84
1.84
1.69
0

2.42
1.70
1.77
.

2.52
1.18
0.91
.

1
1
1
0

0.11
0.28
0.34
.

MTM services
Never
Rarely
Sometimes
Frequently

3.03
2.30
1.64
0

1.11
1.08
0.99
.

7.51
4.59
2.73
.

1
1
1
0

0.01*
0.03*
0.10
.

CE in SUD

1.23

0.76

2.67

1

0.10

*Significant difference at p <0.05
^ Threshold 1 = cutoff value between low stigma and medium stigma
2 = cutoff value between medium stigma and high stigma
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VI] Qualitative Results
Table 31 presents the frequency distribution of all 20 codes in the protocols listed in
descending order of frequency. Overprescribing and scale or severity of the epidemic
were the most frequent themes while
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Table 31: Frequency distribution of qualitative codes (n = 50)
Codes
Number

Percentage

Overprescribing opioids

16

14.95

Scale and severity of the epidemic

13

12.15

Policy recommendations

9

8.41

Contributor accountability

7

6.54

Negative aspects of Suboxone

7

6.54

Attitude towards naloxone

7

6.54

Prescriber pharmacist relationship

7

6.54

Personal experience

5

4.67

Barriers to practice

4

3.74

PDMP

4

3.74

Access to opioids

4

3.74

Stigma

4

3.74

Education

3

2.80

Resources

3

2.80

Frustration/Hopelessness

3

2.80

Substances other than opioids

3

2.80

Mental health

2

1.87

Patients without formal SUD diagnosis

2

1.87

Substitution of opioids

2

1.87

Therapy/ Counseling

2

1.87

Total

107

100.00

159

Table 32 presents the results of the axial analysis on the protocols and codes. Frequently
occurring relationships between codes are described. Causal or associated relationships
between codes, intervening codes, codes that occur as action strategies and codes that are
consequences of the central code are listed.
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Table 32: Axial analysis of codes
Code
Causal/
Association
Pharmacist
prescriber
relationship

Contributor
accountability
(lack)

Scale and severity
of the epidemic

Overprescribing,
education (lack),
Contributor
accountability
(lack), stigma,
access to opioids
(easy)

Overprescribing

Education (lack),
Mental healthcare
(lack), Contributor
accountability
(lack)

Contributor
accountability

-

Intervening
codes
Barrier to
practice

-

Action strategies

-

Consequences

Frustration/Hope
lessness

Education, Policy
recommendations,
Resources,
Prescriber
pharmacist
relationship

Substances other
than opioids
(increase)

Access to opioids
(difficult)

Resources,
Substitution of
opioids, Contributor
accountability,
policy
recommendations

Scale and
severity of the
epidemic

Barriers to
practice

Policy
recommendations,
PDMP

Overprescribing,
prescriber
pharmacist
relationship
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Chapter 5
DISCUSSION AND CONCLUSION
This chapter includes a discussion of the key findings of the study, categorized according
to the descriptive data, seven objectives and qualitative data. This is followed by the
limitations of the study, the conclusion, study implications and finally direction for future
research.
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I] Key Findings
1) Descriptive
The pharmacists surveyed in this study were mostly young (below 40 years of
age), female, and predominantly Caucasian. The majority had PharmD versus B.S in
Pharmacy degrees. There was a significant correlation between degree obtained and year
of graduation. It only became mandatory to have a Pharm D degree to obtain a license to
practice as a pharmacist in 2000 in the US and therefore the younger pharmacists
surveyed in the study resulted in more pharmacists having a PharmD. A total of 14.9% of
the current study sample also had other advanced degrees.
The survey also assessed pharmacy and professional characteristics. Pharmacists
on average worked for 15 years and about 37 hours per week, although standard
deviations for both were around 9 years and 9 hours/ week. This was likely due to the
large range in the ages of pharmacists, even among younger age group which affected
work experience. Also, some pharmacists had more than two degrees (some in unrelated
fields), significantly reducing years of work experience as a community pharmacist.
Moreover, the study responders were full-time or part-time community pharmacists
which would render a variance in the number of hours worked per week. Most
pharmacies had 2-3 pharmacists working per shift, but the amount of prescriptions filled
per week as reported by the pharmacists varied greatly. This was because some
pharmacists worked in tele-pharmacies (and so did not fill any prescriptions) while some
were full-time pharmacists working in large pharmacies and reportedly filled 10,000
prescriptions per week. However, most pharmacists reported filling approximately 2000
prescriptions per week. With regards to SUD prescriptions, pharmacists mostly reported
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‘frequently’ dispensing SUD medications. This is consistent with the high prevalence of
SUD, but literature regarding SUD medication dispensing from the pharmacist’s
perspective is limited. Most studies have assessed dispensing practices specific to
naloxone. Studies have assessed attitudes of pharmacists and have found it was generally
positive as discussed in the systematic literature review.161 There was an equal
distribution of patients estimated to belong to the low and middle-income groups while
few belonged to the impoverished and high-income groups, according to the pharmacists.
Assuming that this holds true for the SUD patients as well, there might be a correlation
between socioeconomic group and prevalence of SUD. This is consistent with literature,
where frequency of SUD is less in people with high socioeconomic status as compared to
people in lower socioeconomic status groups.199 However, these studies do not
necessarily measure the true prevalence but may be indicating measured prevalence. With
respect to their position in the pharmacy, the majority of respondents were full-time
pharmacists as compared to part-time pharmacists. A significant proportion of
pharmacists were also pharmacy managers, interspersed with a few owners. This
strengthens the collected data because responses from different viewpoints within the
community pharmacy system was available.
The survey also assessed educational characteristics of the pharmacists. Only 53%
reported that they received SUD-specific education as part of their curriculum which is
especially concerning with the current large-scale prevalence of SUD. Moreover, of these
53%, only 1.5% strongly agreed and 31.3% agreed that the education they received was
adequate to treat patients, leaving two thirds of the pharmacists who received SUD
education believing that it was not adequate to understand and treat SUD. These findings
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are not surprising because most pharmacy programs do not provide sufficient SUD
education or training as reported by a recent study that utilized a sample of US pharmacy
curriculum representatives and College of Psychiatric and Neurologic Pharmacy (CPNP)
members with teaching affiliations.25 The study reported that even though 94% of the
programs reported teaching SUD content in their core curriculum, the average hours
taught still fell short of the American Association of Colleges of Pharmacy (AACP)
recommendations.200 The recommendations stated that at least four hours of SUD specific
education concerning identifying, prevention and treatment of SUD should be provided in
the curriculum. However, the average hours taught in this study of all US schools was 2.7
in 2015.200 This points towards a severe gap in the basic education of pharmacists which
needs to be rectified to improve their role in prevention and treatment of SUD. CE in
SUD and naloxone can be used to overcome this gap in knowledge. More than half the
sample had received CE in SUD and naloxone, indicating that pharmacists are interested
in gaining knowledge in the area. However, this still leaves a significant portion of the
sample (about 40%) who did not report that they have received CE. This is especially
concerning because the use of MAT is on the rise. A surprisingly large number of
pharmacists (22.4%), especially when accounting for social desirability bias, reported
having personal experience with SUD. However, a study assessing substance use among
pharmacists reported that slightly more than half the sampled pharmacists reported using
a non-prescribed drug in their lifetime and greater proportion of pharmacists reported
lifetime use of minor opiates as compared to other health care professionals. 201 Therefore,
social desirability bias may still be present in the result obtained in this study. However,
this conclusion cannot be directly compared to the result obtained as the question is
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confounded by including the pharmacists’ social network in their personal experience
with SUD.

2) Objective 1: Assessing Knowledge
The first factor that the study aimed to measure was the knowledge of pharmacists
with regards to SUD. The questions primarily focused on SUD medications because
pharmacists are expected to have adequate knowledge regarding MAT for patients. One
question however concerned a policy, specifically standing orders for naloxone.
Together, the scale proved to be very reliable with a high reliability coefficient. The
knowledge scores in the study sample averaged at 5.52 out of 8, meaning the pharmacists
on average achieved 69% of the questions right. This indicates that increased education
and knowledge regarding SUD should be further emphasized through targeted CE and
curriculum development. The literature regarding knowledge of pharmacists in SUD
seems to be limited with most papers only assessing their knowledge as an evaluation of
a training program or CE rather than overall assessment. One study however, assessed
overall knowledge and found that pharmacists were deficient in prevention and treatment
of SUD.202 Moreover, pharmacy is a knowledge-based profession and their knowledge is
linked to professionalism (more knowledge makes better pharmacists), 203 making it
essential for the pharmacist to have high levels of knowledge specific to SUD. Although
the pharmacists in the sample answered majority of the questions correctly in the
knowledge section, they did not fare equally well on all questions. This could probably
be attributed to the varying difficulty level of the questions. Some questions were
straightforward and were expected to be common knowledge among pharmacists such as
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scheduling of buprenorphine (the most commonly used treatment for SUD) or the drug of
choice for emergency treatment of opioid overdose (with options including only
maintenance treatments apart from naloxone). However, some questions not only tested
basic knowledge but required a deeper understanding and experience with dispensing the
specific treatments. For example, the question regarding starting naltrexone within seven
days of opioid therapy was especially nuanced. Although, it may be started within seven
days, it is highly advisable not to do so to avoid severe opioid withdrawal syndrome in
case the patient had physiological opioid dependence. A naloxone challenge is necessary
to be performed to confirm the absence of dependence if starting naltrexone. However, to
avoid complications and difficulties of performing the challenge, it is generally advised
to wait for a week before starting naltrexone. The ability of buprenorphine to potentiate
opioids was another question where pharmacists performed poorly. This is because
buprenorphine is in fact a partial opioid receptor agonist which may have prompted
pharmacists to answer incorrectly. However, apart from being a partial agonist it also has
greater affinity to the receptor than other opioids and displaces them, thereby attenuating
their activity and not potentiating it. Other than the questions regarding medications, the
standing order question also received mostly correct answers indicating that most
pharmacists were aware of the newest significant policy change in the treatment of SUD.

3) Objective 2: Assessing Practice
The second factor assessed in the study was the SUD-related practice
characteristics of the pharmacists. Contrary to the hypothesis in which it was expected
that the majority of pharmacists would be involved in treating SUD in some way, almost
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an equal number of pharmacists did and did not play a role in SUD treatment. This
reduced the sample size considerably for the practice scale, which was administered only
to the pharmacists who reported that they played a role in SUD. There were seven items
on the practice scale, each corresponding to a specific intervention that pharmacists are
expected to perform. However, results on the scale were skewed with a high percentage
of pharmacists dispensing and counseling, but very few referring patients to practitioners
or monitoring patients and assisting self- monitoring practices. The mean score on the
scale was 3.53 (out of 7), meaning pharmacists on average performed 50% of the
interventions listed. The practice with SUD patients in this study followed the basic
model of dispensing with some counseling without emphasis upon monitoring and
referral for further interventions. Opportunities need to be made for pharmacists to be
able to monitor SUD patients and refer when necessary for further evaluation and
treatment. This would include both more extensive education and the reduction of time
and reimbursement barriers in community pharmacy, so that the potential of the
community pharmacist can be realized for addressing the current epidemic. Although the
current literature concludes that pharmacists play a key role in treatment and prevention
of SUD and provide recommendations for new roles that can be implemented, it is hard
to find studies that assess overall current practices of pharmacists in this area. Another
important finding was that frequency of performing MTM services for general diseases
had large variation with almost equal responses across the scale. A study conducted in
2006 reported that pharmacists are eager to provide MTM services for all the prescription
drug plans for Medicare Part D.204 Another report by Centers for Medicare and Medicaid
Services (CMS) stated that pharmacists were leading provider of MTM services across
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all MTM programs and were utilized by 99.5% of their plans. 205 Outside the CMS,
however only 68% of the respondents reported providing MTM services. 205 This variance
is replicated in these results as well but it is starkly different from treatment of SUD
specifically. Pharmacists on average reported that they ‘rarely’ provided clinical services
to SUD patients which points to a significant distinction between treatment of SUD
versus other diseases. SUD maybe occur in combination with other diseases like
cardiovascular diseases leading to higher complications, providing opportunity to treat
both.206 Further research needs to be conducted on why this difference exists.

4) Objective 3: Assessing Screening
The third objective of the study was to evaluate the importance of screening for
SUD in the pharmacists’ opinion. All red flags listed as part of the screening question
were regarded as either ‘very’ or ‘extremely important’. This indicates that given an
opportunity and adequate resources, pharmacists are extremely willing to screen for SUD
and enhance their role in the treatment of SUD. The unanimous nature of the responses
resulted in a high correlation coefficient, proving that this scale was very reliable in this
sample. Although, the respondents reported that they believed screening for SUD to be
highly important, it does not necessarily translate into practice. Screening for drug abuse
has hurdles such as first and foremost establishing a professional belief within themselves
and the patients that the questions are only for therapeutic concerns, removing hesitation
on part of the patients to answer deeply personal questions without intruding in their
lives, being sensitive, respectful and maintaining confidentiality. 207 Lack of private space,
increased work burdens, and lack of effective training add to these barriers. These
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external barriers compound the already existing internal barriers such as stigma and
negative attitudes.

5) Objective 4: Assessing Stigma
As part of assessing attitude, this study focused on stigma specifically by utilizing
a standardized scale developed for SUD. Even though it was a standardized scale, the
correlations between the items were not very high in this sample. This could be attributed
to the omission of two items (to decrease responder burden) from the original scale, the
small alterations made in the statements, or simply this specific sample. Pharmacists in
general had a slightly stigmatizing attitude to all items on the scale. It is possible that the
overall amount of stigma was underestimated due to social desirability bias. A systematic
review of studies assessing stigma in SUD by health-care professionals stated that they
stigmatized patients as being violent, manipulative, and poorly motivated for treatment.
This resulted in providers being less involved or empathetic towards these patients. 208
Research shows that not only do health care providers commonly have stigmatizing
attitudes towards patients with SUD but this also leads to sub-optimal health care for
these patients.208

6) Objective 5: Assessing Attitude
The final factor was to assess general attitudes of pharmacists towards harm
reduction strategies and maintenance treatments. The section was shortened to only four
specific statements from the original intended in order to reduce responder burden.
However, the small number of disparate items resulted poor internal consistency and
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therefore limited reliability. But on correlating the harm reduction items and treatment
items separately, significant correlation coefficients were obtained. Pharmacists had
slight positive attitudes towards participating in harm reduction strategies like needle
exchange and dispensing naloxone and had slightly positive attitudes concerning
maintenance treatments like buprenorphine and naltrexone as well. However, attitudes
towards both were not as positive as expected from pharmacists. The literature as
observed in the systematic review is divided on attitudes towards harm reduction
strategies such as prescription free needles and naloxone dispensing but there has been
evidence of an increasingly positive attitude among pharmacists over the years. Also, it is
important to note that attitudes might differ if the policy is needle exchange (which
includes collecting and disposing used needles) or non-prescription needles. 209 Our study
only measured attitudes towards non-prescription needles. However, pharmacists
unexpectedly had only slight positive attitudes towards maintenance treatments. This is
especially surprising as studies that assessed pharmacists’ attitudes towards treatments
like Suboxone® were quite positive.210,211 However, these studies were conducted when
buprenorphine/naloxone was first introduced or when it became popular as a treatment
for SUD. There is no literature measuring the current attitudes. It is possible that attitudes
have become less positive because of limitations of the treatment or inappropriate
prescribing/use of treatments in practice. No literature could be found that assessed
pharmacist attitudes towards naltrexone in the US for comparison with our results.
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7) Objective 6: Relationships between knowledge, stigma and practices with
descriptive data
Multiple t-tests and ANOVAs as well as correlations were carried out to complete
this objective. Only four relationships were found to be significant. The first was the
relationship between performing MTM services and stigma. It is possible that
pharmacists who perform MTM have more positive professional attitudes towards SUD
patients. However, it is important to note that MTM services were for generalized care
and stigma was specifically evaluated for SUD.
The relationship between frequency of performing clinical services and stigma
scores was also significant. The literature describes the negative effects on treatment
outcomes due to stigma in general. However, studies assessing the relationship between
stigma and services offered in SUD are hard to find. Therefore, a relationship can be
hypothesized based on these findings between reduction in stigma and increased
practice/interaction with these patients, but further research is needed to definitively
establish this relationship. On the other hand, high stigma may lead pharmacists to not be
motivated to perform MTM or clinical services for these patients and therefore it is more
appropriate to hypothesize associations rather than causality.
Furthermore, stigma scores were also found to be significantly negatively
correlated with screening scores. This result might seem counterintuitive at first, but it is
possible that pharmacists who stigmatize SUD tend to label these patients and may also
label patients who do not have a formal diagnosis of SUD but display addictive or violent
behaviors. Also, it is important to note that the motivation for screening can be based
upon catching infractions versus a genuine desire to intervene therapeutically. The
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assessment for motivation for screening was beyond the scope of this study. These
pharmacists may believe screening to be more important because they label patients as
having SUD even before a diagnosis can be made. A study analyzing stigma in dual
diagnosis patients with mental illness and SUD found that stigmatizing attitudes lead to
improvement in their well-being because they received medical treatment. 212 However,
stigma is generally a negative factor in establishing a helping relationship and the
literature on this hypothesis is divided. As a result, more research needs to be conducted
to specify the relationship of stigma to practice.
The last correlation that was found to be significant was between screening and
practice scores. This indicates that being highly involved in the care of SUD patients in
the form of practicing large number of interventions lead pharmacists to screen patients
that do not have a formal diagnosis of SUD but may show presence of red flags or vice
versa. A study describing creation and evaluation of an opioid misuse screening tool
describes how the motivation and commitment of pharmacists to provide better services
to their patients prompted the creation of the screening tool. 213 This indicates that positive
attitudes and involvement in treatment of SUD can motivate pharmacists to screen as a
treatment and prevention strategy.

8) Objective 7: Predicting knowledge, practice, screening, and stigma
The final objective of the study was to look at the possible factors that together
predict the scores on the individual scales. Four regression models were designed, and all
models were found to be significant.
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The first model was designed to predict knowledge and predictors included CE in
SUD and naloxone, personal experience, number of years worked as a community
pharmacist, frequency of dispensing SUD medication, gender and stigma scores. Of these
predictors, number of years worked and CE in naloxone were significant predictors
individually in this model. Number of years worked was the only predictor with negative
regression coefficient, meaning that an increase of work experience by one year would
lead to a corresponding decrease in the knowledge score. It is possible that pharmacists
who have worked for many years have moved on to managerial positions and do not
actively dispense medications leading to a lesser knowledge of current medications.
Although, we asked pharmacists about their position in the pharmacy, it was possible to
choose all applicable options, thereby making it impossible to confirm this hypothesis.
Also, the more recent development of MAT and the recent emphasis upon the opioid
epidemic has led to more awareness and education regarding SUD in health professions
and pharmacy schools respectively. CE in naloxone being a significant predictor is not
unexpected. Considering, most CE programs are designed to improve knowledge levels
of pharmacists and the questions on the scale were specific to SUD medication including
naloxone, CE in both would definitely help pharmacists increase their knowledge scores.
The second model predicted how often pharmacists offered clinical services for
SUD patients and the predictors included in the model were stigma, knowledge and
attitude scores, practice scores, gender and personal experience. All threshold values
were significant and stigma was the only significant predictor individually. This meant
that an increase in stigma scores lead to an increase in the odds of the pharmacist offering
clinical services. Since, higher stigma scores meant lower stigma, this finding indicates
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that having lower stigma increases the odds of pharmacist regularly offering clinical
services for SUD. This is consistent with stigma literature in general.
The third model predicted screening scores with predictors like gender, stigma
and knowledge scores, personal experience and number of years worked. Stigma score
was individually a significant predictor in this model too. It had a negative regression
coefficient, meaning lower stigma led to a decrease in the screening score. This meant
that pharmacists who had more stigmatizing attitudes towards SUD tended to regard
screening as more important. As discussed before, this could be because pharmacists who
tend to label patients with SUD negatively, may screen more in order to refuse opioids.
Stigmatizing behavior stems from believing that SUD is a behavioral problem that
patients refuse to control instead of it being a biopsychosocial disorder. Hence,
pharmacists who stigmatize these patients would believe that dispensing opioids is only
contributing towards continuing this behavior. Therefore, stigmatizing attitudes may lead
to higher screening but does not necessarily lead to treatment of SUD or improved
outcomes for the patient. Number of years was also significant where increase in work
experience by a year lead to a significant increase in the square root of the screening
score. Again, this indicates that dealing and interacting with patients with SUD would
help pharmacists to recognize red flags as well realize the importance of providing
treatment to these patients; the first step of which is screening and receiving a formal
diagnosis.
The fourth model predicted total stigma scores where a combination of predictors
like screening and practice scores, patient socioeconomic class, MTM services and CE in
SUD were found to be significant. Both threshold values were significant, meaning there
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was a significant difference between pharmacists who had low and medium as well as
medium and high stigma scores. Of all the predictors in the model, screening scores and
‘never’/ ‘rarely’ performing MTM services were found to be significant individually. The
result indicated that an increase in screening scores meant an increase of odds of the
pharmacist falling in the medium stigma category instead of low and being in the high
stigma group instead of medium. As, described before, this indicates a relationship
between high stigma and believing screening to be an important practice. Pharmacists
who never or rarely performed MTM services were more likely have high stigma than
those who frequently performed MTM services. Therefore, routine performance of MTM
services could significantly predict occurrence of low stigma in pharmacists.

9) Content analysis
Overprescribing opioids was clearly a significant issue for most pharmacists when
discussing the opioid epidemic. They believed it to be the primary cause for the opioid
epidemic and stated that it needed to be regulated (many believed regulation to be in
process) to control the epidemic. The literature also shows that overprescribing and
inappropriately prescribing opioids has indeed been the major cause of the current opioid
epidemic.26,214 The pharmacists also believed substitution for opioids and improving
policies and resources were some of the action strategies that could be useful. For
example, one pharmacist stated:
“Doctors need to stop prescribing opioids so frequently/casually and use other drugs
which are just as effective without the abuse potential”
Another stated:
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“…Overprescribing of opioids is the reason why we are in this crisis, and the only way
we can recover is to implement stricter prescribing laws (which is already happening) in
addition to investing in drug rehabilitation…”
Some pharmacists also believed that the current regulations made it hard for
genuine chronic pain patients who need opioid treatments to receive opioids. A review
conducted to look at opioid therapy for chronic pain patients suggested that physicians
usually reject the idea of prescribing opioids, especially with recent regulations but it is
possible to treat and monitor these patients without them developing an opioid use
disorder.215 The ultimate goal is that the history of overprescribing opioids does not affect
patients who are in genuine need of these medications.
It was not surprising that pharmacists spoke about the scale and severity of the
epidemic considering the question had the opioid epidemic as the central theme.
However, many pharmacists noted that it was such a severe a problem that it would need
a multi-faceted approach. This indicates that pharmacists strongly believe in a possible
solution but expect it to involve every contributor. Some pharmacists also believed the
scale of the epidemic would result in increase of other substances. They state:
“… Heroin is going to continue to grow (possibly at higher rates) as prescribers stop
writing for opioids and insurance companies stop paying for medications. …”
This leads us to, contributor accountability which pharmacists seem to strongly
advocate for. Of all contributors however, physicians seem to be the contributors that
need to be held most accountable in the eyes of the pharmacists especially for
inappropriately prescribing opioids. One pharmacist, however, spoke about how
increasing physician accountability would also increase the burden of work on the
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pharmacist and was thus a barrier to practice. This was a legitimate concern; for example
use of PDMP programs as a method to responsibly prescribe medications resulted in
increased work load for all providers and time constraints were a major barrier. 216
Increasing the number of community pharmacists in every shift might reduce this burden.
PDMP was especially advocated for by the pharmacists. They believed that if physicians
viewed the PDMP before prescribing opioids it would go a long way in deterring them
from prescribing opioids. Research suggests use of PDMP does lead to a decrease in
‘doctor shopping’ behavior which patients exhibit in order to procure opioids. 217 One
pharmacist states:
“Many doctors are not taking the time to check the PDMP-although it seems to be
helping with the number of patients drug shopping.”
Moreover, pharmacists discussed how a lack of contributor (physician)
accountability would lead to problems in the prescriber-pharmacist relationship. Since,
physicians are not held accountable for prescribing opioids unnecessarily, the onus fell on
the pharmacists to intervene and refuse to dispense. This led to angry patients and
pharmacists being labeled as intrusive by the physicians as reported by the pharmacists.
One study evaluating communication between prescribers of opioids and pharmacists
qualitatively found that these communications are only common indirectly via patients or
voicemail. Direct communication was ineffective and these uncomfortable conversations
were generally avoided by both providers.218 These findings point towards a serious gap
in the physician-pharmacist relationship that needs to be addressed.
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II] Recommendations
Based on the gaps identified in the literature as well as the results of this study,
policy recommendations can be made in the following areas:

1) Educational recommendations
Increasing SUD specific education (clinical and policy) in the curriculum may
result in a decrease of stigmatizing behavior. Our study found a significant lack in
education of pharmacists and stigmatizing attitudes. The increased knowledge and
awareness will lead to greater willingness to offer pharmacy services to the SUD
population. Increasing experiential education for pharmacy students in SUD may be
effective as studies implied a relationship between experience and positive attitudes.
Pharmacists had a general negative attitude towards treatments, especially Suboxone ®
due to how it was being prescribed and reported poor relationships with providers.
Training programs for naloxone and MAT that involve the background/importance of
treatments, information on all products (nasal/ kits/ injectable), business/operations tips
and suggestions for storing and dispensing these treatments, and communication skills
with both patients and providers may help. Increasing CE certificate programs for SUD
may help pharmacists who are currently practicing.

2) Governmental recommendations
Below are some specific recommendations:
1. Implementing standing orders in all states.
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2.

Increasing the role of the community pharmacist in needle-exchange
programs and screening practices for SUD through regulations.

3. Increasing take home naloxone (THN) programs, especially in high
prevalence areas.
4. Needle distribution or non-prescription needles instead of needle exchange
programs, which can increase access to sterile syringes and needles for
patients.
5. Many pharmacists in the study also discussed regulations such as disposal
programs, adherence packaging, mandatory PDMP use and legalization of
marijuana as possible strategies.

3) Pharmacy practice
Below are some practice recommendations:
1. Offering MTM and screening services for SUD patients and at-risk
individuals. Pharmacists in this study regarded screening as a very important
practice.
2. Obtaining education and training to implement MTM services effectively.
Pharmacists in this study discussed how overprescribing of opioids was the
primary reason for the current epidemic.
3. Implementing a pain–management consult service, thereby decreasing
overprescribing and incidence of SUD.
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4. Augmenting roles in contacting providers, provision of products, education of
patients and providers, and spreading of SUD specific information throughout
the community.
It is important to note that these practice recommendations may be difficult to
implement based on the inherent structure of community pharmacies. Organizational
policies of pharmacies and the policies of all organizations within the umbrella of health
care may impede effective implementation of these recommendations. However,
implementing many if not all the policy suggestions for both preventive and educational
roles of the pharmacist, supported by governmental and educational policies will greatly
help in improving the health care provided to patients with SUD.

III] Limitations
1) Response rate
The response rate of the study was nearly 14%, but was typically lower than
survey research involving health care professionals. This may be attributed primarily to a
lack of strong incentive. As the incentive was based on a random drawing of only twenty
gift certificates, pharmacists may have believed the chance to win wasn’t very high,
especially since the sample size was very high (the entire mailing list). Additionally, the
amount of the gift certificate was $30 and may not have been sufficient to elicit
responses. However, the survey was sent out through the director of operations of the
pharmacy chain as a strategy to increase response. Although, Giant Eagle allowed
pharmacists to complete the survey during work hours, this may or may not have had a
significant effect on response rate. Moreover, the length of the survey may have been an
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additional deterrent as some partial responses indicate. A similar study was conducted in
mental illness and community pharmacists with a national sample and had a lesser
response rate.219 The sample characteristics were similar, indicating that the small
response rate might still have provided a representative sample.

2) Generalizability
The study was conducted in the local tristate area (PA, WV, OH) only and caution
must be exercised before drawing conclusions for other states or regions. More
importantly, the study sample was mostly comprised of pharmacists from only one
community chain pharmacy. Practices, policies and general work atmosphere and ethic at
this chain may have affected the responses. Responses from pharmacists working in other
chains and maybe even dealing with different patient profiles may significantly change
the results of the study. This study did include community pharmacists from Duquesne
University alumni network and this may have increased generalizability due to variation
in the pharmacists’ backgrounds. However, email lists for both groups of pharmacists
were not available to identify which group the responses belonged to. Separation of the
responses into the groups and subsequent comparison analysis could have helped confirm
this hypothesis. A separate study conducted in 2012 by researchers affiliated with APhA
as part of the Career Pathway Evaluation Program studied chain community pharmacists
all over the country identified similar descriptive patterns. 220 The only differences in the
results was the average age of the pharmacists was slightly higher at 46 years old and
they mostly had B.S. versus PharmD. Degrees. However, as discussed previously, the
degree obtained and age of respondents is highly correlated. This study had very similar
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sample characteristics as other national studies even though it was conducted only in
Ohio, Pennsylvania and West Virginia.220,219

3) Self-reported data
The third significant limitation (having self-reported data) tends to affect all
survey research in some way, especially where responders’ data cannot be verified by
other means. Self-reported data is susceptible to several biases. Firstly, social desirability
bias may have occurred where pharmacists provide answers that are more socially
acceptable. This bias is especially of concern in this study because of the sensitive nature
of certain questions such as personal experience. The results although high, were still less
than what is commonly observed in the literature, as discussed previously. 201 Social
desirability bias can also affect responses on non-sensitive questions such as screening or
other personal response questions. The questionnaire has been designed to control for this
bias as much as possible. Apart from the anonymous nature of the survey, questions and
instructions were designed to reduce the effect of this bias as discussed in detail
previously. The results indicate that there was less effect of this bias. For example, almost
half the sample stated that they do not play any role in the practice and results indicated
stigmatizing attitudes. Both results are socially undesirable behaviors. Similarly, a
smaller number of correct responses on difficult questions were received and a proportion
of the sample admitted to having personal experience with SUD. These results also point
towards a valid response set. Some questions in particular may also be subject to recall
bias, like number of years or hours worked or number of prescriptions filled, etc. These
questions however are minor and not the key factors being measured. Also, results seem
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consistent with few outliers for these variables and recall bias if any would not alter
responses on these variables drastically. Finally, selection bias may have occurred
because responders could choose the questions they wanted to answer. The survey
allowed responders to skip questions without responding and a couple of pharmacists
have skipped sections while a couple others have skipped specific questions. This reduces
the total number of responses that can be analyzed. For regression models the sample size
was reduced to less than 100 which may have affected results. However, Qualtrics ®
software allows downloading of the response file where responders who have viewed the
question but not answered and those who have not viewed the question itself can be
differentiated. All analyses have differentiated these two groups as far as possible.

IV] Future Research
Future studies must aim to eliminate the limitations of this study as much as possible
while maintaining the quality and if possible adding to the depth of the data collected.
Increased resources can be used to fund a large-scale project like a national survey of
community pharmacists in chains as well as independent pharmacies. This would make
the results of the study highly generalizable. The larger funding source could also be
utilized to provide higher incentive to get a larger response rate. In this study, the crosssectional study design limited the interpretation of findings to associations and
correlations only. Causal associations could not be made based on the data collected.
Conducting a longitudinal study in the future would enable researchers to overcome some
of these limitations. Using other research methods like a database study to study
prescription practices, intervention studies where pharmacists are provided with
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screening tools, or qualitative methods like interviews or focus groups might help remove
the biases that may exist in this study. Future research should also incorporate important
topics like use of PDMP as a screening tool, role of experiential education in knowledge
and attitude as well as studying stigma in depth, both perceived and concrete stigma and
how it affects various aspects of treatments. It is also important to study the entire health
care system and contributions from different sectors in treatment and of SUD. Future
studies could incorporate health care providers, insurance, industry and other segments in
relation to pharmacy functioning to better understand the barriers to pharmacist practice.

V] Study Implications
There were differences in stigma between pharmacists who performed MTM versus
those who did not and frequency of providing clinical services was less in pharmacists
with high stigma. This implied that more engagement with SUD patients is related to less
stigma. Approximately one- third of pharmacists demonstrated negative attitudes toward
harm reduction. Large percentage of pharmacists believed their education to be
inadequate. This argues for mandatory curriculum and competency statements
specifically developed for pharmacy schools. Moreover, experiential education should be
emphasized because it encourages engagement with patients. The most common themes
in qualitative analysis were overprescribing and the vast extent of the SUD problem
demonstrating that pharmacists understand the nature of the public health crisis. Lack of
prescriber accountability was also a common belief among the pharmacists.
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VI] Conclusion
This study was the first comprehensive survey of knowledge, attitudes and
practices of community pharmacists in SUD conducted in recent times. The knowledge
section of the study assessed medication and policy knowledge levels among
pharmacists. Knowledge levels were high on average, but some specific areas had room
for improvement. Also, the study successfully evaluated current practices of pharmacists,
specifically screening. The findings of the study are especially relevant considering the
increased expectation of screening for SUD to be conducted by pharmacists. A clear
picture of current practices of pharmacists in practice can be drawn based on the results
of the study. The study also included the attitude section that evaluated attitudes towards
relevant treatment strategies which haven’t been studied before or attitudes that have
changed over time (Suboxone®). As stigma was a major factor involved in overall
attitude, the study not only evaluated stigma but also related it to other factors. The
results indicate that stigma on the part of health care providers exists and its effects on
treatment outcomes as well as practices of the provider have been studied. Significant
relationships were established between these factors as well as the extensive descriptive
information that we collected. These significant relationships can be used to conduct
further research, help re-evaluate current practices and policies as well as assist in making
future recommendations and policy and practice changes, both on the micro and macro
level. Finally, the regression models recognized predictors of the factors evaluated in this
study. These models provide evidence for the strong connection between the factors
themselves as well as other descriptive and practice characteristics. Moreover, the
qualitative analysis elaborated the findings of the quantitative survey and produced
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information that was previously not discussed. The overall study findings can be a step
forward in improving the research conducted in the area, treatment outcomes and health
care available to patients with SUD, ultimately improving their lives.
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APPENDICES
Appendix 1: Survey Instrument
I.

Background Information:
This section gathers information about you and your practice. All responses will be kept
confidential.
A) Demographics:
Age: ________ years
Gender: ___ Male ___Female
Race: ___Caucasian ___African American ___Asian
__American Indian ___Hispanic ___Pacific Islander Other: ________
iv. Pharmacy degree(s) attained: ___B.S. Pharm. ___Pharm.D.
v.
Year of last pharmacy degree graduation: ___________
vi. Other degree(s) attained: ___Masters ___Ph.D. Other: __________
vii. Year of last other degree graduation: __________
viii. Please list any board certification(s) you have obtained: ______
i.
ii.
iii.

i.
ii.
iii.
iv.
v.
vi.

B) Practice Characteristics:
Number of years working in community pharmacy: ___________
Average number of hours worked per week: ___________
Primary practice site location (choose most applicable response):
___Urban ___Rural ___Suburban
On average, how many pharmacists work at the pharmacy during a typical shift?
___________
On average, how many prescriptions does your pharmacy fill during a typical
week? ___________
How often do you dispense prescriptions in a given week for SUD? (E.g. Naloxone,
Buprenorphine, Naltrexone etc.)
1
2
3
4
Never
Rarely
Sometimes
Frequently

vii. What is the most frequent SUD medication do you dispense in your pharmacy?
(E.g. Naloxone, Buprenorphine, Naltrexone etc.)
______________________
viii. In your opinion, the majority of patients visiting your pharmacy belong to which
socioeconomic class? (Choose the most applicable option)
___Impoverished ___Low income class ___Middle income class ___High Income
class
ix. Which of the following best represents your position in the pharmacy? (Please
check all that apply).
___Full time staff pharmacist ___Part time staff pharmacist
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___Pharmacy manager ___
C) Education:
i.
I received substance abuse education in pharmacy school: __Yes __No
ii.
If yes, I believe the education I received was adequate to effectively treat
patients with substance use disorder (SUD).
1
Strongly disagree
iii.

2
Disagree

3
Agree

4
Strongly
agree

In the last 2 years, I have had:
a. Continuing education (CE) related to SUD: __Yes __No
b. Continuing education (CE) related to naloxone: __Yes __No

iv. Do you have any personal experiences with SUD? (e.g. friend, family, self)
___ Yes ___No ___Prefer not to disclose
II.

Knowledge:
This section gathers information about your knowledge regarding the treatment of SUD.
All responses will be kept confidential.
Answer the following questions to the best of your ability. This is not a test of your
personal knowledge, but rather an assessment in aggregate of pharmacist knowledge base
regarding SUD. All data reported in aggregate and not identified as individual responses.
i.

I have good current knowledge on medication therapy for SUD.
1
2
3
4
Strongly disagree
Disagree
Agree
Strongly agree

ii.
a)
b)
c)
d)

_________ is a Schedule III controlled substance.
Naloxone
Buprenorphine
Naltrexone
Not sure

iii.
a)
b)
c)
d)

__________ is an opioid receptor antagonist and can reduce tolerance to opioids.
Naloxone
Buprenorphine
Naltrexone
Not sure

iv.

__________ is the drug of choice for emergency treatment of opioid overdose.
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a)
b)
c)
d)

Naloxone
Buprenorphine
Naltrexone
Not sure

v.

Is a prescription required for dispensing naloxone in your state? ___Yes
___No___Not sure

vi.

Buprenorphine can be used to potentiate opioids. ___True ___False ____Not sure

vii. Naloxone can be administered orally.___True ___False ____Not sure
viii. Opioid administration to a patient on naltrexone is an effective pain management
strategy.
___True ___False ____Not sure
Naltrexone can be started within 7 days of last opioid use. ___True ___False
____Not sure

III.

Practice:
A) Services provided:
This section gathers information about how you assess patients for potential substance
use disorder. All responses will be kept confidential
i.
Do you play any role in providing services for SUD patients? __ Yes __ No
If yes, which of these duties do you perform (Please check all that apply)
__Dispensing medications for SUD.
__ Counseling patients with SUD about substance use medications.
__ Provision of a private space for counseling/medication reviews when needed.
__ Patient monitoring or assisting patients to self-monitor for SUD medication
efficacy and safety.
__ Advising individuals about serious adverse effects associated with SUD
medications (e.g. respiratory depression, seizures, etc.)
__ Recommending/advocating for SUD therapy changes to optimize cost or
formulation.
__ Referring patients to trusted SUD practitioners in the community.
__ Other: ___________
ii.

How often do you perform formalized medication therapy management clinical
services for patients in general who would benefit from it, defined as “a service or
group of services that optimize therapeutic outcomes for individual patients”?
1
2
3
4
Never
Rarely
Sometimes
Frequently

206

iii.

How often do you provide clinical services for patients with diagnosed SUD?
1
2
3
4
Never
Rarely
Sometimes
Frequently
B) Screening:
i.
Please select how important the following are to further investigate the
possibility of abuse potential for medication?

___Repeatedly receiving "cocktailed" prescriptions (e.g. medications used in
combination to enhance physical effects such as a “high”)
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
___Failure of prescribers to individualize dosing strategies for patients
1
2
3
Not important at all
Somewhat important
Very important
important

4
Extremely

___Receiving multiple prescriptions for the strongest/most addiction-prone formulations
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
___Requests for early refills from patients
1
2
Not important at all
Somewhat important
important

3
Very important

4
Extremely

___Prescribers located far away from pharmacy sending prescription requests
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
___Receiving a large volume of prescriptions for controlled substances by one particular
physician
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
___Patients travelling in groups to the pharmacy to pick up controlled substances
1
2
3

207

4

Not important at all
important

Somewhat important

Very important

Extremely

___Receiving requests for controlled substance prescriptions to be paid for with cash
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
___Prescribers verifying prescriptions as legitimate when contacted, but without
explanation other than their own directive (e.g. “Fill it because I said so.”)
1
2
3
4
Not important at all
Somewhat important
Very important
Extremely
important
IV.

Attitude:
This section gathers information about how you assess patients for potential substance
use disorders. All responses will be kept confidential.
A) Stigma:

1. For the following questions please select the response that best expresses your attitude
and beliefs towards SUD:
i.

Most pharmacists would willingly accept someone who has been treated for
substance use as a close friend.
1
Strongly disagree

ii.

2
Disagree

3
Agree

4
Strongly agree

Most pharmacists believe that someone who has been treated for substance use is
just as trustworthy as the average citizen.
1
Strongly disagree

iii.

3
Agree

4
Strongly agree

Most pharmacists would accept someone who has been treated for substance use
as a teacher of young children in a public school.

1
Strongly disagree
iv.

2
Disagree

2
Disagree

3
Agree

4
Strongly agree

Most pharmacists would hire someone who has been treated for substance use to
take care of their children.
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1
Strongly disagree
v.

2
Disagree

3
Agree

4
Strongly agree

Most pharmacists think less of a person who has been in treatment for substance
use.
1
Strongly disagree

vi.

2
Disagree

3
Agree

4
Strongly agree

Most pharmacists would be willing to date someone who has been treated for
substance use.

1
Strongly disagree

2
Disagree

3
Agree

4
Strongly agree

B) General attitude:
2. For the following questions please select the response that best expresses your attitude
and beliefs towards general strategies to address the drug abuse epidemic:
i.

Pharmacists dispensing needles without prescriptions (or a demonstrated
legitimate medical need) leads to an increase in frequency of substance abuse.
1
Strongly disagree

ii.

2
Disagree

3
Agree

4
Strongly agree

Pharmacists dispensing naloxone acts as a safety net leading to an increase (or
encouragement) in substance abuse.
1
Strongly disagree

iii.

2
Disagree

3
Agree

4
Strongly agree

Dispensing buprenorphine/naloxone (Suboxone®) is an effective way for
pharmacists to assist in the overall treatment of SUD.
1
Strongly
disagree

2
Disagree

3
Agree
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4
Strongly agree

iv.

Pharmacists dispensing oral/long acting naltrexone is an effective method to treat
SUD.

1
Strongly disagree

V.

2
Disagree

3
Agree

4
Strongly agree

Qualitative
Finally, we would be interested in your thoughts about prescription drug abuse.
Please take a few minutes to share your thoughts with us regarding the question
below. You may type your response in the space provided. What are your views
regarding the current opioid prescription drug epidemic?
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Appendix 2: Email
Dear Pharmacist,
This email is to invite you to participate in a research survey developed in partnership by
pharmacists/researchers at Duquesne University School of Pharmacy in Pittsburgh, PA.
and Giant Eagle Pharmacy.
The purpose of the research study is to explore community pharmacists’ knowledge of
and attitudes toward substance use disorder (SUD) and the services they provide. This
survey is intended for community pharmacists. The email consists of a link to the online
survey. The survey should take approximately 5-10 minutes of your time. Your response
is crucial for the success of this project. The survey link can be found at:
https://duq.az1.qualtrics.com/jfe/form/SV_ahsuTsWvmRFj7Ol
You will be asked a series of questions regarding your thoughts and opinions regarding
the care of patients with SUD. Your answers will help to identify barriers and stigma
associated with SUD and its treatment. To assure confidentiality, your responses will be
coded and your name will not appear in any data analysis or research reports. Therefore,
we assure you of as much confidentiality as legally possible. Your participation in this
research study is voluntary. Your completion and submission of the survey will constitute
your consent to participate in the study. You do not need to answer all questions even
though we would prefer that you do. A summary of the results will be supplied to you, at
no cost, upon request. The study has been approved by the Duquesne University
Institutional Review Board (IRB).
To thank you for your time, upon submission of your survey, your email address will be
entered in a random drawing for one of twenty $30.00 Amazon gift cards.
If you have any questions regarding the research project or survey, please feel free to
contact Dr. Giannetti at 412.396.6379, Dr. Kamal at 412.396.1926, Dr. Covvey at
412.396.2636 or Dr. David Delmonico, Chair of the Duquesne University Institutional
Review Board, at 412.396.1886
Thank you in advance for your time and input.
Regards,
John De James R.Ph.
Sr. Manager of Clinical Programs | Giant Eagle, Inc.
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Appendix 3: Pilot test
Pilot test: Community Pharmacist and Substance Use Disorders

1. Were any of the questions or responses unclear?

2. Did the responses appear to be complete? Are there any other categories you
would like to add to responses in any of the questions?

3. Are there any other questions that you think could improve the study?

4. Please comment on the length of the survey and how long it took you to complete.
Would the length be an impediment to completing the survey?

5. Do you have any other comments you would like to add regarding the survey?
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Appendix 4: Codebook
1. Overprescribing opioids
2. Scale and severity of the epidemic
3. Policy recommendations
4. Contributor accountability
5. Negative aspects of Suboxone
6. Attitude towards naloxone
7. Prescriber pharmacist relationship
8. Personal experience
9. Barriers to practice
10. PDMP
11. Access to opioids
12. Stigma
13. Education
14. Resources
15. Frustration/Hopelessness
16. Substances other than opioids
17. Mental health
18. Patients without formal SUD diagnosis
19. Substitution of opioids
20. Therapy/ Counseling
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